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Abstract
Invading organisms are detected by the innate immune system, through the 
recognition o f conserved microbial structures. Innate responses are known to 
influence the development o f adaptive immune responses, which are crucial for 
preventing infection and eliminating pathogens. Characterising the signals that 
initiate the induction o f efficient cellular and humoral adaptive immune responses is 
particularly relevant for the rational design o f new vaccines. The aims o f this study 
were first to assess the ability o f a broad range o f conserved microbial stimuli to 
induce CD8+ T cells responses by cross-priming and enhance antibody responses 
against exogenous soluble protein antigens, and secondly to investigate the 
mechanisms by which microbial stimuli induced cross-priming. Stimulation of Toll­
like receptors (TLR) is believed to play a major role in the activation o f innate and 
subsequent adaptive responses. All TLR agonists tested enhanced antigen-specific 
antibody responses, and in particular zymosan (TLR2/6), poly(I:C) (TLR3), LPS 
from E. coli (TLR4) and CpG DNA (TLR9) promoted IgG2a responses, which are 
thought to contribute effectively to protective mechanisms against pathogens in mice. 
However, only poly(I:C), LPS from E. coli and CpG DNA were able to stimulate the 
induction o f cross-priming, whereas zymosan, peptidoglycan (TLR2/?) and R-848 
(TLR7) were ineffective. It is known that LPS from different bacteria species can 
elicit different immune responses. LPSs from Klebsiella pneumoniae and from 
Neisseria meningitidis, but not the unconventional LPS from Porphyromonas 
gingivalis, were able to induce cross-priming. Microbial mannose structures, as 
present in yeast mannan, Influenza hemagglutinin and polymannose LPS, were 
demonstrated for the first time to be able to induce functional cross-priming. In 
addition, mannan and polymannose LPS were found to enhance antigen-specific 
antibody responses and promote IgG2a responses. IFN-oc/p and signalling through 
costimulatory molecules play a central role in the licensing o f cross-priming. 
Experiments using knock-out mice showed that in all cases licensing o f cross­
priming was dependent on IFN-a/pR signalling, albeit to a varying degree. In 
contrast, signalling through CD40 was not required for induction o f cross-priming by 
mannan and polymannose LPS. Induction o f cross-priming by LPS from E. coli and 
by mannan was TLR4-dependent, whereas induction by polymannose LPS was 
TLR4-independent.
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This study thus identifies LPS from some bacteria species as cross-priming-inducing 
stimuli. It also confirms that activation o f TLR can initiate induction o f cross­
priming, while indicating the existence of TLR-independent pathways. In addition, 
this work illustrates the importance o f IFN-a/pR signalling as a cross-priming 
licensing stimulus.
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Chapter 1
Introduction
The immune system is a coordinated body o f specialised cells and soluble factors 
that cooperate to confer protection against harmful self and non-self.
Two divisions have evolved to form the immune system of vertebrates: the 
evolutionary conserved innate immune system, under the control o f germline- 
encoded genes, and the adaptive immune system, characterised by somatic gene 
recombination and mutation. Pathogens that breach entry into the body are initially 
detected by the innate immune system, which is able to identify the nature of the 
pathogen and start eliminating it, while alerting the adaptive immune system and 
directing it for further appropriate defence mechanisms.
A particular type o f innate cells, the dendritic cells (DC), is now known to play a 
pivotal role at the junction between the innate and adaptive immune systems. DC are 
able to integrate signals generated during the innate response and translate them into 
instructions for T cells and B cells, which activate effector functions accordingly. 
CD4+ T cells coordinate the action o f B cells and CD8+ T cells, and provide feedback 
activation signals to innate effector cells.
CD8+ T cells are the T cells in charge of killing infected cells. DC constantly present 
CD8+ T cells with samples o f intracellular contents. Infected DC themselves 
therefore present samples o f invading pathogen to CD8+ T cells. If CD8+ T cells have 
a T cell receptor (TCR) specific for an antigen, and if  the presenting DC has received 
information that the nature o f the invader requires cell lysis for elimination, then 
specific CD8+ T cells are primed to differentiate into cytotoxic T lymphocytes (CTL) 
and to lyse all cells bearing the specific antigen.
DC can also acquire pathogen samples from other infected cell types, which allows 
DC to initiate adaptive responses against pathogen that have no tropism for DC. 
Antigens acquired from the extracellular environment were traditionally thought to 
be presented exclusively to CD4+ T cells. DC have the unique capacity to cross­
present antigens acquired from other cells to CD8+ T cells. However, similarly to 
priming o f CD8+ T cells against antigens synthesised within DC, full activation o f
14
specific CD8+ T cells against acquired antigens, which occurs by a process called 
cross-priming, is strictly controlled.
Cross-priming o f CD8+ T cells by DC needs to be authorised. Some microbial 
molecules have been found to allow cross-priming to occur, and a couple of  
signalling events, downstream of microbial recognition, have been described as 
cross-priming licensing stimuli.
It is important for adjuvant and vaccine development to define further which type o f  
microbial molecules are able to stimulate authorisation o f cross-priming and which 
licensing mechanisms may be involved in the generation o f antigen-specific 
cytotoxic T cell responses. Current knowledge on how pathogens are detected, how 
the innate and adaptive immune systems are activated and what the adaptive 
response consist of, was taken into account for the design o f this project.
1.1 Pathogen detection and activation of innate 
immunity
In order to explain peripheral tolerance o f adaptive immune cells to normal self­
antigens while considering adaptive cells requirement for costimulatory signals 
before clonal activation, Charles A. Janeway, Jr hypothesised that evolutionary 
primitive receptors controlled activation o f both the innate and adaptive immune 
responses by stimulating effector functions only in response to infectious non-self 
molecules. Specificity to infectious non-self would be insured by multiple 
evolutionary selected innate receptors, each recognising a conserved structure 
common to a range of pathogens (Janeway, 1989; Janeway, 1992). These structures, 
targets o f innate immune recognition, were termed pathogen-associated molecular 
patterns (PAMPs).
At least one soluble innate immune receptor, the mannan-binding lectin (MBL) (see 
paragraph 1.1.1.1.2) (Kuhlman et a l , 1989), able to bind specific pathogen 
structures, was already known. Within the following ten years though, the existence 
o f evolutionary conserved receptors, able to recognise PAMPs and initiate specific 
intracellular signalling, was demonstrated in insect first, then in mammals (Lemaitre 
et a l , 1996; Medzhitov et a l , 1997; Rock et a l ,  1998). Other receptors have been 
reported since. The major families of receptors involved in recognition o f and 
responses to PAMPs are described below.
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1.1.1 Innate immune receptors
1.1.1.1 Extracellular and membrane-bound receptors
1.1.1.1.1 Toll-like receptors
Toll-like receptors (TLR) are innate receptors homologous to the Drosophila Toll 
protein. Drosophila Toll was identified as a component o f a signalling pathway 
controlling dorsoventral polarity in the fly embryo (Hashimoto et a l ,  1988). Toll was 
found to have a cytoplasmic domain that is related to human interleukin-1 receptor 
(IL-1R) (Gay et al., 1991), which can induce translocation o f NF-kB, a gene 
transcription factor for a wide variety o f immune response genes, to the nucleus. 
Drosophila Toll pathway was later found to be involved in the specific expression of 
antifungal immune response in the fly, since inactivation o f toll gene resulted in high 
susceptibility to fungal infection but not to bacterial infection (Lemaitre et al., 1996). 
Other members of the Toll family, along with more recently described receptors, 
such as peptidoglycan recognition proteins (PGRP), enable Drosophila to 
discriminate between classes o f pathogens (fungi, Gram-positive and Gram-negative 
bacteria) and activate the secretion o f killing peptides with appropriate activity 
against the structure of the pathogen (Tauszig et a l ,  2000; Leclerc et a l ,  2004).
Shortly after the contribution o f Toll to Drosophila immunity was described, a 
family o f human homologues o f Toll was identified and termed Toll-like receptors 
(Rock et a l ,  1998). Since then, the protein sequences o f 13 mammalian TLR have 
been described (Tabeta et a l ,  2004), and the specificity o f most o f them has been 
characterised (Akira, 2003; Takeda et a l ,  2003; Kawai et a l ,  2005a).
TLR are membrane-bound glycoproteins that are present either at the cell surface or 
sequestered in intracellular compartments (endosome). Their agonist recognition 
domain faces outside the cell or the lumen of the endosome. TLR recognition domain 
contains leucine-rich repeats (LRR) (Bell et a l ,  2003).
The first TLR to be characterised was TLR4. First, a constitutively active mutant was 
constructed, and transfected cells were found to be induced to express genes coding 
for cytokines and costimulatory molecules, as well as to activate NF-kB, indicating 
that this TLR had the capacity to activate innate immune signalling pathways that 
can lead to innate responses that support the generation o f adaptive responses 
(Medzhitov et a l ,  1997). Importantly, the tlr4 gene was assigned to a chromosomal
16
region that corresponded to the location o f the Lps gene, where the mutation 
responsible for hyporesponsiveness to endotoxin in C3H/HeJ mice was mapped 
(Watson et ah, 1978). After cloning o f mouse tlr4, the exact mutation responsible for 
the phenotype o f both C3H/HeJ and C57Bl/10ScCr mice was characterised (Poltorak 
et al., 1998; Qureshi et al., 1999). The generation and study o f TLR4-deficient mice 
confirmed that the release o f pro-inflammatory cytokines and B cell proliferation in 
response to LPS from E. coli and S. minnesota depended on TLR4 (Hoshino et al., 
1999). TLR4 activity is not restricted to bacterial LPS, since recently TLR4 was 
shown to be involved in responses to fungal and viral components (Tada et al., 2002; 
Jiang et al., 2005).
TLR4 does not act alone. LPS is first bound by a serum protein, lipopolysaccharide 
binding protein (LBP), that binds the lipid A moiety of LPS (Tobias et al., 1989), 
helps disrupting LPS micelles and transfers LPS monomers to CD 14 to form a 
complex (Schumann et al., 1990; Wright et al., 1990; Gioannini et al., 2004). CD 14- 
LPS then binds myeloid differentiation protein 2 (MD-2), a glycoprotein that 
interacts with TLR4 LRR domain and that is essential in LPS recognition (Schromm 
et al., 2001; Nagai et al., 2002). Signalling through TLR4 is probably stimulated by 
TLR dimerisation and change in conformation, which may be influenced by CD 14 
and/or MD-2 (Gangloff et ah, 2004; Saitoh et al., 2004; Kim et ah, 2005a). Induction 
o f CD 14-dependent and -independent immune responses to LPS has been reported 
(Perera et ah, 1997; Hamann et ah, 2005; Jiang et ah, 2005).
CD 14 is also a co-receptor for some o f TLR2-mediated responses. TLR2 responds to 
PAMPs from various organisms, including from Gram-negative bacteria (porins 
from Neisseria meningitidis (Massari et ah, 2002), LPS from some non- 
enterobacterial species (Tanamoto et ah, 1997; Werts et al., 2001; Erridge et ah,
2004) ), from Gram-positive bacteria (lipoteichoic acid (LTA) (Henneke et ah, 2005) 
) and from yeast (zymosan (Underhill et ah, 1999) ). TLR2 has been reported to form 
heterodimers with at least TLR1 or TLR6, which allows differential immune 
responses depending on agonists. Triacylated lipopeptides and lipoproteins, such as 
synthetic bacterial structure PamsCSiQ and Mycobacterium tuberculosis 19kDa 
lipoprotein, are detected by TLR2/TLR1, while diacylated lipopeptides Pan^CSKj 
and MALP-2 are detected by TLR2/TLR6 (Takeuchi et ah, 2002). CD 14 has been 
reported to participate in TLR2/TLR1-mediated binding o f lipopeptides (Vasselon et
17
al., 2004; Manukyan et al., 2005), and TNF-a secretion in response to diacylated 
lipopeptide Pani2 CSK4  (TLR2/6) has been shown to be partially CD 14-dependent 
(Jiang et al., 2005). As TLR1 and TLR6, TLR10 (Chuang et al., 2001) is structurally 
related to TLR2, and it has been suggested it may form heterodimers with TLR2 
(Akira, 2003).
Responses to protein PAMPs that may have in common a role in pathogen mobility 
and invasion have been found to be mediated by TLR5 (for bacterial flagellin 
(Hayashi et al., 2001)) and murine TLR11 (for protozoal profilin (Yarovinsky et al.,
2005)).
Although closely related to TLR5, TLR3 mediates responses to a different category 
o f PAMPs. Indeed, double-stranded RNA (dsRNA), generated as a synthesis 
intermediate or a transcription by-product during viral replication, can be recognised 
by TLR3 (Alexopoulou et al., 2001).
TLR7 and human TLR8 detect guanosine- and uridine-rich single-stranded RNA 
(ssRNA) (Diebold et al., 2004; Heil et al., 2004), as well as synthetic 
imidazoquinolines such as imiquimod (R-837) and resiquimod (R-848) (Hemmi et 
al., 2002; Jurk et al., 2002).
TLR9 recognises unmethylated deoxyribonucleotide sequences containing cytidine- 
phosphate-guanosine motifs (CpG DNA) from bacteria and viruses (Hemmi et al., 
2000; Krieg, 2002; Abe et al., 2005). TLR9 was recently shown to respond to a non- 
DNA agonist, hemozoin, which is a product from malaria’s catabolism o f host 
haemoglobin (Coban et al., 2005).
In contrast to other TLR expressed at the cell surface on antigen presenting cells, 
TLR3, TLR7/8 and TLR9 are localised primarily in endosomes, where their 
recognition domain samples the inside o f the endosome (Matsumoto et al., 2003; 
Latz et al., 2004a; Latz et al., 2004b; Nishiya et al., 2004).
Recognition and response to some PAMPs may be mediated by TLR in collaboration 
with other innate receptors, including some members o f the lectin family 
(Mukhopadhyay et al., 2004).
1.1.1.1.2 Lectins
Lectins are non-enzymatic proteins that can bind carbohydrates. C-type lectins in 
particular possess at least one carbohydrate recognition domain (CRD) that requires
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calcium to interact with its ligand. Since many “lectins” structurally related to C-type 
lectins have CRD that function without calcium, these lectins are often collectively 
referred to as C-type lectin-like receptors, and their CRD are called C-type lectin-like 
domains. Many C-type and C-type lectin-like receptors are involved in immune 
processes (Cambi et a l , 2003a; Rogers et a l , 2003; McGreal et a l , 2004).
Dectin-1 was the first C-type lectin-like receptor reported to collaborate with a TLR 
(TLR2) for stimulation of cytokine and chemokine production in response to yeast 
zymosan (Brown et a l , 2003; Gantner et a l , 2003a). Dectin-1 actually recognises the 
p-glucan moiety of zymosan, and soluble and particulate p-glucans in general 
(Brown et a l , 2001; Brown et a l , 2005), and can also trigger cytokine production 
independently o f TLR through its own cytoplasmic ITAM-like signalling domain 
(Rogers et a l , 2005).
Dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing non- 
integrin (DC-SIGN) and SIGN-related (SIGN-R) receptors (Geijtenbeek et al., 2000; 
Park et a l , 2001; Geijtenbeek et a l , 2004) are C-type lectins that recognise high- 
mannose structures, such as presented by viral envelope glycoprotein gpl20 from 
HIV, by mannose-capped lipoarabinomannan from M. tuberculosis, or by yeast 
mannan (Tailleux et a l , 2003; Takahara et a l , 2004; Snyder et a l , 2005). 
Specificity o f DC-SIGN and SIGN-R homologues for high-mannose structures is 
achieved by multiple oligomerisation, forming tetramers of monomers, and 
clustering (Feinberg et a l , 2001; Mitchell et a l , 2001; Cambi et a l , 2005a; Cambi et 
a l , 2005b). The function o f these C-type lectins is being debated, but recent reports 
support a role for DC-SIGN (Snyder et a l , 2005; Tacken et a l , 2005) and marginal 
zone macrophage SIGN-R1 (Kang et a l , 2003) in endocytosis and antigen 
presentation (Engering et a l , 2002; Cambi et a l , 2003b). On peritoneal 
macrophages, SIGNR-1 has been shown to collaborate with dectin-1 for the 
detection o f zymosan, which contains p-glucan and mannan, although cytokine 
production in response to zymosan was independent o f SIGNR-1 (Taylor et a l , 
2004), consistent with the fact that SIGNR-1 and others members o f this group have 
no obvious signalling motif. There is evidence however that recognition of specific 
PAMPs by DC-SIGN and SIGN-R promote stimulation of signalling pathways and 
immune responses (Geijtenbeek et a l , 2003; Bergman et a l , 2004), possibly by 
collaborating with TLRs, such as TLR4 (Nagaoka et a l , 2005).
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The mannose receptor (MR) is the best characterised C-type lectin, mediating 
phagocytosis and endocytosis (Kruskal et al., 1992; Sallusto et a l ,  1995; Stahl et a l ,  
1998) o f molecules bearing repeated polymers o f mannose (Mullin et a l ,  1994), such 
as displayed by some bacteria, viruses and yeasts (Milone et a l ,  1998; Stehle et a l ,  
2000; Cinco et a l ,  2001; Zamze et a l ,  2002; Nguyen et a l ,  2003; Porcaro et a l ,
2003). A role for MR in antigen presentation has also been reported (Martinez- 
Pomares et al., 1996; Prigozy et a l ,  1997). In contrast, the precise contribution of  
MR to induction of immune responses has not been as well characterised. MR was 
shown however to be involved in mannose-dependent cytokine secretion in response 
to some viruses and to Candida albicans (Yamamoto et a l ,  1997; Milone et a l ,  
1998). A probable collaboration with another innate receptor, possessing an 
intracellular signalling domain, has not been described.
DEC-205 (Jiang et a l ,  1995) is structurally related to the MR and has therefore been 
classed as a member of the mannose receptor family (East et a l ,  2002); carbohydrate 
binding activity or ligand specificity have still not been defined. DEC-205-specific 
antibodies have been used to target the receptor and it has been confirmed that DEC- 
205, which has an internalisation cytoplasmic tail motif, is an endocytic receptor 
(Mahnke et a l , 2000). In addition, DEC-205 possesses another motif that enables it 
to target ligands to late endosome and lysosome compartments where processing for 
antigen presentation takes place (Mahnke et a l ,  2000). Targeting antigens to DEC- 
205 has been found to result in efficient MHC I and MHC II antigen presentation 
(Mahnke et a l , 2000; Bonifaz et a l , 2002).
Specificity for mannose and polymannose structures, such as displayed by DC- 
SIGN/SIGNR and MR, is characteristic o f many other C-type lectins, including 
members o f the collectin family (Hoppe et a l ,  1994). Mannan-binding lectin (MBL) 
is an evolutionary conserved molecule that binds PAMPs and activates the 
complement proteolytic pathway (Hoffmann et a l ,  1999; Teillet et a l ,  2005). MBL 
recognises specific mannose structures on bacteria (Devyatyarova-Johnson et al., 
2000; Swierzko et al., 2003; Lynch et a l ,  2004), viruses (Gadjeva et a l ,  2004; Botos 
et a l ,  2005; Ji et al., 2005) and fungi (Neth et a l ,  2000; Pellis et a l ,  2005), through 
oligomerisation of three monomers into trimers, which insures a spatial configuration 
appropriate for PAMP binding (Wallis, 2003). Two surfactant proteins (SP), SP-A 
and SP-D, also belonging to the collectin family, are not able to activate the
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complement system, but bind various carbohydrate structures and are involved in 
innate responses to many pathogens (Hickling et a l , 2004; Palaniyar et al., 2004). 
Complement receptor 1 (CR1) and the chaperone protein calreticulin are among the 
candidate receptors for SP-A and SP-D, but the role o f SP-A and SP-D in immune 
responses will be better defined once their receptor(s) has been identified (Hickling 
et a l , 2004).
1.1.1.1.3 Complement proteins
C-reactive protein (CRP) is an acute phase serum protein that belongs to the 
evolutionary conserved family o f pentraxin proteins (Du Clos et a l , 2003). CRP 
binds bacterial phosphocholine in particular, and phosphorylated carbohydrates 
(Volanakis et a l , 1971; Culley et a l , 2000; Lysenko et a l , 2000). CRP, upon PAMP 
binding, primarily activates the complement system by binding complement protein 
Clq. CRP is also able to stimulate intracellular signalling, through Fey receptor 
(FcyR) II, and innate cytokine responses (Ballou et a l ,  1992; Galve-de 
Rochemonteix et a l ,  1993; Chi et a l ,  2002).
Complement protein Clq, like MBL, is often classed as a defence collagen. It has a 
collagen-like domain and globular domains that are able to bind polyanionic 
molecules such as bacterial LPS, as well as membrane components from bacteria, 
viruses and fungi, although precise PAMPs have not been characterised (Gasque,
2004). C lq may share its receptor, mediating phagocytosis and/or signalling 
activities, with SP-A and SP-D (Gasque, 2004; Hickling et a l ,  2004). Complement 
protein C3 can also be activated on the surface o f pathogens by binding 
carbohydrates and proteins. PAMPs-bearing pathogens can then be targeted to the 
complement receptor 3 (CR3, CD1 lb/CD 18). CR3 also possess a carbohydrate 
binding site (Forsyth et a l ,  1998; Brown et a l ,  2005). CR3 is able to recognise p- 
glucan (Thornton et a l ,  1996; Noubir et a l ,  2004) and LPS, and is thought to 
cooperate with other receptors that would mediate activation o f immune responses 
(Ehlers, 2000). CR3 for instance cooperates with CD 14 to stimulate intracellular 
immune signalling (Medvedev et a l ,  1998), possibly through triggering of a TLR. 
CR3 is also indispensable to FcyR Ill-mediated induction o f cytotoxicity (Kushner et 
a l ,  1992; van Spriel et a l ,  2001).
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1.1.1.1.4 Scavenger receptors
Scavenger receptors (SR) have been shown to be able to recognise PAMPs through 
their collagenous domain or their cysteine-rich domain (SRCD) (Linehan et al., 
2000; Taylor et al., 2005). SR-A binds diverse polyanionic ligands. It can recognise 
lipid A from Gram-negative bacteria and LTA from Gram-positive bacteria (Dunne 
et al., 1994). SR-A was also found to bind poly-G sequences and may play a role in 
helping the stimulation o f cytokine production by A-class CpG DNA sequences, 
which is mediated by TLR9 (Lee et al., 2000). CD36 is a different type o f SR, which 
has no collagenous domain. It is a conserved receptor (Franc et al., 1996), and is able 
to recognise diacyl lipopeptides LTA and MALP-2, and contribute to responses 
induced through TLR2/TLR6 (Hoebe et al., 2005; Stuart et al., 2005).
In contrast to the membrane bound or soluble receptors described above, some 
receptors involved in PAMPs recognition and in initiation o f immune responses are 
present in the cytoplasm.
1.1.1.2 Cytosolic receptors
Evolutionary conserved receptors with LRR domains, other than TLRs, can detect 
PAMPs. Nucleotide-binding oligomerisation domain (Nod) proteins Nodi and Nod2 
can mediate activation of signalling pathways in response to LPS (Inohara et al., 
2001; Ogura et al., 2001). Both Nodi and Nod2 recognise peptidoglycan, although 
each receptor specifically detects distinct motifs (Philpott et al., 2004). Nodi senses 
peptidoglycan from Gram-negative bacteria, while Nod2 recognises muramyl 
dipeptide present in peptidoglycan from both Gram-negative and Gram-positive 
bacteria. Nod2 was shown to be involved in controlling Thl cytokine production in 
response to peptidoglycan and muropeptides (Pauleau et al., 2003; Watanabe et al., 
2004; Fritz et al., 2005).
A few IFN-inducible proteins present in the cytoplasm have been shown to bind 
dsRNA and activate signalling pathways. RNA helicase-containing proteins RIG-1 
and mda-5 recognise intracellular synthetic dsRNA poly(I:C) and dsRNA-producing 
viruses (Andrejeva et al., 2004; Yoneyama et al., 2004). dsRNA is also recognised 
by protein kinase PKR, which signals for cytokine production (Balachandran et a l , 
2000; Diebold et al., 2003).
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The immune system has hence evolved to detect pathogens, through the recognition 
o f conserved structures by many innate receptors. Membrane-bound and soluble 
receptors make use o f a variety o f binding domains, including LRR, C-type lectin­
like CRD, cysteine-rich and RNA binding domains, to collectively recognise PAMPs 
from all classes of pathogens, such as bacteria, viruses, fungi and parasites. 
Individual receptors however have defined specificities, and the immune system has 
evolved to gain further specificity through various combinations o f cooperating 
receptors. Combinational recognition o f a PAMP, multiplied by the however many 
PAMPs displayed by a pathogen, allows the immune system to initiate responses 
that, with evolutionary experience, proved to be appropriate to the 
class/species/strain o f the PAMPs-bearing pathogen.
Differential innate immune responses are actually initiated by the triggering o f the 
innate receptors that possess a domain capable o f transducing a signal, in the specific 
context o f other receptors that may form the PAMP-binding complex. The innate 
immune signalling pathways that are activated by PAMPs are being studied 
extensively, to try to decipher the codes for induction of immune responses to 
different pathogens. Current understanding o f signalling pathways activated by 
PAMPs is summarised below.
1.1.2 Activation of innate immune genes
TLRs are a major family o f signalling innate receptors, and results from numerous 
studies have enabled the characterisation of various intracellular events that take 
place when specific PAMPs activate individual TLRs.
TLRs, IL-1 receptors (IL-1R) and IL-lR-related receptors form a superfamily, which 
is defined by a homologous signalling domain called the Toll/IL-IR homology 
domain (TIR) (Gay et a l , 1991; Rock et a l , 1998; O'Neill et a l ,  2000). Notably, 
MyD88, a member of the TLR/IL1-R superfamily that lacks an extracellular domain, 
was found to play an important role in transducing signal from IL-1R (Wesche et a l , 
1997). The role o f MyD88 was studied in the context o f TLR signalling, and the 
contribution o f other TIR-containing molecules as TLR adaptor molecules was 
investigated and characterised.
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1.1.2.1 The TLR/MyD88 pathway
Homologies in the TIR domain o f IL-1R and TLR suggested that, by analogy, TLRs 
may also use MyD88 as an adaptor molecule to transduce signals to the nucleus. 
Indeed, at least TLR2, TLR4, TLR5, TLR7/8, TLR9 and TLR11 have been shown to 
activate NF-kB and subsequent expression o f inflammatory cytokines through 
MyD88 (Kawai et al., 1999; Akira et al., 2004; Coban et al., 2005; Yarovinsky et al.,
2005). In contrast, TLR3 does not share the MyD88 pathway (Akira et al., 2004).
TLR stimulation by ligation o f PAMP and accessory receptors (Kennedy et al., 2004; 
Vasselon et al., 2004; Jiang et al., 2005) promotes the recruitment o f MyD88 to the 
TLR cytoplasmic TIR domain (Akira et al., 2004). When MyD88 and TLR TIR 
domains interact, MyD88, which contains a death domain (DD), can interact with the 
DD of a serine/threonine protein kinase (IL-1R associated protein kinase, IRAK). In 
the case o f TLR2 and TLR4 signalling, another TIR-containing molecule, TIR 
domain-containing adaptor protein (TIRAP), also known as Mai, binds to TLR2 and 
TLR4 and contributes to MyD88 signalling (Homg et al., 2001; Yamamoto et al., 
2002a). MyD88 interaction with IRAK leads to a kinase signalling cascade. IRAK4 
in particular (Suzuki et al., 2002) autophosphorylates and activates IRAKI, which 
dissociates from the receptor complex and associates with TNF-receptor associated 
factor 6 (TRAF6) (Jiang et al., 2002). TRAF6 transmits the phosphorylation signal to 
the IkB kinase (IKK) complex, which in turn activates the transcription factor NF-kB 
(Nomura et al., 2000). NF-kB induces expression of inflammatory cytokines and 
chemokines (Collart et al., 1990; Hiscott et al., 1993; Garoufalis et al., 1994; 
Hoffmann et al., 2005; Osterlund et al., 2005). The MyD88-TRAF6 signalling 
pathway can also activate the transcription factor IFN regulatory factor 5 (IRF5), 
which induces the expression o f inflammatory cytokines (Barnes et al., 2002a; 
Barnes et a l ,  2004; Takaoka et al., 2005). TLR7/8 induce IRF5-mediated production 
o f IFN-a/p (Schoenemeyer et al., 2005). TLR7/8 and TLR9 can additionally activate 
IRF7, which regulates the expression of IFN-a/p (Honda et al., 2004; Kawai et al., 
2004; Honda et al., 2005b; Schoenemeyer et al., 2005; Uematsu et a l ,  2005).
MyD88-independent TLR-mediated responses have been described (Kawai et al., 
1999; Alexopoulou et a l ,  2001; Kawai et al., 2001), and the adaptor molecules 
mediating those responses have been characterised.
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1.1.2.2 The TLR/TRIF pathway
TLR3 and TLR4 can activate MyD88-independent signalling pathways (Kawai et al., 
2005a). It has been found that TIR-containing adaptor molecule TRIF (also known as 
TICAM-1) mediates TLR3-induced NF-kB and IRF3 activation (Yamamoto et al., 
2002b; Hoebe et al., 2003a; Oshiumi et al., 2003a); IRF3 is a nuclear transcription 
factor that induces the expression o f IFN-p (Taniguchi et al., 2001). TIC AM-2, also 
known as Tram, a TIR-containing molecule homologous to TRIF, was shown to 
form a heterodimer with TRIF to bind TLR4 and mediate activation o f IRF3 and NF- 
kB (Fitzgerald et al., 2003b; Oshiumi et al., 2003b; Yamamoto et al., 2003; Cusson- 
Hermance et al., 2005).
IRF3 activation is likely to occur through TRIF-induced phosphorylation o f TRAF- 
family-member-associated NF-kB activator (TANK) binding kinase 1 (TBK1) and 
IKKs (Fitzgerald et al., 2003a; Sharma et al., 2003; McWhirter et al., 2004). TLR3- 
dependent and TLR4-dependent activation o f NF-kB involves phosphorylation o f  
TRAF6 and receptor-interacting protein-1 (RIP1) (Sato et al., 2003; Meylan et a l ,  
2004; Cusson-Hermance et al., 2005). RIP2 may contribute to TLR4-activated 
signalling (Chin et al., 2002; Kobayashi et al., 2002; Lu et al., 2005), possibly 
through a cross-talk between TLR4 and the Nod signalsome.
Indeed, RIP2 interacts with both Nodi and Nod2 and mediates the activation of NF- 
kB (Girardin et al., 2001; Kobayashi et al., 2002).
Intracytoplasmic PRR RIG-1 probably activates IRF3 and NF-kB through signals 
transduced by its caspase recruitment domain (CARD) (Yoneyama et al., 2004). A 
new adaptor, termed IFN-p promoter stimulator (IPS-1), has been shown to contain a 
CARD homologous to RIG-1 and mda-5 domains, and to interact with them (Kawai 
et a l ,  2005b). IPS-1 was found to mediate activation of NF-kB and IL-8 production, 
through RIP1 and Fas-associated death domain (FADD) (Balachandran et al., 2004; 
Kawai et al., 2005b), and to activate IRF3-IRF7 and IFN-a/p expression, through 
TBK1 and IKKe.
The TLR/MyD88 and TRIF pathways are represented in Figure 1.1.
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Figure 1.1. MyD88 and TRIF signalling pathways of Toll-like receptors.
NF-kB and/or IRF3, IRF5 and IRF7 signalling pathways of TLR2, TLR3, TLR4, 
TLR7/8, TLR9, and cytoplasmic helicases RIG-1 and mda-5, that control the 
expression of major immunostimulatory cytokines. Adapted from (Akira et al., 2004; 
Kawai et a l,  2005a) and from reports referenced in 1.1.2.1 and 1.1.2.2.
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A few categories of PAMPs, by stimulating certain TLR or cytolosic receptors, are 
hence able to trigger signalling cascades that control the expression o f IFN-a/p in 
particular, which play an important role in promoting adaptive immune responses.
1.1.3 Induction of IFN-a/p expression
IFN-a/p are also known as type I interferons and belong to a family o f many 
structurally related cytokines, which comprises IFN-a (subdivided into many 
subtypes), IFN-p, IFN-5, IFN-s, IFN-k, IFN-t, IFN-co; all type I IFN bind a unique 
common receptor, the IFN-a/p-R (Pestka et al., 2004). IFN-a/p, first characterised 
for their antiviral properties, were found to play an important role in various aspects 
o f the development of innate and adaptive immune reponses, thereby serving as a 
link between the two arms o f the immune system (Biron, 2001; Le Bon et al., 2002; 
Theofilopoulos et al., 2005).
IFN-P and IFN-a expression relies on the activation of nuclear transcription factors 
NF-kB and/or IRFs. (Merika et al., 2001; Lohoff et al., 2005), and as described in the 
previous paragraphs, stimulation o f some TLR and a few cytosolic PRR activate 
phosphorylation pathways that induce expression o f IFN-a/p. Expression is indeed 
selective, since TLR2 for instance, whether as a TLR2/TLR1 or a TLR2/TLR6 
heterodimer, was found to be unable to induce the expression of IFN-a/p (Kawai et 
al., 2001; Toshchakov et al., 2002), and Nod2 was not able to stimulate the IRF3- 
dependent expression o f these cytokines in response to intracellular bacteria infection 
(Stockinger et al., 2004). In contrast, TLR3, TLR4, TLR7/8, TLR9, PKR, RIG-1 and 
mda-5 can induce IFN-a/p expression. Hence, synthetic dsRNA poly(I:C) was 
shown to induce the secretion o f IFN-a/p through the activation o f TLR3 and 
adaptor TRIF (Hoebe et al., 2003b), or, when located in the cytoplasm, through the 
activation of PKR (Diebold et al., 2003). Secretion o f IFN-a/p was also 
demonstrated in response to stimulation of RIG-1 by infection with Newcastle 
disease virus (NDV), which is an RNA virus (Kato et al., 2005), and in response to 
stimulation o f mda-5 by poly(I:C) (Andrejeva et al., 2004). LPS from enterobacteria, 
lipid A, and vesicular stomatitis virus (VSV), were shown to induce secretion of  
IFN-a/p through CD 14-dependent activation of TLR4 (Jiang et al., 2005), and 
through adaptor TRIF (Hoebe et al., 2003b). Secretion o f IFN-a/p in response to 
imidazoquinoline R-848 (Hemmi et al., 2002) and ssRNA (Diebold et al., 2004) is
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mediated by the activation of TLR7. Infection with influenza virus (Diebold et al.,
2004) or NDV (Kato et a l ,  2005) could also induce IFN-a/p secretion through TLR7 
and adaptor MyD8 8 . It was shown that CpG DNA induce secretion o f IFN-a/p 
through TLR9 and adaptor MyD8 8  (Honda et al., 2005a).
The innate immune system hence relies on different combinations o f receptors to 
stimulate signalling receptors that in turn use different combinations o f TIR domain 
adaptors to activate the transcription o f specific sets of genes, coding for innate 
immune effector functions. Besides the activation of inflammation and microbicidal 
pathways (Schaefer et al., 2004; Remer et al., 2005), PAMP recognition can induce 
the expression of immunomodulatory cytokines, such as IFN-a/p, and costimulatory 
molecules that influence the priming o f adaptive immunity (Dalpke et a l ,  2002; 
Iwasaki et a l ,  2004). Dendritic cells in particular are innate cells that mediate the 
translation o f pathogen recognition by the innate immune system into adaptive 
immunity (Reis e Sousa, 2004).
1.2 Activation of adaptive immunity by dendritic cells
Dendritic cells (DC) are professional antigen presenting cells (APC) that play an 
important role in regulating adaptive immune responses, by tolerising or activating 
naive T cells (Steinman et a l ,  1980; Banchereau et a l ,  1998; Banchereau et a l ,  
2000; Steinman et a l ,  2003). DC inspect their environment by ingesting surrounding 
materials, and processing them into peptides that are presented to T cells. 
Concomitantly, DC integrate signals that may be emitted as a result o f the 
recognition of PAMPs or other signs of danger (Matzinger, 1994), and accordingly, 
either prime T cells or render them non-functional. Processes o f antigen presentation 
and priming are described below.
1.2.1 Antigen presentation
1.2.1.1 Antigen uptake
DC use various mechanisms to internalise antigens (Underhill et a l ,  2002). Large 
volumes o f soluble antigens are efficiently internalised by macropinocytosis 
(Sallusto et a l ,  1995), which is an actin-dependent process. Phagocytosis is also a 
cytoskeleton-dependent type o f internalisation, but is initiated by the engagement of
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specific receptors, which induce actin polymerisation and antigen uptake (Greenberg 
et a l , 2002). Endocytic receptors include some C-type lectins, such as the mannose 
receptor and DEC-205 (Jiang et a l , 1995; Sallusto et a l , 1995), FcyR (Lanzavecchia, 
1990; Regnault et a l , 1999), CR3 (Underhill et a l ,  2002; Gasque, 2004) and 
scavenger receptor CD36 (Platt et a l ,  1998; Gough et a l ,  2000; Stuart et a l ,  2005). 
Actin assembly during phagocytosis is induced through a family o f guanosine 
triphosphatases (GTPases) (Etienne-Manneville et a l ,  2002; Greenberg et a l ,  2002), 
and a role for TLR stimuli in enhancement o f actin assembly has been reported 
(West et a l ,  2004). Endocytic receptors can also mediate actin-independent uptake 
o f macromolecules through clathrin-coated vesicles. Internalised antigens are then 
processed through the MHC II presentation pathways.
1.2.1.2 Antigen processing in the MHC II pathway
DC state of activation regulates MHC II-restricted antigen presentation. Indeed, 
immature DC retain antigens in late lysosomes, where a suboptimal pH slows the 
proteolytic degradation of antigens and of MHC II invariant chain Ii, which blocks 
MHC II binding groove (Lennon-Dumenil et a l ,  2002). In contrast, DC maturation 
(Banchereau et a l ,  2000; Mazzoni et a l ,  2004) induces a better acidified 
environment, and digested peptides and possibly large antigen fragments (Trombetta 
et a l , 2005) bind rapidly to MHC II. The stable peptide-MHC II complexes are then 
transported to endosomal vesicles where they colocalise with costimulatory 
molecules, before being targeted to the cell membrane where they present antigenic 
peptides to CD4+ T cells (Guermonprez et a l ,  2002). PAMPs and inflammatory 
signals such as cytokines, which induce DC maturation, also regulate the formation 
o f  peptide-MHC II complexes (Inaba et a l ,  2000; Manickasingham et a l ,  2000; 
Turley et a l ,  2000; Fiebiger et a l ,  2001; Thery et a l ,  2001).
Antigen presentation to CD8 + T cells occurs via the MHC I pathway, as described 
below.
1.2.1.3 Antigen-processing in the MHC I pathways
Endogenous cytosolic proteins are degraded into peptides by a large catalytic 
multisubunit protease complex called the proteasome (Dick et a l ,  1994; 
Guermonprez et a l ,  2002). Peptides are transferred to the endoplasmic reticulum 
(ER) by specialised transporters (transporters associated with antigen presentation,
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TAP). In the lumen of the ER, a chaperone-mediated assembly generates a stable 
complex containing MHC I, P2-microglobulin and the peptide (Li et a l , 2002). This 
complex then leaves the ER and is transported through the Golgi apparatus to the cell 
surface, where it can present the peptide to CD8 + T cells.
It had been observed that CD8 + T cells could be primed against exogenously 
acquired antigens (Bevan, 1976a; Bevan, 1976b). It was then shown that peptides 
generated from endocytosed antigens could gain access to the cytosol and be 
processed through the MHC I presentation pathway, a process termed cross­
presentation (Pfeifer et al., 1993; Kovacsovics-Bankowski et a l , 1995; Reis e Sousa 
et a l , 1995; Kurts et a l ,  1996; Heath et a l ,  2001). Three internalisation pathways 
may lead to cross-presentation. Macropinocytosis allows constitutive receptor- 
independent cross-presentation o f soluble antigens (Norbury et al., 1995; Brossart et 
a l ,  1997; Norbury et a l ,  1997). Recently, peptides transferred from one cell to 
another through gap junctions were found to be cross-presented (Neijssen et a l ,  
2005). However, the major route for antigen uptake and cross-presentation may be 
phagocytosis (Kovacsovics-Bankowski et a l ,  1995; Gagnon et a l ,  2002). 
Phagocytosis of bacteria (Weiskirch et a l ,  1997; Rescigno et a l ,  1998), o f apoptotic 
and necrotic cells (Albert et a l ,  1998; Fonteneau et a l ,  2002), and antibody- 
opsonised antigens (Regnault et a l ,  1999; Rodriguez et a l ,  1999) can provide 
antigens that are cross-presented. Particulate and cell-associated antigens have 
actually been found to be cross-presented more efficiently than soluble antigens 
(Kovacsovics-Bankowski et a l ,  1993; Li et a l ,  2001). Cell-derived fragments, such 
as carried by exosomes (Thery et a l , 2002), may be a source o f antigens that can be 
cross-presented (Wolfers et a l ,  2001). Heat shock protein (Hsp), released from 
necrotic cells for instance, have also been shown to convey antigens and mediate 
cross-presentation (Singh-Jasuja et a l ,  2000; Binder et a l ,  2001; Binder et a l ,
2005).
Two pathways for peptide loading onto MHC I, TAP and proteasome-dependent or - 
independent, have been described (Castellino et a l ,  2000; Sigal et a l ,  2000; Norbury 
et a l ,  2001; Ackerman et a l ,  2004). The TAP-proteasome-dependent pathway is 
considered dominant, since more efficient. Both phagocytosed and pinocytosed 
antigens can get into contact with ER-like compartments, where they are processed 
for MHC I loading (Gagnon et a l ,  2002; Ackerman et a l ,  2005). Indeed, the ER can
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donate some of its membrane to phagosomes, which become equipped for self- 
sufficient cross-presentation (Ackerman et a l ,  2003; Guermonprez et a l ,  2003; 
Houde et a l ,  2003). Soluble antigens in pinosomes are delivered to the ER, possibly 
by active retrieval or by membrane fusion (Ackerman et a l ,  2005).
While macrophages (Kovacsovics-Bankowski et a l ,  1993; Reis e Sousa et a l ,  1995; 
Castellino et a l ,  2000), B cells (Ke et a l ,  1996; Hon et a l ,  2005) and DC (Rock et 
a l ,  1993; Regnault et a l ,  1999) were all found to cross-present antigens, it was 
demonstrated that DC were sufficient and necessary for cross-presentation and 
functional activation o f CD8 + T cells to take place (Kurts et a l ,  2001; Jung et a l ,
2002). DC are constitutively able to cross-present, but DC maturation, induced by 
innate signals, may enhance this process (Datta et a l ,  2003; Gil-Torregrosa et a l ,  
2004). CD1 lc+ DC have been divided into two subsets according to the expression of 
CD8 a  and myeloid marker CD l ib  (Pulendran et a l ,  1997; Vremec et a l ,  2000). 
CDl lbhighCD8a"CD4+ and C D llb highCD8aCD4‘ DC have been classed as 
“myeloid” DC, while CDl lb lowCD8 a + have been referred to as “lymphoid” DC. 
“Lymphoid” DC were first described as the only subset able to cross-present antigens 
(den Haan et a l ,  2000; Pooley et a l ,  2001), probably through its capacity to 
endocytose dead cells (Iyoda et a l ,  2002; Schulz et a l ,  2002). Actin-dependent 
mechanisms are involved in uptake o f apoptotic cells, and selective inhibition of 
Racl GTPase expression in DC was found to result in decreased uptake o f dying 
cells by CD8 a + DC, and decreased cross-presentation of cell-associated exogenous 
antigen (Kerksiek et a l , 2005). “Myeloid” DC were also shown to be able to mediate 
cross-presentation in the mesenteric lymph node (Chung et a l ,  2005), and in the 
spleen provided that the cells were activated through the FcyR by antibody-opsonised 
antigens (den Haan et a l , 2002). In contrast, CD8a’CD4+ myeloid DC may be more 
efficient at presenting antigens to CD4+ T cells (Pooley et a l ,  2001; den Haan et a l ,  
2002).
Antigen presentation to CD4+ T cells or CD8 + T cells does not necessarily result in 
functional T cell responses. Requirements for effective priming and cross-priming 
are described below.
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1.2.2 Antigen-specific priming of T cells and B cells
T cell receptor (TCR) and B cell receptor (BCR) possess a highly variable antigen- 
binding site, to provide a repertoire that can ensure recognition o f some antigens 
from possibly nearly every pathogen. Binding o f a specific antigen by the TCR or 
BCR however is not sufficient to induce T cell or B cell clonal expansion. Indeed, 
both cell type need to receive a costimulatory signal, also referred to as second 
signal.
1.2.2.1 CD4+T cell priming
TCR on CD4+ T cells recognise peptides, processed from antigens and presented by 
APC, in the context o f MHC II. The second signal required by T cells for 
proliferation is the stimulation o f costimulatory molecule CD28 by members o f the 
B7 family (CD80 and CD8 6  molecules) present on mature APC (Lenschow et a l , 
1996; Janeway et a l , 1998). Stimulation o f CD28 activates IL-2 and IL-2 receptor 
synthesis, which signal the T cells to proliferate (Jenkins et a l , 1991; Cerdan et a l , 
1992; Cerdan et a l , 1995). DC maturation is stimulated by signals induced by the 
recognition of pathogens for instance, and many PAMPs, including peptidoglycan, 
LTA, poly(I:C), LPS from E. coli, flagellin and CpG DNA have been shown to 
induce upregulation o f CD80 and CD8 6  expression on DC in vivo and in vitro (Datta 
et a l , 2003; Schwarz et a l , 2003). It was demonstrated for example that flagellin 
from Salmonella was able to enhance antigen-specific CD4+ T cell expansion, 
through the induction of CD80 and CD8 6  expression (McSorley et a l , 2002). Other 
PAMPs, such as LPS, have also been shown to augment antigen-specific CD4+ T cell 
proliferation and differentiation, in a model of adoptive transfer o f CD4+ TCR 
transgenic T cells specific for a protein antigen (Pape et a l , 1997; Pulendran et a l ,  
2001).
In addition to providing signal 1 (antigen-MHC II complex) and signal 2 
(costimulatory interactions) for CD4+ T cell priming, DC are also central to CD4+ T 
cell differentiation into different types o f effector cells, by providing what is 
sometimes referred to as signal 3: cytokines that polarise CD4+ T cell differentiation 
into type 1 (Thl) or type 2 (Th2) T helpers cells; the function o f Thl and Th2 cells 
will be described later on (Mosmann et a l ,  1989; Kalinski et a l ,  1999). In response 
to microbial stimuli, including LPS from E. coli, DC are able to rapidly produce IL-
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12 (Macatonia et al., 1995; Trinchieri, 1995; Heufler et al., 1996; Magram et a l ,  
1996; Reis e Sousa et al., 1997; Morelli et al., 2001), which is a major factor in the 
development of Thl cells (Macatonia et al., 1995; Trinchieri, 1995; Magram et al., 
1996). Early IL-12 production allows DC to induce, in synergy with IL-18 (Okamura 
et al., 1995), the secretion o f IFN-y by innate cells (Ohteki et a l ,  1999; Fukao et a l ,  
2000; Stober et al., 2001; Kamath et al., 2005), which facilitates Thl differentiation 
(Stoll et al., 1998; Yoshimoto et al., 1998). IFN-y hence contributes to the 
amplification process of priming DC into IL-12 producing cells (Vieira et al., 2000). 
In the presence of microbial stimuli such as heat-killed bacteria, parasite antigen or 
CpG DNA, IL-12-primed Thl reciprocally signal DC to terminally mature into Thl- 
priming cells, by triggering IL-12 production through CD40 signalling (Snijders et 
al., 1998; Schulz et al., 2000; Quezada et al., 2004). Although IFN-a/p alone are not 
sufficient to directly induce antigen-specific Thl development in mice, as opposed to 
humans (Parronchi et al., 1992; Wenner et al., 1996; Rogge et al., 1997; Kadowaki 
et al., 2000), it was found that poly(I:C)-activated murine DC can promote Thl 
polarisation (Celia et al., 1999; Celia et al., 2000). IFN-a/p were shown to cooperate 
with IL-18 to prime Thl cells in response to S. typhimurium (Freudenberg et al.,
2002), and were shown to enhance the priming of IFN-y-producing CD4+ T cells (Le 
Bon et a l ,  2001). It was also demonstrated that IFN-a/p signalling could regulate IL- 
12 production from DC in response to viral infection or stimulation with PAMPs 
(Dalod et al., 2002; Gautier et al., 2005), thereby controlling Thl polarisation.
IL-4 is a major Th2 cytokine, but was not found to play an important role in DC- 
mediated differentiation o f CD4+ T cells into Th2 cells (Schmitz et al., 1994). In 
contrast to the cytokine-induced Thl polarisation, it is possible that Th2 polarisation 
develops by default, as a result o f microbial stimuli that do not stimulate the 
production of IL-12, or o f factors that downregulate production o f IL-12, such as IL- 
10 (Mosmann et al., 1991). In this way, IL-10 is involved in Th2 polarisation in 
response to Schistosoma mansoni for example (Sher et al., 1991; Hoffmann et al., 
2000; Patton et a l ,  2001). Nematode parasite Nippostrongylus brasiliensis was 
shown to drive the differentiation o f adoptively transferred CD4+ TCR transgenic T 
cells into Th2 cells through stimulation of autocrine IL-4 production from antigen- 
specific Th2 T cells (Liu et al., 2005).
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DC are able to induce differential Th polarisation depending on the nature of the 
microbial stimulus. Indeed, TLR enable DC to distinguish between PAMPs. 
Therefore, while LPS from P. gingivalis, which is recognised by TLR2 (Hirschfeld et 
al., 2001), was not able to induce IL-12 production from DC and induced the 
differentiation of antigen-specific T cells into Th2 cells, LPS from E. coli stimulated 
a TLR4-dependent production o f IL-12 from DC and induced Thl polarisation of  
antigen-specific T cells (Pulendran et al., 2001). DC activated by TLR2 agonist 
lipopeptide PamaCSIQ (Takeuchi et al., 2002) similarly induced an antigen-specific 
Th2 polarisation o f CD4+ TCR transgenic T cells (Dillon et al., 2004).
One o f the main functions o f primed CD4+ T cells is the activation o f antigen- 
specific B cells.
1.2.2.2 B cell priming
The BCR recognises motifs on pathogens. Upon BCR binding by a protein antigen, 
B cells behave as APC. Indeed, the antigen-BCR complex is internalised and the 
BCR delivers the antigen to endosomes where it is processed into peptides that are 
then loaded onto MHC II molecules (Lanzavecchia, 1985; Mitchell et al., 1995; 
Stoddart et al., 2005; Trombetta et a l ,  2005). This mechanism allows B cells to 
present peptides from protein antigens to CD4+ T cells and receive accessory signals 
from DC-primed CD4+ T cells that are specific for the same antigen. Accessory 
signals are indeed required for B cell priming against protein antigens (Parker, 1993). 
Signalling through CD40 on B cells in particular is crucial for B cell activation in 
response to protein antigens (Lane et al., 1993; Nonoyama et al., 1993; van Essen et 
al., 1995; Lee et al., 2003b). CD40 on B cells is required for immunoglobulin isotype 
switching, as illustrated by the X-linked hyper IgM syndrome (Aruffo et al., 1993; 
Durandy et al., 1993; Kawabe et al., 1994). The use of anti-CD40 antibodies has 
proved that CD40 stimulation supports antigen-specific B cell-responses by both 
inducing CD4+ T cell help and directly activating B cells (Valle et al., 1989; Carlring 
et al., 2004; Barr et al., 2005).
It has been demonstrated that IFN-a/p enhance B cell responses and promote isotype 
switching (Le Bon et al., 2001). The same study also showed that DC stimulated 
with IFN-a/p were sufficient to mediate these effects.
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It has been reported that B cells can be primed directly by DC, which possibly 
provide cell-contact and cytokine-mediated signals (Dubois et a l ,  1997; Wykes et 
a l ,  1998).
Some microbial carbohydrate structures, including polysaccharides and nucleic 
acids, can activate and costimulate B cells directly, by cross-linking the BCR through 
multivalent motifs (Dintzis et a l ,  1982), or by simultaneously binding the BCR and 
TLR expressed by B cells. Polysaccharide antigens can activate the complement 
cascade through various pathways that generate cleavage products of complement 
protein C3 (Griffioen et a l ,  1991; Carroll, 1998). C3b and C3d for instance opsonise 
microbial carbohydrates and can activate B cells through the BCR and co-receptor 
complex, composed o f CD 19 and complement receptor 1 (CR1, also known as 
CD35), which binds C3b, and CR2 (CD21), which binds C3d (Fearon et a l ,  2000; 
Haas et a l ,  2002; Pozdnyakova et a l ,  2003). CR2 was shown to also play an 
important role in B cell activation against protein antigens (Aheam et a l ,  1996; 
Molina et a l ,  1996). C3b and C3d were found to enhance B cell priming against 
protein antigens (Ross et a l ,  2000; Villiers et a l ,  2003; Bower et a l ,  2004; Haas et 
a l ,  2004).
B cells can be activated by TLR agonists: by lipopetide MALP-2 through TLR2 
(Borsutzky et a l ,  2005), by CpG DNA through TLR9 (Bemasconi et a l ,  2003) and 
by LPS through TLR-related receptor complex RP105/MD-1 (Ogata et a l ,  2000; 
Nagai et a l ,  2002; Yazawa et a l ,  2003). A synergistic effect o f signalling through 
TLR9 and CD40 on B cell activation has been reported (Gantner et a l ,  2003b). 
Stimulation of TLR2, TLR9 or RP105 can also lead to B cell priming against protein 
antigens (Borsutzky et a l ,  2005; Nagai et a l ,  2005; Tudor et a l ,  2005).
1.2.2.3 CD8+ T cell priming
1.2.2.3.1 Direct priming
CD8 + T cell TCR recognises peptides, processed from antigens and presented by 
APC, in the context o f MHC I. As for CD4+ T cells, stimulation o f costimulatory 
molecule CD28 by CD80 and CD8 6  on mature APC provides the second signal 
required by T cells for proliferation. However, in addition to TCR stimulation by 
peptide-MCH I complexes and CD28 activation by B7 molecules, CD8 + T cell 
priming may require other signals, depending on the nature o f the pathogen. Indeed,
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CD8 + T cells may or may not also require CD4+ T cell help (Ahmed et a l ,  1988). 
Priming o f CD8 + T cells against some viruses, such as y-herpesvirus (Cardin et al., 
1996) and Herpes simplex virus 1 (HSV-1) (Jennings et al., 1991) is dependent on 
CD4+ help, while priming against mousepox virus (Buller et a l ,  1987), influenza 
virus (Liu et al., 1989), Sendai virus (Hou et al., 1992), lymphocytic 
choriomeningitis virus (LCMV) (Borrow et al., 1996; Whitmire et al., 1999) or VSV 
(Andreasen et al., 2000; McAdam et al., 2000), and against some intracellular 
bacteria such as Listeria monocytogenes (Shedlock et a l ,  2003b), is independent of 
CD4+ T cell help. CD4-independent CD8 + T cell priming probably reflects the 
properties of some pathogens to stimulate strong DC activation and survival, through 
PAMP-induced signals for example (Schuurhuis et a l ,  2000), and conditioned DC 
would then be able to induce CD8 + T cell priming, through costimulatory signals 
from CD40/CD40 ligand (CD40L, also known as CD 154) (Lee et al., 2003a) or 
B7/CD28 (Andreasen et a l ,  2000; McAdam et a l ,  2000) interactions, and cytokine 
production (Adam et al., 2005) for instance.
In some cases of chronic viral infection, CD4+ T cell help may consist in IL-2 
production that prolongs CD8 + T cell activation (Matloubian et a l ,  1994). In most 
cases, CD4+ T cells provide help by activating the APC that presents the antigen to 
the CD8 + T cell, and the conditioned DC then stimulates the CD8 + T cell, a process 
termed licensing (Guerder et a l ,  1992; Lanzavecchia, 1998). It has been shown that 
CD8 + T cell responses against HSV-1 for example depend on cognate licensing of 
DC by CD4+ T cells (Smith et al., 2004). It has been demonstrated that interactions 
between CD40L on CD4+ T cells and CD40 on DC can activate DC to license CD8 + 
T cell to develop effector functions (Ridge et a l ,  1998). Therefore CD4+ T cell- 
dependent CD8 + T cell priming against viruses such as HSV-1 may also occur 
through CD40L/CD40-mediated activation o f DC. CD40, which expression on DC is 
upregulated by PAMPs (Schwarz et a l ,  2003), is a costimulatory molecule that 
belongs to the TNF receptor superfamily (Quezada et a l ,  2004). CD4+ T cell- 
mediated signalling through CD40 induces further DC activation. Activation o f DC 
can trigger the expression o f other costimulatory molecules from the TNF receptor 
family, such as CD70 (Watts, 2005). CD70 interaction with its ligand CD27 on CD8 + 
T cells has been shown to contribute to the activation of CD8 + T cell effector 
functions (Hendriks et al., 2000; Hendriks et a l ,  2003; Borst et al., 2005).
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In addition to the three-cell (CD4+ T cell-DC-CD8 + T cell) model of CD4+ T cell 
help for CD8 + T cell priming, it has been shown that CD4+ T cells can activate CD8 + 
T cells directly. It has been demonstrated that T cells, through their TCR complex, 
absorb molecules from APC, including peptide-MHC complexes (Huang et a l , 1999; 
Hwang et a l , 2000) and costimulatory molecules (Xiang et a l , 2005). CD4+ T cells 
in particular that acquire peptide-MHC I complexes have been shown to be able to 
prime CD8 + T cells (Kennedy et a l , 2005; Xiang et a l , 2005). CD4+ T cells may 
also signal directly to CD8 + T cells, which can express CD40, through CD40L/CD40 
interactions (Bourgeois et a l , 2002a).
When specific conditions are met, CD8 + T can be primed against antigens that are 
cross-presented, through a process termed cross-priming (Yewdell et a l ,  2005).
1.2.2.3.2 Cross-priminq
As described in paragraph 1.2.1.3, antigens captured by APC can be processed 
through the MHC I presentation pathway. However, the generation o f functional 
CD8 + T cells responses through cross-priming is controlled. Indeed, it was found, 
using the rat insulin promoter (RIP)-mOVA transgenic mouse model (Kurts et a l ,  
1996), that cross-presentation o f self-antigen led to tolerance mechanisms rather than 
cross-priming o f OVA-specific CD8 + T cells (Kurts et a l ,  1997). OVA-specific 
CD8 + T cell tolerance was also observed when OVA, exogenously administered and 
targeted to DC through the endocytic receptor DEC-205, was cross-presented 
(Bonifaz et a l ,  2002). In a model o f mouse tumour cells expressing the defined 
adenovirus ad5ElA antigen, no CD8 + T cell responses were elicited in vivo against 
the tumour, whilst El A was cross-presented (van Mierlo et a l ,  2004). In contrast, 
administration of OVA in combination with microbial products, such as CFA 
(Bennett et a l ,  1997) or CpG DNA (Cho et a l ,  2000), injection o f monophosphoryl 
lipid A (MPL) or CpG DNA into ad5ElA-expressing-tumour bearing mice (van 
Mierlo et a l ,  2004), or induction o f tumour cell apoptosis in vivo (Nowak et a l ,
2003), induced cross-priming against the soluble or tumour cell-associated antigens. 
dsRNA, present in virally infected cells, also promotes cross-priming against virus- 
expressed antigens (Schulz et a l , 2005).
Since CD8 + T cell cross-priming is not constitutive, it has been hypothesised that, as 
for CD8 + T cell direct priming during presentation of endogenous antigens, licensing
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mechanisms control the onset of CD8 + T cell effector activities against cross­
presented antigens (Lanzavecchia, 1998). It was found that in the case o f cross­
presentation o f cell-associated antigens, such as OVA-loaded splenocytes (Bennett et 
a l ,  1997), Ad5El-expressing allogeneic cells (Schoenberger et a l , 1998) and male 
antigen H-Y-expressing cells (Ridge et a l ,  1998), cross-priming required cognate 
CD4+ T cell help. It was demonstrated in CD40- and CD40L-deficient mice that 
CD4+ T cell help was mediated through CD40L/CD40 interactions (Bennett et a l ,  
1998). The use o f activating anti-CD40, or/and CD40L-blocking antibodies 
(Schoenberger et a l ,  1998), in CD4+ T cell-depleted mice (Snapper et a l ,  1987; 
Bennett et a l , 1998) showed that CD4+ T cells stimulated CD40 signalling to induce 
cross-priming against cell-associated antigens (cellular cross-priming).
DC, activated in vitro by anti-CD40 antibodies, were found to be able to induce 
cellular cross-priming (Ridge et a l ,  1998), while B cells were shown to be 
dispensable in vivo (Schoenberger et a l ,  1998). Selective diphteria toxin-induced 
apoptosis o f C D llc  cells in vivo demonstrated that DC mediated the licensing of 
adoptively transferred CD8 + TCR transgenic T cells against Malaria sporozoite- 
infected cells (Jung et a l ,  2002). In a tumour model, adoptive transfer o f CD40- 
proficient and CD40-deficient adElA-specific TCR transgenic CD8 + T cells into 
tumour-bearing CD40-deficient or wild-type mice showed that CD40 expression on 
CD8 + T cells was not required for cross-priming (van Mierlo et a l ,  2004). Those 
experiments support the hypothesis that cellular cross-priming can be licensed by the 
conditioning o f DC by antigen-specific CD4+ T cells through CD40 signalling. How 
stimulation o f CD40 on DC conditions them to license cross-priming is unclear, 
although it has been suggested that CD40L-mediated activation of DC favours 
induction o f cross-priming through other costimulatory molecules interactions, such 
B7/CD28 and CD70/CD27, since antibody-blocking o f B7 molecules and CD70 on 
DC impaired cross-priming (Bullock et a l , 2005).
Although CD80 and CD8 6  may not be sufficient individually to generate signals that 
license cellular cross-priming, these costimulatory molecules were found to be 
involved in the licensing process when both were stimulated (Ridge et a l ,  1998). 
Using B7-and CD28-deficient mice, it has been demonstrated that signalling through 
CD28, even in the absence o f CD4+ T cells, contributes to licensing o f cellular cross­
priming (Prilliman et a l , 2002).
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CD8 + T cells can be cross-primed against soluble antigens in the presence o f some 
microbial stimuli, in which case licensing was found to be CD4+ T cell-independent. 
Hence, CFA and CpG DNA induced cross-priming against soluble antigens in CD4+ 
T cell-depleted mice or CD4-deficient mice (Bennett et al., 1997; Sparwasser et a l , 
2000). It is thought that these stimuli bypass requirements for CD4+ T cell help by 
conditioning DC in their own way for licensing of cross-priming. CpG DNA was 
shown to be able to induce cross-priming independently o f CD40 or CD40L, while 
costimulation with B7 molecules was required (Cho et al., 2002).
It has been suggested that CD40-independent pathways o f DC activation for cross­
priming involve soluble factors such as cytokines (Wild et al., 1999; Lu et al., 2000). 
IL-12 for instance was shown to contribute to the induction of cross-priming against 
a soluble antigen by CpG DNA (Cho et a l , 2002). The role of IFN-a/p was also 
investigated, and induction o f cross-priming by CpG DNA was shown to partially 
depend on IFN-a/p receptor signalling (Van Uden et a l , 2001; Cho et a l , 2002). 
IFN-a/p was characterised as an important soluble licensing stimulus, as viral 
infection-induced IFN-a/p was shown to induce cross-priming against a soluble 
antigen, and DC activation by IFN-a was shown to license cross-priming (Le Bon et 
a l , 2003). It was also demonstrated that IFN-a was able to license cross-priming in 
the absence o f CD4+ T cells and independently of CD40-mediated activation. 
Furthermore, IFN-a was able to provide signals that could replace the CD4+ T cell 
help required for induction o f cellular cross-priming, since cross-priming against a 
cell-associated antigen could be licensed, in the presence o f IFN-a, in MHC IF7'- 
deficient mice.
Whether or not initial priming o f CD8 + T cell effector functions can occur in the 
absence of CD4+ T cells, it is now known that CD4+ T cells are crucial for the 
development o f CD8 + T cell memory, which contributes to protective immunity 
against reinfection (Bourgeois et a l , 2002a; Bourgeois et a l , 2002b; Janssen et a l , 
2003; Shedlock et a l , 2003a; Sun et a l , 2003). CD4+ T cells therefore play a major 
role in orchestrating the adaptive immune response, which is crucial to the defence 
against pathogens, as illustrated by the severe combined immunodeficiency (SCID) 
phenotype, where absence/impairment of T and B cell functions results in 
susceptibility to all classes o f pathogens (Mead et a l , 1991; Chang et a l , 1994; 
Rottenberg et a l , 1999; Ellison et a l , 2000; Bitsaktsis et a l , 2004).
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1.3 The adaptive immune response
T and B cells, once activated in the appropriate conditions, are primed, and thereby 
differentiate into cells that perform specific effector functions, which cooperate to 
eliminate pathogens.
1.3.1 T helper cell responses
CD4+ T helper cells play a strategic role. Their function is to activate and control the 
defence mechanisms that are appropriate for killing the invading pathogen. CD4+ T 
cell priming by DC determines whether T cells differentiate into Thl or Th2 cells. 
Thl and Th2 subsets differ in the cytokines they produce, and thereby activate 
distinct types o f adaptive responses. Thl cells are characterised primarily by the 
secretion o f IL-2, IFN-y and TNF-p (Mosmann et al., 1986; Constant et al., 1997; 
Murphy et al., 2002). IL-2 acts on Thl cells themselves to sustain the clonal 
expansion and therefore increase the number o f effector cells (Bodeker et al., 1980; 
Minami et al., 1993). Thl cells coordinate cytotoxic mechanisms that are directed 
against phagocytosed pathogens. Macrophages are phagocytes that can also process 
and present antigens in the context o f MHC II. Thl cells that recognise peptide-MHC 
II complexes enhance macrophage functions by signalling through CD40L/CD40 
interactions and by secreting cytokines, such as IFN-y and TNF-P, at close range 
(Nathan et al., 1983; Seid et al., 1986; Orme et al., 1993; Soong et al., 1996; 
Mencacci et al., 1998; Yamauchi et a l ,  2000). Activated macrophages increase their 
antigen processing activities, which results in lytic enzyme-mediated killing of 
pathogens and contributes to the priming of more CD4+ T cells. Macrophages also 
secrete IL-12, which promotes Thl polarisation, and increase production of  
microbicidal metabolites, such as nitric oxide (NO) and oxygen free radicals 
(Munoz-Femandez et al., 1992; Ehlers et al., 2003; Shrivastava et al., 2004). If 
macrophages fail to digest phagocytosed pathogens, Thl cells can induce apoptosis 
o f the infected macrophage by binding Fas through its Fas ligand, which triggers 
signalling pathways that lead to DNA degradation and cell death (Hahn et al., 1995). 
IFN-y secretion by Thl cells also activates NK cells, which contribute to the killing 
of pathogen-infected cells by inducing apoptosis, through a process called antibody- 
dependent cell-mediated cytotoxicity (ADCC). Particular antibody isotypes mediate
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ADCC, and Thl cells can promote the production of appropriate antibodies by 
inducing B cell antibody isotype switching (Stevens et a l , 1988), through 
CD40L/CD40 interactions and the secretion of IFN-y (Gracie et a l ,  1996; Sulica et 
a l ,  2 0 0 1 ).
Th2 cells in contrast are characterised primarily by the secretion o f IL-4, IL-5, IL-9 
and IL-13 (Seder et al., 1994). IL-4, in addition to driving the clonal expansion of 
Th2 cells (Femandez-Botran et a l ,  1986; Kim et a l ,  2005b), activates B cells in the 
presence o f CD40 signalling, which results in increased B cell antigen presentation 
capacity, proliferation and differentiation into antibody-secreting plasma cells. IL-5 
and IL-13 also contribute in stimulating B cell growth and differentiation. IL-4 also 
promotes antibody isotype switching to IgGl and IgE (Snapper et a l ,  1987; Lebman 
et a l , 1988), which participate in neutralising pathogen, to prevent infection, and in 
killing pathogens that have not infect cells. IgE-mediated responses are supported by 
IL-5, IL-9 and IL-13, as IL-5 induces differentiation of eosinophils (Yokota et a l ,  
1987) and IL-9 enhances mast cells activity (Hultner et a l ,  1990) while potentiating 
the effects o f IL-4 (Petit-Frere et a l ,  1993). IL-13 and IL-10 contribute to the 
inhibition o f Thl responses by downregulating macrophage inflammatory responses 
(Bogdan et a l ,  1993; de Waal Malefyt et a l ,  1993).
Thl and Th2 CD4+ T cells therefore orchestrate the adaptive immune response, by 
directing the activation o f cells which functions are most appropriate for the 
elimination o f pathogens. Thl cells primarily support cell-mediated immune 
responses that can kill pathogens that are within cells, while Th2 cells induce 
humoural responses that mediate killing of extracellular pathogens.
Antibodies, produced by B cells, contribute to many Thl- and Th2-induced pathogen 
killing mechanisms.
1.3.2 Antibody responses
Antibodies are secreted by B cells that have recognised the antigen they are specific 
for, and have received the appropriate signals to differentiate into plasmablasts, and 
later into plasma cells. In the early stages of the response, mostly IgM antibodies, 
which initially serve as BCR on naive B cells, are secreted. In response to various 
differentiation signals, including cytokines and CD40/CD40L interactions, 
plasmablasts undergo isotype switching and express immunoglobulins o f a different
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isotype. Isotypes have specialised functions. IgM can form pentamers (Parkhouse et 
a l ,  1970; Brewer et al., 1997), and are thereby suited to recognise repeating 
antigens, such as presented by microbial polysaccharides. The pentameric form also 
efficiently activates the complement classical pathway (Davis et al., 1989; Taylor et 
al., 1994). Indeed, the Fc portions of pentamers bound to microbial surfaces are in 
the most appropriate spatial arrangement to bind complement protein Clq and induce 
the conformational change that will activate the complement cascade, resulting in 
pathogen killing by the membrane-attack complex. IgG2a antibodies in mice have 
also a particular ability to activate complement-mediated killing (Oishi et al., 1992; 
Sato et a l ,  1997). IgG2a antibodies bound to pathogens are also able to induce 
killing by cross-linking Fc receptors on macrophages and NK cells (Kipps et a l ,  
1985). Cross-linking o f FcyRIII, as well as FcyRI on macrophages, activates 
intracellular signalling pathways leading to the release o f inflammatory and toxic 
molecules (Sanchez-Mejorada et a l ,  1998). Macrophages express NO, oxygen free 
radicals, antimicrobial peptides and proteases, and NK cells, which like cytotoxic T 
cells contain lytic granules, secrete antimicrobial and apoptosis-inducing molecules 
(Bonnema et a l ,  1994; Jensen et a l ,  1998; Stenger et a l ,  1998; Ernst et a l ,  2000; 
Ochoa et a l ,  2001), resulting in the killing of antibody-coated target pathogens or 
cells. FcyRI can also be activated on phagocytes by IgGl antibodies. IgGl efficiently 
opsonise pathogens by coating them and targeting them to phagocytes through their 
Fc portion. Signalling through FcyRI induces phagocytosis and killing of pathogens 
by enzymes in lysosomes. The killing of extracellular pathogens, parasitic helminth 
in particular, can be mediated by IgE antibodies, which coat parasites and activate 
eosinophils. Indeed, cross-linking o f FceR on eosinophils (Kinet, 1999), among other 
mechanisms (Arase et a l ,  2003), triggers degranulation that can result in the death of  
parasites.
While humoral responses mediate mechanisms effective at killing extracellular 
pathogens, cytotoxic CD8 + T cells are specialised in eliminating intracellular 
pathogens by instructing the infected cell to commit suicide.
1.3.3 Cytotoxic CD8+ T lymphocyte responses
CD8 + T cells that have been primed by the appropriate signals while recognising 
their specific antigen differentiate into CTL that are equipped for target cell killing
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(Oehen et a l ,  1998; Opferman et al., 1999; Morishima et al., 2005) and cytokine 
secretion (Erard et al., 1993; Sad et al., 1995; Kemp et al., 2001; Kemp et al., 2005).
Upon TCR activation, and depending on the cytokine environment, CTL locally and 
systemically secrete cytokines such as IFN-y, TNF-a, IL-4, IL-5 and IL-10, which 
may participate in the immunomodulation o f the response (Prezzi et al., 2001; 
Woodland et al., 2003; Beadling et al., 2005), and, in the case o f IFN-y and TNF-a, 
contribute to the response against intracellular pathogens (Ramshaw et al., 1997; 
White et al., 2000; Lichterfeld et al., 2004). These cytokines can induce the 
expression o f cytosolic proteins that decrease transcription and/or replication of  
several viruses (Wong et al., 1986; Slifka et al., 2000). Cytokines also enhance MHC 
I expression and antigen exposure, recruitment o f cells such as macrophages, and 
enhancement of macrophage antigen presentation and antimicrobial activities. These 
cytokine-induced mechanisms contribute to limiting the spread of intracellular 
pathogens, supporting the primary effector function of CTL, which is to kill infected 
cells.
CTL store perforin, granzymes and Fas ligand in lytic granules, which are part of the 
cell’s secretory lysosome system (Clark et a l ,  2003). When effector cells re­
encounter the antigen on MHC I of infected cells, TCR activation triggers a 
polarisation o f the lytic granules that concentrate at a focal point by the TCR. The 
content o f the granules is thereby secreted by exocytosis specifically towards the 
target cell, in the tight space at the point o f contact between CTL and target cell. 
Exocytosis also controls some o f the surface exposure o f Fas ligand (Bossi et al., 
1999; Haddad et a l ,  2001). Target cells are killed by being instructed to undergo 
programmed cell death, termed apoptosis. CTL can use two mechanisms to induce 
apoptosis: by engaging death receptors on target cells, or by releasing the contents of 
lytic granules. Signalling through death receptor Fas on target cells, activated by Fas 
ligand on CTL, induces cell death through proteolytic cascades that result in the 
breakdown of the nuclear membrane and DNA degradation (Simon et a l ,  2000; 
Thorbum, 2004). It is thought however that CTL killing mechanisms are principally 
mediated by granzymes and perforin (Barry et a l ,  2002; Russell et a l ,  2002). 
Perforin molecules can insert into the target cell membrane and polymerise, forming 
transmembrane pores (Podack et a l ,  1984; Catalfamo et a l ,  2003). Perforin pores 
contribute to osmotic lysis o f cells, but perforin is mainly necessary for effective
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granzyme-induced apoptosis, as illustrated by studies o f apoptosis in perforin- 
deficient mice (Kagi et a l ,  1994; Badovinac et al., 2003). The exact role o f perforin 
in granzyme-induced apoptosis remains to be determined, as it is debated whether 
perforin pores mediate granzyme entry into the target cell, or whether granzymes are 
endocytosed and perforin is involved in the release of granzymes from endosomes 
into the cytosol (Browne et al., 1999; Shi et al., 2005a). Granzyme B is the most 
studied granzyme (Lieberman, 2003). Evidence from various studies suggest that 
granzyme B may be able to enter target cells through receptor-dependent endocytosis 
(Shi et a l ,  1997; Pinkoski et al., 1998), but which receptor mediates uptake is 
controversial (Motyka et al., 2000; Trapani et al., 2003; Dressel et al., 2004; 
Veugelers et al., 2004). Granzyme A and granzyme B are the most abundant 
granzymes. They synergistically induce cell death through DNA degradation (Anel et 
a l ,  1997; Beresford et al., 1999; Fan et al., 2003). Granzyme A attacks the integrity 
of the nuclear membrane, contributes to the opening o f chromatin and activates a 
DNase that cuts into DNA single strands (Russell et al., 2002; Lieberman et al.,
2003). Granzyme A also damages mitochondria, which releases pro-apoptotic factors 
(Martinvalet et al., 2005). Granzyme B, either directly or through a protease cascade, 
activates a DNase that breaks DNA double strands (Lord et al., 2003). Granzyme B 
also damages mitochondria. Other less well characterised granzymes participate in 
the induction o f apoptosis (Grossman et al., 2003).
CTL therefore produce various molecules that deliver signals precisely to target cells 
and induce cell death through numerous pathways, resulting in the coincidental 
killing o f intracellular pathogen in a controlled manner.
CD8 + T cell-mediated responses are indispensable for the control and clearing of  
many viral infections, such as infections with HIV (Matano et al., 1998; Madden et 
al., 2004), HSV (Simmons et a l ,  1992), measles (Permar et al., 2003), EBV 
(Rickinson et al., 1997), bacterial infections with Mycobacterium tuberculosis (Flynn 
et al., 1993; Smith et a l ,  1999), Listeria monocytogenes (Ladel et al., 1994), 
Chlamydia pneumoniae (Rottenberg et a l ,  1999), fungal infections with Histoplasma 
capsulatum (Deepe, 1994), Paracoccidioides brasiliensis (Cano et al., 2000), and 
parasitic infections with Toxoplasma gondii (Parker et al., 1991; Shirahata et al., 
1994). Understanding what induces CD8 + T cell effector functions, and how, is 
particularly important for the rational design o f new safe vaccines. New vaccines are
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indeed much needed against pathogenic intracellular organisms, such as HIV and M. 
tuberculosis for example, which have a heavy impact on public health and can be a 
major cause o f death. Although live-attenuated viruses have been successfully used 
as vaccine agents, it is recognised that risks are associated with this approach. Live- 
attenuated organisms can behave as opportunistic pathogens in immunocompromised 
recipients, and may revert to pathogenic strains and cause disease in healthy 
recipients. Using recombinant protein antigens as vaccines is a safer option, and it is 
known that the induction o f CD8 + T cell responses is not restricted to antigens from 
infectious agents through direct priming, but cross-priming can also elicit functional 
responses, against exogenous antigens. Induction of cross-priming is a controlled 
process. Identifying the signals that initiate the induction o f cross-priming, and 
studying the pathways that authorise cross-priming, will contribute to a better 
understanding o f this process, and detailed knowledge on the induction of cross­
priming is crucial to the design o f potent and safe vaccines.
1.4 Research project objectives
A few microbial stimuli have been reported to induce cross-priming. The aim of this 
project was to assess the ability o f a broader range of microbial stimuli to induce 
cross-priming, and to investigate the mechanisms by which they trigger this 
response. While it is important to ensure the generation of functional CD8 + T cell 
responses, it is often desirable to enhance protective antibody responses. Therefore 
the effect o f these microbial stimuli on the enhancement o f immunoglobulin G 
responses was also assessed. The study was organised into three main parts:
• Study of the effects of Toll-like receptor agonists on the enhancement of 
antibody responses and on the induction of cross-priming
Microbial products have been shown to enhance antibody responses through 
activation of TLR signalling pathways. In addition, some o f the microbial stimuli 
reported to induce cross-priming are TLR agonists, and a category o f agonists was 
shown to induce cross-priming through their specific TLR. Therefore, the effects of  
representative agonists for a range of TLRs on the enhancement o f immunoglobulin 
G responses and on the induction of cross-priming against model protein antigens 
were studied.
45
• Study of the effects of carbohydrate microbial structures on adaptive 
immune responses
Some biochemical structures are shared by organisms across kingdoms. High- 
mannose carbohydrate molecules are exposed by organisms as diverse as bacteria, 
viruses and fungi, and have been found to trigger responses from the adaptive 
immune system. Therefore, in order to further characterise the effect of high- 
mannose molecules on antigen-specific adaptive immune responses, their capacity to 
induce cross-priming, to polarise CD4+ T cell responses and to enhance 
immunoglobulin G responses was assessed.
• Investigation of the mechanisms of induction of cross-priming by 
microbial stimuli
Particular signals, such as IFN-a/p and CD40/CD40L interactions, generated during 
the immune response have been shown to be able to control the licensing of cross­
priming. The contribution o f those signals to the induction o f cross-priming by TLR 
agonists and high-mannose molecules was thus assessed. Since immune responses 
and cross-priming licensing signals can be initiated by the recognition o f microbial 
stimuli by innate receptors, the involvement of relevant innate receptors in the 
induction o f cross-priming by high-mannose carbohydrate molecules was 
investigated.
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Chapter 2
Materials and methods
2.1 Animal model
Inbred mice o f various strains were used as a mammalian model to study the effect of  
particular PAMPS on adaptive immune responses in vivo. All experiments followed 
protocols approved by the Ethical Review Committee o f the Institute for Animal 
Health (IAH) and in accordance with the Animals (Scientific Procedures) Act 1986 
and Home Office guidelines.
2.1.1 Mouse strains
Abbreviation Strain name and characteristics Supplier
B 6 C57B1/6 : CD45.2 (H-2b) Harlan: Harlan UK Ltd., 
Bicester, Oxfordshire, UK 
Institute for Animal Health 
specific pathogen-free (SPF) 
breeding unit: IAH, Compton, 
Berkshire, UK
B 6  CD45.1 C57B1/6: CD45.1 (H-2°) SPF
OT II OT II: all CD4+ T cells express 
a MHC II I-Ab-restricted
O V A 3 2 3 - 3 3 9  -specific TCR (B6 , 
CD45.2/Rag I 7' background)
SPF
129 129/SvEv (H-2b) SPF
IFNa/pR7' IFN-a/p receptor-deficient (129 
background)
SPF
m h c  ir'- I-A-deficient (B6  background) SPF
CD40’'- CD40-deficient: Tnfrsf5'mlK' 
targeted mutation (B6  
background)
JAX® Mice: The Jackson 
Laboratory, Bar Harbor, 
Maine, USA 
Stock number 002928
IL-12'y- IL-12p35-deficient: Il-12atmIJm 
targeted mutation (B6  
background)
JAX® Mice 
Stock number 002692
B10 C57Bl/10ScSnJ: both B6  and 
BIO are sub-lines of the C57B1 
line (H-2b)
JAX® Mice 
Stock number 000476
TLR4'/_ C57Bl/10ScNJ: TLR4-deficient 
(1tlr4lps'del on BIO background).
JAX® Mice 
Stock number 003752
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MR' Mannose receptor-deficient (B6  
background)
Breeding pairs were a gift 
from Prof. Siamon Gordon 
(Sir William Dunn School of 
Pathology, Oxford University, 
UK). These mice originated 
from Prof. Michel C. 
Nussenzweig’s laboratory 
(Laboratory o f Molecular 
Immunology, Howard Hughes 
Medical Institute, The 
Rockefeller University, NY, 
USA). Mice were housed and 
bred at the IAH.
2.1.2 Injection protocols
Microlance™3 needle 30 gauge (GA) BD Biosciences 304000
Microlance™3 needle 27 GA BD Biosciences 302200
Microlance™3 needle 26 GA BD Biosciences 303800
Route o f injection Site o f injection Sample volume_______ Needle GA
Intramuscular (i.m.) Thigh o f each leg 50 pL per leg 30
Intravenous (i.v.) Tail vein 200 pL 27
Intraperitoneal Abdomen 200 pL 26
Subcutaneous (s.c.) Right flank 200 pL 26
2.2 Cell and blood sample preparation
2.2.1 General reagents and buffers
Red Blood Cell Lysing Buffer Sigma R 7757
RPMI 1640 medium
with GlutaMAX™, 25 mM HEPES
Invitrogen (Gibco) 72400
Foetal bovine serum (FBS) Invitrogen (Gibco) 10106
Batch
40G2027K
Phosphate-buffered saline (PBS) pH 7.4 
(lOx)
(10 mM KH2 P 04, 1.54 M NaCl, 30 mM 
Na2HP0 4 .7H20 )
Invitrogen (Gibco) 14200
Distilled water (dH2 Q) Baxter UKF7114
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2.2.1.1 RF10 buffer (RPMI, 10% FBS)
RPMI 1640 500 mL
FBS (heat inactivated) 50 mL
2.2.1.2 Wash buffer RF5 (RPMI, 5% FBS)
RPMI 1640 500 mL
FBS (heat inactivated) 25 mL
2.2.1.3 PBS
PBS 1 Ox 100 mL
dFLO add to 1 L
2.2.2 Preparation of single-cell suspensions
Frosted microscope slides Erie Scientific 2951
Petri dishes Bibby Sterilin 101RT
Cell strainers 45 pm BD Falcon™ 352340
50 mL conical tubes BD Falcon™ 352070
Improved Neubauer counting chamber Weber Scientific International AS 1000
Red Blood Cell lysing buffer Sigma R 7757
Trypan blue stock solution (0.4%) Sigma T 8154
To prepare a single-cell suspension, lymphoid organs collected from mice were 
gently mashed between frosted slides in a Petri dish in RF5 medium (see 2.2.1). The 
cell suspension was filtered through a cell strainer, centrifuged at 300 x g for 7 min 
at 4°C, and red blood cells were lysed in ammonium chloride buffer for 3 min on ice. 
Cells were washed and live cells were counted in trypan blue 0.1%; trypan blue is an 
exclusion dye that stains dead cells violet-blue.
2.2.3 CD8* T cell enrichment
Anti-mouse CD4 hybridoma supernatant 
(clone GK1.5)
In-house preparation (Memory 
Group, EJIVR)
Anti-mouse MHC II hybridoma 
supernatant (clone M5/114.15.2)
In-house preparation (Memory 
Group, EJIVR)
Anti-mouse B220 hybridoma supernatant 
(clone RA36B2)
In-house preparation (Memory 
Group, EJIVR)
Dynabeads® M-450 sheep anti-rat IgG Dynal Biotech 110.08
Dynabeads® M-450 sheep anti-mouse 
IgG
Dynal Biotech 1 1 0 . 0 2
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cEnriched CD8 + T cell were obtained by negative selection using magnetic 
Dynabeads. Splenic single-cell suspensions were pelleted and resuspended in a 
cocktail of anti-CD4, anti-MHC II and anti-B220 antibodies. After 15 min incubation 
on ice, cells were washed and resuspended in RF10 (see 2.2.1) containing a mixture 
o f anti-rat and anti-mouse IgG Dynabeads. After 40 min incubation at 4°C with 
continuous rotation, samples were placed against a cell separation magnet and 
supernatants, enriched in CD8 + T cells, were collected for further use.
2.2.4 CD4* T cell enrichment
Anti-mouse CD8  hybridoma supernatant 
(clone 53-6.72)
In-house preparation (Memory 
Group, EJIVR)
Anti-mouse MHC II hybridoma 
supernatant (clone M5/114.15.2)
In-house preparation (Memory 
Group, EJIVR)
Anti-mouse B220 hybridoma supernatant 
(clone RA36B2)
In-house preparation (Memory 
Group, EJIVR)
Dynabeads® M-450 sheep anti-rat IgG Dynal Biotech 110.08
Dynabeads® M-450 sheep anti-mouse 
IgG
Dynal Biotech 1 1 0 . 0 2
As for CD8 + T cell enrichment, CD4+ T cell were purified by negative selection, 
using a cocktail o f anti-CD8 , anti-MHC II and anti-B220 antibodies followed by 
magnetic separation.
2.2.5 Preparation of antigen presenting cells
2.2.5.1 Reagents and culture medium
2-Mercaptoethanol, 50 mM Invitrogen (Gibco) 31350
Penicillin (10,000 units/mL) / 
streptomycin (10,000 pg/mL)
Invitrogen (Gibco) 15140
Anti-mouse Thy-1.1,1.2 hybridoma 
supernatant (clone T24.2)
In-house preparation (Memory 
Group, EJIVR)
Guinea-pig complement Cedarlane CL4051
RF10 growth medium (RPMI, 10% FBS)
RPMI 1640 500 mL
FBS (heat inactivated) 50 mL
2-Mercaptoethanol 50 mM 0.5 mL
Final concentration is 50 pM
Penicillin (10,000 units/mL) / streptomycin (10,000 pg/mL) 5 mL
Final concentration is penicillin (100 units/mL) / streptomycin 
(100 pg/mL)
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2.2.5.2 T-cell depletion
For enrichment in antigen-presenting cells, splenic single-cell suspensions from 
naive mice were depleted of T-cells by antibody-directed complement lysis. Cells 
were incubated with anti-Thy-1.2 antibodies, in the presence of complement, for 1 h 
at 37°C. Cells were filtered, washed and irradiated at 3,000 rad. Cells were then 
filtered, washed, counted and diluted to the appropriate concentration in RF10 
growth medium.
2.2.6 Separation of mononuclear cells from blood
Heparin (1,000 IU/mL) Leo Laboratories
Histopaque®-1083 Sigma 1083-1
Blood samples were collected on heparin (50 IU/mL final concentration), diluted 1:1 
in PBS and under layered with the polysucrose gradient medium Histopaque®-1083 
(density 1.083 g/mL). Mononuclear cells were isolated by density gradient 
centrifugation at 460 x g for 20 min at RT, with the centrifuge brakes switched off. 
The layer o f mononuclear cells, situated on top o f the gradient medium, was 
collected and cells were washed twice in PBS.
2.2.7 Separation of serum from blood
Blood samples were collected from mice by tail-vein bleeding. Serum was separated 
from clotted blood by centrifugation at 17,530 x g for 20 min at 4°C. Sera were 
stored at -20°C.
2.3 Model proteins and PAMPS
2.3.1 Proteins
Ovalbumin (OVA) grade VI Sigma A 2512
Chicken y globulin (CGG) Jackson ImunoResearch 
Laboratories
003-000-0020
2.3.2 TLR agonists
Peptidoglycan
from Staphylococcus aureus
TLR2/X InvivoGen tlrl-pgn
Zymosan
from Saccharomyces cerevisiae
TLR2/6 InvivoGen tlrl-zyn
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Polyinosinic-polycytidylic acid 
(poly I:C)
TLR3 Sigma P 1530
Lipopolysaccharide (LPS) 
from Escherichia coli
TLR4 Sigma L 4524
R-848 TLR7/8 InvivoGen tlrl-r848
CpG2216
5’-ggG GGA CGA TCG TCg 
ggggg-3’
TLR9 MWG Biotech Custom
synthesis
CpG 2216 control
5’-ggG GGA GCA TGC TGC
ggggg-3’
MWG Biotech Custom
synthesis
C pG 1668
5’-tcc atg acg ttc ctg atg ct-3’
TLR9 MWG Biotech Custom
synthesis
CpG 1720 (CpG 1668 control ) 
5’-tcc atg age ttc ctg atg ct-3’
MWG Biotech Custom
synthesis
2.3.3 Glycolipids
Escherichia coli 09:K9(L9):H12 (E. coli 
0 9 )
National Collection o f Type 
Cultures (NCTC)
9009 Bi 316/42
LPS (E. coli 055.B5) Sigma L 4524
LPS (Porphyromonas gingivalis) InvivoGen tlrl-pglps
LPS from Klebsiella pneumoniae 03:K55 and K. pneumoniae K52 were obtained 
from Dr Susanne Zamze (Carbohydrate Immunology Group, EJIVR). 
Lipooligosaccharides (LOS) from Neisseria meningitidis 44/76 and N. meningitidis 
44/76 mutant 4 were obtained from Dr Graeme Frith (Carbohydrate Immunology 
Group, EJIVR). LPS and LOS were extracted from bacteria by the hot phenol-water 
method.
2.3.3.1 Bacteria culture and extraction of lipopolysaccharide
Luria-Bertani (LB) broth Media Services, IAH
LB agar Media Services, IAH
Phenol Sigma P 1037
Molecularporous membrane tubing 
12,000-14,000 molecular weight cut-off 
(MWCO)
Spectrum 132 700
A sample o f freeze-dried E. coli 0 9  was rehydrated in LB medium according to 
NCTC recommendations, plated onto LB agar and incubated overnight (O/N) at 
37°C. A colony was transferred to 20 mL LB broth to make a starter-culture. After 
incubation O/N at 37°C at 0.4 x g in a shaker, 2.5 mL of starter-culture were cultured 
in 4 L o f LB broth O/N at 37°C at 0.3 x g. The bacterial suspension was centrifuged
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at 10,000 x g for 30 min at 4°C. The pellet was resuspended in 50 mL PBS and LPS 
was extracted with hot 45% aqueous phenol: 50 mL of saturated aqueous phenol 
(90% (w/v)) were heated to 65°C and then added to the equal volume o f pre-heated 
bacterial suspension. The suspension was stirred at 65 °C for 15 min. Phase 
separation was obtained by cooling the preparation on ice before centrifugation at 
230 x g for 15 min at 4°C. The aqueous phase, which contains LPS, was collected. 
LPS extraction from the preparation was repeated, after replacing the aqueous phase 
by an equal volume o f water. The aqueous phases from both extractions were 
combined and dialysed extensively against dLLO, using 12-14,000 MWCO dialysis 
tubing. After dialysis, the solution was ultra-centrifuged at 100,000 x g at 4°C O/N, 
and the LPS pellet was resuspended in dtLO.
2.3.3.2 Purification of glycolipids
Phenol-extracted LPS and LOS and commercial LPSs were further purified by size 
exclusion chromatography in a detergent-containing buffer, to remove LPS- and 
LOS-associated proteins (Andersen et al., 2002).
2.3.3.2.1 Reagents and buffers
HiLoad 26/60 Superdex 75 gel filtration 
column
Amersham Biosciences 17-1070-01
Hiload 26/60 Superdex 200 gel filtration 
column
Amersham Biosciences 17-1071-01
TSKgel G5000PW gel filtration column Tosoh Bioscience 05764
Stericup™ Filter unit 0.22 pm Millipore SCGPU1 ORE
Molecularporous membrane tubing 
6 ,0 0 0 -8 , 0 0 0  molecular weight cut-off 
(MWCO)
Spectrum 132 650
Sodium deoxycholate Sigma D 5670
T ri s-(hydroxymethy l)-aminomethane 
(Tris)
Sigma (Riedel de Haen) 33742
Hydrochloric acid (HCI) 7M VWR(BDH) 18036 5D
Ethylenediaminetetraacetic acid (EDTA) Sigma E 5134
Sodium chloride (NaCI) VWR (BDH) 443827W
Endotoxin-free water InvivoGen Tlrl-h2olal25
Ethanol VWR (BDH) 10107
Sodium deoxycholate (NaDOC) dissociating buffer (20 mM Tris / HCI, pH 8.5, 
2 mM EDTA, 0.154 M NaCI and 1% (w/v) NaDOC)
Tris 2.423 g
pH was adjusted to 8.5 with HCI
EDTA 0.744 g
NaCI 9.009 g
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cdH2 0  add to 1 L
The solution was filtered through a 0.22 pm membrane, using a Stericup™ filter 
unit, before the addition o f NaDOC.
NaDOC 10 g
2.3.3.2.2 Preparative high performance liquid chromatography (HPLC) and 
ethanol- precipitation
Glycolipid samples were solubilised in NaDOC buffer and injected into a Superdex 
75, a Superdex 200 or a TSK G5000 gel filtration column. The refractive index (RI) 
o f the eluant and absorbance at 280 nm were monitored. This method allowed for 
proteins and nucleic acid contaminants to elute separately from LPS and LOS, which 
were detected by an increased RI. Glycolipid-containing fractions were pooled and 
dialysed extensively at RT against dfhO, using 6-8,000 MWCO dialysis tubing. 
After dialysis, samples were freeze-dried. LPS and LOS were precipitated by 
addition o f 0.2 M NaCI and ice-cold 80% (v/v) ethanol (final concentration). LPS 
and LOS pellets were recovered after centrifugation, left to dry and resuspended in 1 
mL of endotoxin-free water.
2.3.3.3 Characterisation of the glycolipid preparations
Purified samples were analysed by polyacrylamide gel electrophoresis (PAGE) in the 
presence o f sodium dodecyl sulphate (SDS), and LPS and LOS were visualised by 
silver staining.
2.3.3.3.1 SDS-PAGE
Mini-PROTEAN II electrophoresis 
Module
Bio-Rad 165-2944
30% Acrylamide/bisacrylamide solution 
29:1
Bio-Rad 161-0156
Tris Bio-Rad 161-0716
SDS Invitrogen (Gibco BRL) 15525-025
Ammonium persulfate Amersham Biosciences 76322
N,N,N ’ ,N ’ -tetra-methy 1-ethy lenediamine 
(TEMED)
Bio-Rad 161-0800
Laemmli sample buffer Bio-Rad 161-0737
2 -mercapthoethanol Sigma M 3148
Tris/glycine/SDS buffer lOx
(25 mM Tris, 192 mM glycine, 0.1%
SDS, pH 8.3)
Bio-Rad 161-0732
Perfect Protein™ molecular weight 
markers 15-150 kDa
Novagen 69149-3
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Buffers and gels were prepared according to (Sambrook et al., 1989a) 
Resolving gel buffer (1.5 M Tris-HCI pH 8.8 and 0.1% SDS)
Tris 18.17 g
pH was adjusted to 8 . 8  with HCI
SDS 10% (w/v) 1 mL
dH20  add to 100 mL
12% polyacrylamide resolving gel
dH20  3.3 mL
30% Acrylamide / bisacrylamide solution 4.0 mL
1.5 M Tris (pH 8 .8 ) 2.5 mL
SDS 10% 0.1 mL
Ammonium persulfate 10% (w/v) 0.1 mL
TEMED 0.004 mL
Stacking gel buffer (0.5 M Tris-HCI pH 6.8 and 0.1% SDS)
Tris 6.06 g
pH was adjusted to 6 . 8  with HCI
SDS 10% (w/v) 1 mL
dH20  add to 100 mL
5% polyacrylamide stacking gel
dH20  3.4 mL
30% Acrylamide / bisacrylamide solution 0.83 mL
0.5 M Tris (pH 6 .8 ) 0.63 mL
SDS 10% 0.05 mL
Ammonium persulfate 10% (w/v) 0.05 mL
TEMED 0.005 mL
SDS-PAGE gels were casted between glass plates (inner plate, 102x82 mm, and 
outer plate, 102x73 mm). Once the resolving gel was set, the stacking gel was poured 
on top and wells were moulded with a Teflon comb. Gels were mounted onto the 
electrode clamping frame, in the electrophoresis tank containing Tris/glycine/SDS 
running buffer. Glycolipid samples were diluted 1:2 in reducing sample buffer 
(Laemmli buffer, 5% (w/v) 2-mercaptoethanol), then heated for 3 min in boiling 
water and deposited into wells in the gel. A 25 mA current was applied between the 
electrodes until the dye front had moved into the resolving gel, then the current was 
increased to 40 mA. The electrophoresis process was stopped when the dye front 
reached the bottom o f the resolving gel.
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2.3.3.3.2 Silver staining of SDS-PAGE gels
Silver staining was performed as described by (Tsai et a l , 1982)
Acetic acid (CH3COOH) VWR (BDH) 10001CU
Periodic acid (I06 H5) Sigma P-5463
Sodium hydroxide (NaOH) Sigma S-8045
Ammonium hydroxide (NH4OH) 28% Sigma A-6899
Silver nitrate (AgNOa) Sigma S-6506
Sodium citrate, tribasic Invitrogen (Gibco BRL) 15584-022
Formaldehyde 37% Sigma (Aldrich) 25,254-9
Methanol Sigma (Fluka) 65543
Fixing solution (40% ethanol, 5% acetic acid)
Ethanol 200 mL
Acetic Acid 25 mL
dH20 add to 500 mL
Oxidising solution (0.7% (w/v) periodic acid in fixing solution)
Periodic acid 0.7 g
Fixing solution 100 mL
Silver staining reagent (0.67% (w/v) AgNOs)
0.1 M NaOH (0.4% (w/v)) 14 mL
NH4 OH 1 mL
A gN 0 3 0.5 g
dH20 58 mL
Developing solution
Sodium citrate 50 mg
Formaldehyde 0.5 mL
dH20 1 L
Glycolipids were fixed in the polyacrylamide gel using fixing solution. Gels were 
incubated for 1 h with gentle agitation on a rotating rocker. The fixing solution was 
replaced with 50 mL of oxidising solution for 5 min. After three 30 min washes with 
dH2 0, freshly prepared silver staining reagent was poured and gels were incubated 
for 10 min. After three 10 min washes with dH2 0, gels were developed until desired 
band intensity was obtained. The reaction was then quenched with 50% methanol for 
a few minutes. Gels were stored in dH2 0.
SDS-PAGE gel drying
DryEase® Mini-gel drying system Invitrogen N12387
Glycerol Invitrogen (Gibco BRL) 15514-011
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Drying solution (30% ethanol, 5% glycerol)
Ethanol 150 mL
Glycerol 25 mL
dH20  add to 500 mL
Stained gels were equilibrated in drying solution, according to manufacturer’s 
instructions, placed between two sheets o f cellophane previously wetted with drying 
solution, and mounted onto a frame to dry.
2.3.3.3.3 Glycolipid quantification
Sodium (meta)periodate (NaI04) Sigma (Fluka) 71859
Purpald
(4-Amino-5-hydrazino-1,2,4-triazole-3 - 
thiol)
Sigma (Aldrich) 16,289-2
LPS (E. coli) Sigma L 4524
LPS (N. meningitidis) 2mg/mL In house-preparation (Dr S. R. 
Andersen, G. R. Guile) 
(Andersen et al., 2002)
Sodium periodate 32 mM
NaI04  684.5 mg
dH20  100 mL
Sodium periodate 64 mM
NaI04  1.369 g
dH20  100 mL
Purpald reagent 136 mM in 2N NaOH
NaOH 800 mg
dH20  10 mL
Purpald 199 mg
Concentrations of the purified glycolipids were determined by comparison with LPS 
standards using the purpald colorimetric assay, as described by (Lee et al., 1999). In 
a 96-well plate, 50 pL samples were oxidised for 25 min with 50 pL o f 32 mM 
N aI04, producing formaldehyde. Addition of 50 pL o f 136 mM purpald reagent led 
to a reaction with formaldehyde. The resulting colourless product was converted to a 
purple chromogene by oxidisation for 20 min with 50 pL of 64 mM NaI04. 
Absorbance was measured at 550 nm.
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2.3.4 Mannan and high-mannose structures
2.3.4.1 Preparation of modified-mannan ovalbumin conjugates
Mannan from Saccharomyces cerevisiae Sigma (Fluka) 63557
Sodium phosphate, dibasic (Na2HP04) Sigma S-9763
Sodium phosphate, monobasic 
(NaH2P0 4 .H20)
Sigma S-3522
Sodium bicarbonate (NaHCCb) VWR (BDH) 102475W
Sodium borohydride (BH4Na) Sigma (Fluka) 71321
Ethylene glycol (C2H6 0 2) Sigma E-9129
PD-10 desalting columns Amersham Biosciences 17-0851-01
Micro BCA™ Protein Assay Kit Pierce 23235
2.3.4.1.1 Mannan oxidisation, conjugation to protein and reduction of 
conjugates
From (Apostolopoulos et al., 1995)
0.1 M phosphate buffer, pH 6.0
From (Sambrook et al., 1989b)
Na2 H P0 4  (in 12 mL dH2 0 )  1.704 g
NaH2 P 04. H 20 (in 8 8  mL dH2 0 )  12.144 g
0.1 M bicarbonate solution, pH 8.0-9.0
NaHCOs 8.4 g
dH20  100 mL
Mannan, at 14 mg/mL in 0.1 M phosphate buffer pH 6.0, was oxidised with 0.02 M 
sodium periodate (final concentration) for 60 min at 4°C. The reaction was quenched 
with 10 pL ethylene glycol/mL o f solution, and the oxidised mannan was separated 
through a PD-10 desalting column equilibrated with bicarbonate solution, pH 8-9. 
Oxidised mannan, eluted in the 2 mL void volume, was mixed with 2.5 mg 
ovalbumin and incubated O/N at RT.
Reduced-mannan ovalbumin conjugates (red-M Ova) were obtained by treating 
oxidised-mannan conjugates (ox-M Ova) with 1 mg/mL sodium borohydride for 3 h 
at RT. Conjugates were used without further purification, and OVA contents were 
verified using a protein assay, based on the bicinchoninic acid (BCA) colorimetric 
assay.
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2.3.4.2 Limulus amoebocyte lysate assay
Limulus amebocyte lysate (LAL) 
ENDOSAFE® kinetic turbidimetric 
assay
Charles River ENDOSAFE
LAL reagent water Charles River ENDOSAFE WL110
Depyrogenated glass test tubes Charles River ENDOSAFE TL700
Depyrogenated pipettes, 1 mL Charles River ENDOSAFE PL 100
Depyrogenated pipettes, 5 mL Charles River ENDOSAFE PL500
Microtest 96-well plates, non pyrogenic BD Falcon™ 353072
Presence o f endotoxin in mannan samples was determined using the LAL assay. 
LAL reagents are prepared from clotting enzymes contained in horseshoe crab blood 
granules. Endotoxin activates the Limulus compounds, which induce gelation and 
increased opacity of the solution tested. The LAL assay was performed in a 96-well 
microplate and was standardised with control endotoxin from E. coli 0 5 5 :B5, 
provided by the manufacturer. Pyrogen-free water was used as a negative control. 
After addition o f LAL reagent to samples and controls, absorbance was read at 37°C, 
every 30 s for 1 h at 349 nm, to determine the kinetics of clotting. Endotoxin values 
were calculated in reference to the E. coli endotoxin onset-time standard curve, using 
the SOFTMax® PRO Kinetic Turbidimetric Protocol with a SPECTRAmax® 
Microplate Spectrophotometer.
2.3.4.3 Preparation of bromelain-cleaved hemagglutinin from Influenza
2.3.4.3.1 Reagents and buffer
Influenza X:31, A/Aichi/ 6 8  (H3/N2) Charles River Laboratories 
(SPAFAS)
490715
Bromelain VWR (Calbiochem) 203761
Tris HCI Sigma T 3253
EDTA Sigma E 5134
2 -mercapthoethanol Sigma M3148
NaCI VWR (BDH) 443827W
Slide-A-Lyser® dialysis cassette (10,000 
MWCO)
Perbio (Pierce) 66380
TEM buffer (0.1 M Tris HCI pH 8.0, 1.3 mM EDTA and 0.05 M 
mercaptoethanol)
Tris HCI 1.576 g
pH was adjusted to 8.0
EDTA 48.4 mg
Mercaptoethanol 351 pL
dH20 add to 100 mL
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2.3.4.3.2 Bromelain-cleaved hemaqgiutinin
Hemagglutinin (HA) was released from Influenza X:31 by digestion with bromelain 
as described by (Brand et al., 1972; Bonnafous et a l , 2000), with slight 
modifications. A virus sample (1 mL at 2 mg o f protein per mL) was thawed on ice 
and pelleted by centrifugation at 55,000 x g for 1 h 30 at 4°C. The pellet was soaked 
in 1 mL TEM buffer for 3 h at RT and then resuspended. Bromelain was added at 
virus/enzyme 2:1 (w/w). After incubation for 17 h at 37°C, the viral cores were 
pelleted by centrifugation at 55,000 x g for 40 min at 4°C, and HA was collected 
from the supernatant. The HA preparation was dialysed against PBS using a 10,000 
MWCO dialysis cassette.
2.4 Measure of cytokine concentration in serum and 
cell culture supernatant
2.4.1 Flow cytometry multiplex assays
Cytometric Bead Array (CBA) 
Mouse Inflammation
BD Biosciences 552364
Mouse Thl/Th2 cytokine CBA BD Biosciences 551287
Concentration o f various immunoregulatory cytokines was measured using flow 
cytometry arrays. These assays are based on cytokines being captured with beads that 
are coated with antibodies specific for different cytokines. The antibodies have 
discrete fluorescence intensities, specific for each cytokine tested and detectable in 
the FL3 channel. Mixed bead populations were incubated with serum samples or 
tissue culture supernatants, in the presence of cytokine detection-antibodies 
conjugated to R-phycoerythrin (PE), which is detectable in the FL2 channel. Capture 
beads, cytokines and detection antibodies formed sandwich complexes; fluorescence 
in FL2 channel was proportional to the quantity of cytokine. Standard curves of FL2 
fluorescence, generated with a range of known quantities of recombinant cytokines, 
allowed for calculations o f the concentration of all cytokines tested in the sample.
2.4.2 Interferon-a ELISA
Mouse Interferon Alpha (Mu-IFN-a) PBL Biomedical Laboratories 42100-1
ELISA kit
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The kit is based on a sandwich ELISA. IFN-a from serum samples was captured first 
by an anti-mouse IFN-a antibody in pre-coated 96-well plates. IFN-a, thus retained 
on the plate after washing, was then detected by a second anti-mouse IFN-a antibody 
conjugated to horseradish peroxidase (HRP). Addition of tetramethyl-benzidine 
(TMB), a HRP substrate, resulted in the formation of a chromogene, which 
absorbance was measured at 450 nm. Concentration of IFN-a in samples was 
calculated in reference to a standard curve.
2.5 Characterisation of immunoglobulin responses
2.5.1 Reagents and buffers
96-well flexible plate BD Falcon™ 353912
Sodium bicarbonate (NaHC03) VWR (BDH) 102475W
Sodium carbonate (Na2C0 3 ) VWR (BDH) 102405Y
Dried skimmed milk MARVEL
Tween 20 Sigma P 7949
Phosphate-buffered saline (PBS) pH 7.4 
(lOx)
(10 mM KH2P04, 1.54 M NaCI, 30 mM 
Na2HP04 .7H20)
Invitrogen (Gibco) 14200
Biotin-conjugated rat anti-mouse IgGl 
monoclonal antibody
BD (Pharmingen) 553441
Biotin-conjugated rat anti-mouse IgG2a 
monoclonal antibody
BD (Pharmingen) 553388
Biotin-conjugated rat anti-mouse IgG2b 
monoclonal antibody
BD (Pharmingen) 553393
Biotin-conjugated rat anti-mouse IgG3 
monoclonal antibody
BD (Pharmingen) 553401
Streptavidin-horseradish peroxidase 
(SAv-HRP) conjugate
BD (Pharmingen 554066
o-Phenylenediamine dihydrochloride 
(OPD) tablets
Sigma P 9187
Hydrochloric acid (HCI) 37% VWR (BDH) 101254H
2.5.1.1 ELISA coating buffer (carbonate buffer, pH 9.6)
2.5.1.1.1 1 M NaHCOs
NaHCOs 8.4 g
dH20  100 mL
2.5.1.1.2 Coating buffer
Na2 C 0 3 1.59 g
NaHCOs 2.93 g
pH was adjusted to 9.6 with 1 M NaHC03
dH2Q add to 1 L
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2.5.1.2 Blocking solution (PBS, 4% (w/v) dried milk)
Dried milk 6  g
PBS 150 mL
2.5.1.3 Serum dilution solution (PBS, 1% (w/v) dried milk, 0.2% Tween)
Dried milk 1 . 5  g
Tween 20 0.3 mL
PBS add to l50m L
2.5.1.4 Detection-antibody dilution solution (PBS, 1% (w/v) dried milk)
Dried milk 2.5 g
PBS 250 mL
2.5.1.5 Wash buffer (PBS, 0.05% Tween)
Tween 20 2.5 mL
PBS 5 L
2.5.1.6 Stop solution (3M HCI)
dH20 374.5 mL
HCI 125.4 mL
2.5.2 ELISA protocol
CGG-specific serum antibody titres were measured using ELISA ten days after i.m. 
immunisation. ELISA plates were coated with 100 pL/well o f 5 pg/mL CGG (see
2.3.1) in carbonate buffer and incubated O/N at RT. The coating solution was 
replaced with 150 pL/well of blocking solution to prevent non-specific binding of 
antibodies to plastic, and plates were incubated for 45 min at 37°C. Plates were 
washed three times and 100 pL/well of sera, in twelve two-fold serial dilutions, were 
transferred to the plates and incubated for 1 h at RT, to allow anti-CGG antibodies to 
bind to the antigen. Plates were washed three times. CGG-specific antibody isotypes 
were detected with 100 pL/well of biotinylated rat anti-mouse Ig antibodies for lh  at 
RT. After three washes, 100 pL/well o f HRP-conjugated streptavidin were added for 
lh  at RT, to bind to biotin and amplify the detection of CGG-specific antibodies. 
Plates were washed three times and OPD, a HRP substrate, was added at 100 pL/well 
to induce a chromogenic reaction. Colour development was stopped by addition of 
50 pL of 3 M HCI before the highest dilution of the highest titre serum rose above 
background. Absorbance was measured at 492 nm. Results were expressed as 
reciprocal endpoint titres, which were determined as first dilution below an arbitrary 
threshold o f positivity for optical densities (OD). The threshold o f positivity was
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calculated for each antibody isotype as the average + 3 SD of all dilutions from three 
control mouse sera (i.e. sera from mice injected with PBS).
2.6 Characterisation of antigen-specific CD8+ T cell 
responses
2.6.1 Tetramer and intracellular granzyme B staining
2.6.1.1 Reagents and buffers
Cyanine-5-conjugated anti-mouse CD8 a 
antibody (anti-CD8-Cy5; clone 
YTS.169)
In-house preparation (Memory 
Group, EJIVR)
Fluorescein isothiocyanate-conjugated 
anti-mouse CD8 a antibody (anti-CD8 - 
FITC)
BD (Pharmingen) 553031
R-phycoerythrin-conjugated H-2Kb- 
SIINFEKL tetramers (Tet-PE)
Prolmmune
Allophycocyanin-conjugated H-2Kb- 
SIINFEKL tetramers (Tet-APC)
Prolmmune
APC-conjugated anti-human granzyme B 
antibody
Caltag Laboratories MHGB05
APC-conjugated mouse IgGl isotype 
control
Caltag Laboratories MG 105
Sodium azide (NaN3) Sigma S 8032
Paraformaldehyde Sigma P 6148
Saponin Sigma S 7900
2.6.1.1.1 Fluorescence-activated cell sorting (FACS) buffer (PBS. 2% FBS. 
0.1% (w/v) azide)
PBS 1 Ox 100 mL
FBS (heat inactivated) 20 mL
Sodium azide 1 g
dH20  add to 1 L
2.6.1.1.2 Fixing stock solution (PBS. 4% (w/v) paraformaldehyde. pH 7.4)
Paraformaldehyde 2 g
A couple o f drops, from a glass Pasteur pipette, of concentrated 
NaOH were added to help paraformaldehyde dissolve, then pH 
was adjusted to 7.4 with HCI
PBS 50 mL
2.6.1.1.3 Permeabilisation buffer (FACS buffer. 0.1% (w/v) saponin)
Saponin 10 mg
FACS buffer 10mL
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2.6.1.2 Staining procedures
Eight days after i.m. immunisation, spleens were removed and CD8 + T cells were 
purified from single-cell suspensions (see 2.2.2 and 2.2.3). Alternatively, blood 
samples were collected from immunised mice at day eight and mononuclear cells 
were purified by density gradient centrifugation (see 2 .2 .6 ).
For tetramer staining, cells were incubated for 30 min at RT with Tet-PE first, 
washed twice with FACS buffer, then stained for 10 min at RT with anti-CD8-Cy5. 
Alternatively, cells were stained with Tet-APC and anti-CD8 -FITC. Labelled cells 
were washed twice before being analysed by flow cytometry.
For intracellular granzyme B staining, cells were labelled with anti-CD8 -FITC and 
Tet-PE, and fixed with 2 % paraformaldehyde in FACS buffer for 20 min on ice. 
After one wash, cells were permeabilised for 10 min at RT, and then incubated for 30 
min at RT with anti-granzyme B-APC or isotype control-APC (Wherry et a l , 2003); 
both antibodies were in solution in permeabilisation buffer. Labelled cells were 
washed twice before being analysed by flow cytometry.
All FACS acquisitions were done on a Becton Dickinson FACScalibur and all data 
were analysed using the CellQuest Pro software from BD Biosciences.
2.6.2 IFN-y ELISPOT
Multiscreen™ plate Millipore MAHAS4510
Purified rat anti-mouse IFN-y 
monoclonal antibody
BD (Pharmingen) 551216
Biotinylated rat anti-mouse IFN-y 
monoclonal antibody
BD (Pharmingen) 554410
Alkaline phosphatase-conjugated goat 
anti-biotin antibody
Vector Laboratories SP-3020
Alkaline phosphatase conjugate substrate 
kit
Bio-Rad 170-6432
OVA(257-264) peptide (SIINFEKL) Custom synthesis IAH
Mixed cellulose-ester membrane plates were coated with anti-IFN-y capture antibody 
at 5 pg/mL in carbonate buffer (see 2.5.1) and incubated O/N at 4°C. CD8 + T cells 
purified from immunised mice (see 2 .6 . 1 .2 ) were seeded in duplicate on the plates, at 
1x10s cells/well in RF10 growth medium, and incubated for 36 h with 5x105 
cells/well syngeneic splenocytes (see 2.2.4), in the presence or absence o f 1 pM 
SIINFEKL peptide. Plates were washed eight times with PBS, then with PBS/0.05%
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Tween 20, and captured-IFN-y was detected by adding biotinylated anti-IFN-y 
antibody for 2 h at 37°C. After eight washes with PBS/0.05% Tween 20, the 
detection step was amplified by an alkaline phosphatase-conjugated anti-biotin 
antibody incubated for 2 h at 37°C. IFN-y spots were visualised on the membrane of 
the plates by adding 5-bromo-4-chloro-3-indolyl phosphate, a substrate for alkaline 
phosphatase, in nitroblue tetrazolium solution. The reaction formed a purple 
precipitate at the site where cells had produced IFN-y. Spots were counted under an 
inverted-light microscope.
2.6.3 In vivo cytotoxic T lymphocyte assay
2.6.3.1 Reagents and buffers
Bovine serum albumin (BSA) Sigma A 4503
5(6)-Carboxyfluorescein diacetate N- 
succinimidyl ester (CFSE)
Molecular Probes C-1157
2.6.3.1.1 PBS. 5% FCS
FBS (heat inactivated)
PBS
2.6.3.1.2 PBS. 0.1% (w/v) BSA
BSA 1 g
PBS 1 L
2.6.3.2 Cytotoxicity assay
The assay was adapted from methods described by (Aichele et al., 1997; Oehen et 
a l ,  1998). OVA-specific cytotoxic activity was assessed by measuring the killing of  
target splenocytes pulsed with SIINFEKL. A suspension of naive splenocytes was 
prepared at 2 x l0 7 cells/mL in RF5 medium and divided into two populations. The 
target population was pulsed with 1 nM SIINFEKL for 1 h at 37°C, while the 
internal control population was not pulsed with peptide. Both populations were then 
washed twice with PBS, 0.1% BSA, and diluted to lxlO 7 cells/mL in PBS, 0.1% 
BSA. Target cells were labelled with a low concentration of CFSE (0.1 pM; 
CFSElow), and unpulsed cells with a higher concentration o f CFSE (lpM; CFSEhlgh). 
Cells were stained for 7 min at 37°C before the reaction was quenched by diluting 
each population into 5 volumes of ice-cold PBS, 5% FCS. Cells were filtered, 
washed three times in PBS and counted. Target and control cells were mixed 1:1 in
50 mL 
add to 1 L
PBS and 2 x l0 7 cells were injected i.v. into syngeneic mice immunised nine days 
earlier. Eighteen hours later, spleens from immunised mice were recovered and 
single-cell suspensions were analysed by flow cytometry to measure the proportion 
of remaining CFSElow cells versus CFSEhlgh. A reduction in the proportion of 
CFSElow cells, compared to percentages of CFSEIow and CFSEhlgh cells in control 
mice, represented SIINFEKL-specific lysis of target cells. Specific lysis was 
calculated as follows:
% specific lysis = 1 - % C F S E low sample % C F S E lowcontrol
V
xlOO. W hen
% C F S E h,gh sample »/oC F SE  high
comparing cytotoxic function between two mouse strains, such as wild-type (WT) 
and knock-out (KO), results were sometimes expressed as a reduction in specific 
lysis in KO mice:
% reduction = 1 -
 ^ % SIINFEKL - specific lysis in KO mouse ^
mean % SIINFEKL - specific lysis in 3 WT mice
x 100
2.7 Characterisation of antigen-specific CD4+ T cell 
responses
Mice were immunised subcutaneously with OVA ± adjuvant and were injected 
intravenously with 1.5 xlO6  OVA-specific CD4+ T cells from lymph nodes of OT II 
mice. Ten days after immunisation, draining inguinal lymph nodes were collected 
and single cell suspensions were prepared. Some cells were used to measure 
proliferation of antigen-specific CD4+ T cell, while the rest was used to quantify 
cytokines produced after re-stimulation in vitro.
2.7.1 Measure of proliferation in vivo
Cyanine-5-conjugated anti-mouse CD4 
antibody (anti-CD4-Cy5; clone GK1.5 )
In-house preparation (Memory 
Group, EJIVR)
FITC-conjugated mouse anti-mouse 
CD45.2 monoclonal antibody (anti- 
CD45.2-FITC)
BD (Pharmingen) 553772
To characterise proliferation o f CD4+ OVA-specific OT II cells, CD4+ T cells were 
purified from lymph nodes (see 2.2.4), then labelled with anti-CD4-Cy5 and anti- 
CD45.2-FITC in FACS buffer for 10 min at RT. Cells were washed and analysed by
flow cytometry. Numbers of OVA-specific CD4+ T cells per draining lymph node 
(dLN) were calculated by multiplying the percentage of CD45.2+ CD4+ cells by the 
total number of dLN cells.
2.7.2 Measure of cytokine production
OVA(323-339) peptide Custom synthesis IAH
(ISQAVHAAHAEINEAGR)
CD4+ T cells, purified from lymph nodes , were seeded in a 96-well plate at lxlO 5 
cells/well in RF10 growth medium, and incubated with 5><105 cells/well syngeneic T- 
depleted splenocytes (see 2.2.5), in the presence or absence o f 5 pM OVA(3 2 3 -3 3 9 ) 
peptide. Culture supernatants were collected after 72 h, and assayed for the presence 
o f IL-2, IFN-y, IL-4, and IL-5 using a Thl/Th2 cytokine CBA kit (see 2.4.1). 
Cytokine concentration, produced from lxlO 6  cells/mL as described above, was first 
expressed as pg/mL per lxlO 6  cells, and then data were normalised by calculating, 
from the percentage o f CD45.2+ CD4+, the amount of cytokine secreted by 105 OT II 
cells. Cytokine concentration produced by OVA-specific CD4+ T cells was finally 
expressed as pg/mL per 105 OT II cells.
2.8 Data analysis
Data were represented as mean ± SD, or individual data points and mean value. 
Analysis o f variance was used to evaluate statistical significance, and a probability 
value o f p<0.05 was considered significant; calculations were made using the one­
way ANOVA test or the ANOVA general linear model, with the Minitab-Release 
13.1 software.
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Chapter 3
Effects of Toll-like receptor stimuli on 
adaptive immune responses
3.1 Introduction
The immune system is able to detect pathogens through the recognition o f highly 
conserved structures present in large groups of organisms, such as bacteria, viruses 
and fungi. Microbe-specific structures have been referred to as pathogen-associated 
molecular patterns (PAMPs). Best-known PAMPs are peptidoglycan, lipoproteins, 
flagellin and DNA from bacteria in general, LPS from Gram-negative bacteria, 
lipoteichoic acids from Gram-positive bacteria, dsRNA and ssRNA from viruses, 
mannan and glucan from fungi (Krieg, 2002; Akira, 2003; Weber et al., 2003; 
Masuoka, 2004; Philpott et al., 2004; Kawai et al., 2005a; Miller et al., 2005; 
Salazar-Gonzalez et al., 2005). Recognition o f PAMPs is mediated by receptors 
referred to as pattern recognition receptors (PRRs). A family of evolutionary 
conserved PRRs, the Toll-like receptors (TLRs), play an important role in the 
detection o f and response to all classes of pathogens, as mice deficient for various 
TLRs have increased susceptibility to particular organisms (O'Brien et al., 1980; 
Woods et al., 1988; Takeuchi et al., 2000; Bellocchio et al., 2004; Tabeta et al., 
2004; Zhang et al., 2004). The study o f immune responses to purified or synthesised 
PAMPs in cells transfected with dominant negative TLRs or in mice deficient for 
individual TLRs has defined some of the specificities o f the different TLRs. For 
instance, zymosan, which is a yeast cell wall fraction (Di Carlo et al., 1958) is 
recognised by TLR2/TLR6 heterodimers (Ozinsky et al., 2000). Cells from TLR2- 
deficient mice were found to show impaired responses to peptidoglycan from Gram- 
positive bacteria (Takeuchi et al., 1999), and it had been previously hypothesised that 
TLR2 may cooperate with TLR10 to mediate responses to peptidoglycan (Akira, 
2003). However, recognition and response to peptidoglycan by TLR2 has since been 
controversial (Travassos et al., 2004). It is thought that cell wall contaminants in 
peptidoglycan preparations may have accounted for TLR2 specificity, and that a 
different set o f proteins, Nodi and Nod2, mediate responses to peptidoglycan
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(Philpott et a l , 2004). Viral dsRNA and synthetic dsRNA (poly(I:C)) can be 
recognised by TLR3 (Alexopoulou et al., 2001). Responses to viral ssRNA, synthetic 
ssRNA and guanosine analogs are mediated by TLR7/TLR8 (Hemmi et al., 2002; 
Diebold et al., 2004; Heil et al., 2004; Lund et a l ,  2004). Responses to CpG DNA 
are mediated by TLR9 (Hemmi et a l ,  2000).
Activation of adaptive immune responses against pathogens is essential for resolving 
infections. Recognition of PAMPs by TLRs not only stimulates the production of the 
costimulatory signals indispensable to the priming of adaptive immune cells, but can 
also promote specific responses that are tailored to pathogens through the activation 
of differential cytokine and chemokine gene expression. Indeed, lipopeptide 
PAM3 CysK4  (TLR2/TLR1), poly(I:C) (TLR3), LPS from E. coli (TLR4), 
imidazoquinoline R-848 (TLR7) and CpG DNA (TLR9) can induce up-regulation on 
antigen presenting cells of costimulatory molecules CD80, CD8 6  and CD40, which 
are necessary to provide the second signal for T cell differentiation into effector cells 
(Hemmi et al., 2000; Hemmi et al., 2002; Hoebe et al., 2003b; Lore et al., 2003; 
Dillon et al., 2004). These PAMPs also stimulate the production o f pro-inflammatory 
(TNF-a, IL-1, IL-6 ) and immunomodulatory (IL-12, IL-4, IFN-a/p, IFN-y) 
cytokines, although different PAMPs may stimulate different classes of responses 
(Hoshino et al., 1999; Hirschfeld et a l ,  2001; Agrawal et al., 2003; Yamamoto et al., 
2003), and references above].
Hence, by modulating the expression of cytokines and costimulatory molecules, 
PAMPs play an important role in directing appropriate adaptive immune responses. 
In addition, many PAMPs have been shown to act as adjuvants on antigen-specific 
responses. Enhancement o f antibody responses against T-dependent antigens by LPS 
from E. coli was described early on (Skidmore et al., 1975; Moreno et al., 1984). 
Some o f the effects o f LPS from E. coli on antigen-specific CD4+ and CD8 + T cells 
have been described (Pape et al., 1997; Pulendran et al., 2001; Hoebe et al., 2003b). 
Poly(I:C), and imidazoquinolines and CpG DNA have also been shown to enhance 
antigen-specific responses (Mota et a l ,  1975; Tighe et al., 2000; Vasilakos et al., 
2000; Lore et al., 2003; Ahonen et al., 2004). Augmented antigen-specific adaptive 
responses in response to Mycobacteria products were shown to depend on TLR 
signalling (Schnare et al., 2001).
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CD8 + T cell responses are an important component of adaptive immune responses 
directed against intracellular pathogens. Priming of CD8 + T cells occurs when CD8 + 
T cells bind MHC I-peptide complexes on APC, in the presence o f licensing signals 
such as CD40L/CD40 interactions (Guerder et al., 1992; Lanzavecchia, 1998). This 
model describes the direct priming of CD8 + T cells by APC that present peptides 
from endogenous antigens. As explained in Chapter 1, activation and differentiation 
of CD8 + T cells against exogenously acquired antigens, presented on MHC I, can 
also take place, provided that APC and T cells have received appropriate signals. 
Priming o f antigen-specific effector CD8 + T cells against exogenous antigens is 
referred to as cross-priming. Some PAMPs, such as poly(I:C) and CpG DNA have 
been found to enhance cross-priming induced by virus-like particles (Schwarz et al., 
2003). Other studies have shown that CpG DNA itself is able to induce cross­
priming (Cho et al., 2000; Sparwasser et al., 2000). When the present study was 
undertaken, it was also shown that cross-priming licensing could be TLR-dependent 
(Heit et a l ,  2003).
However, no systematic study of the effect of a broad panel o f TLR stimuli on 
antigen-specific adaptive responses, in particular cross-priming, had been published 
prior to the studies presented here.
Therefore, the aim of the studies in this chapter was to assess the qualitative effects 
of a range of TLR agonists on the enhancement of adaptive immune responses 
against soluble protein antigens in vivo. To that end, antigen-specific humoral and 
CD8 + T cell-mediated responses in the presence of various representative TLR 
stimuli were characterised in mice.
3.2 Induction of adaptive immune responses by 
classical TLR agonists
A panel o f representative agonists for various TLR was selected (Table 3.1). Doses 
of zymosan (Ara et a l ,  2001), peptidoglycan (Tomasic et a l ,  2000), poly(I:C) (Le 
Bon et a l ,  2001), LPS (Ohta et a l,  1985; Schulz et a l ,  2000; Pulendran et a l,  2001; 
Jones, 2004), R-848 (Tomai et a l,  2000; Hemmi et a l,  2002) and CpG DNA 
(Schwarz et a l ,  2003) were chosen in accordance with previous in vivo studies, and 
it was verified that different doses of the same agonist did not have different effects 
on the enhancement of adaptive immune responses.
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Table 3.1. Toll-like receptor agonists used in this study
TLR TLR2/6 TLR2/? TLR3 TLR4 TLR7 TLR9
Agonist(s) Zymosan 
{S. cerevisiae)
Peptidoglycan 
(S. aureus)
Poly(I:C) LPS 
(E. coli)
R-848 CpG2216 
CpG1668
3.2.1 Effect of TLR agonists on induction of antigen-specific 
humoral responses
In order to test the capacity of TLR agonists to elicit humoral responses against a 
soluble protein antigen, and evaluate the quality of this response, serum titres of 
antigen-specific antibodies o f different IgG isotypes were measured. Chicken gamma 
globulin (CGG) is a poorly immunogenic protein. It has been used previously to 
characterise adjuvants (Le Bon et al., 2001; Jones, 2004), and was also chosen here 
as a model protein antigen. IgG responses were characterised first during a primary 
response (early on and two months after immunisation), then during a secondary 
response.
3.2.1.1 Primary response
3.2.1.1.1 Early immunoglobulin G responses
C57B1/6 mice were injected once intramuscularly (i.m.) with CGG alone, or CGG in 
combination with different TLR agonists. Titres of CGG-specific IgGl, IgG2a, 
IgG2b and IgG3 were measured in the serum ten days later, using ELISA (see 2.5.2).
Consistent with the results o f Le Bon and colleagues, CGG induced relatively weak 
IgG responses against itself, consisting mainly o f IgGl (mean titre ± SD: 26,667 ± 
19,610) and very little IgG2a (583 ± 719), IgG2b (1,867 ± 998) or IgG3 (317 ± 342). 
Co-administration of TLR agonists increased CGG-specific IgG responses, each 
agonist enhancing the production of one or more IgG isotypes (Figure 3.1). Results 
are expressed as fold increase in antibody endpoint titre compared to titres induced 
by CGG alone.
Titres of anti-CGG IgGl were higher in mice immunised with CGG + zymosan, 
CGG + poly(I:C) or CGG + CpG 2216, compared to IgGl titres in mice injected with 
CGG alone (Table 3.2). Peptidoglycan, LPS, R-848 and CpG 1668 had no effect on 
this response.
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All agonists except peptidoglycan were able to increase anti-CGG IgG2a titres, albeit 
to a varying extent. Potent responses were induced by zymosan, poly(I:C), CpG 2216 
and CpG 1668, while LPS induced a moderate but significant increase in levels of 
CGG-specific IgG2a. R-848 had a weak effect (5.9 ± 3.9-fold increase).
Anti-CGG IgG2b responses were also enhanced significantly. The greatest increases 
in IgG2b titres were induced by zymosan, poly(I:C) and LPS, to an equal extent, and 
by CpG 2216. CpG 1668 and R-848 also increased CGG-specific IgG2b levels.
A few TLR agonists had an effect on the generation of anti-CGG IgG3. Poly(I:C), 
CpG 2216 and CpG 1668 enhanced the response by over 50-fold. Levels o f IgG3 
were also increased by LPS. R-848 was a weak inducer of anti-CGG IgG3 (5.5 ± 3.6- 
fold increase), while zymosan and peptidoglycan were both ineffective.
Table 3.2. Enhancement of primary anti-CGG antibody responses by TLR agonists.
CGG + 
zymosan
CGG + 
poly(I:C)
CGG + 
LPS
CGG + 
R-848
CGG + 
CpG 2216
CGG + 
CpG 1668
IgGl 7.7 ± 0.0
p=0.000
6.4 ± 1.8 
p=0.017
<6.0 <6.0 7.7 ± 0 .0
p=0.000
<6 .0
IgG2a 32.9 ± 15.5 
p=0.044
58.5 ±20.7  
p=0.017
7.3 ±2 .6  
p=0.036
<6.0 73.1 ±20.7
p=0.008
21.9 ± 0 .0
p=0.000
IgG2b 91.4 ±25.9
p=0.008
91.4 ±25.9
p=0.008
91.4 ±25.9
p=0.008
18.3 ±6 .5
p=0.020
128 ±68.4 36.6 ± 12.9
p=0.018
IgG3 134.7 ± 133.4 94.3 ± 50.4
p=0.022
188.6 ± 100.8 <6.0 134.7 ±38.1
p=0.008
53.9 ± 19.1 
p=0.017
p, statistical significance determined by one-way ANOVA test (titres induced by CGG + agonist 
versus titres induced by CGG alone).
The table shows fold increases in anti-CGG antibody endpoint titres at day 10, compared to titres in 
mice injected with CGG alone, in mice immunised once at day 0 with CGG and TLR agonist (mean ± 
SD, n=3). Only agonists that induced at least a seven-fold enhancement o f fold increase in anti-CGG 
antibody endpoint titres are included in the above table.
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Figure 3.1. The effect of TLR agonists on primary antigen-specific antibody 
responses. C57B1/6 mice were injected i.m. with 100 pg chicken y-globulin (CGG) 
alone or CGG in combination with zymosan (5 mg), peptidoglycan from S. aureus 
(PGN) (200 pg), poly(I:C) (100 pg), LPS from E. coli (10 pg), R-848 (200 pg), CpG 
2216 (20 nmol), CpG 2216 control (20 nmol), CpG 1668 (20 nmol) or CpG 1668 
control (20 nmol). Ten days after immunisation, serum samples were collected and 
titres of CGG-specific IgGi, IgG2b, IgG2a and IgG3 were measured using ELISA. 
Results are expressed as fold-increase in CGG-specific antibody titre compared with 
titres in mice immunised with CGG alone. Data are represented by mean ± SD for 
three mice per group. * p<0.05 versus CGG immunisation group, by one-way 
ANOVA test.
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3.2.1.1.2 Long-term immunoglobulin G responses
In order to test whether TLR agonists could generate a long-lasting CGG-specific 
primary IgG response, titres o f anti-CGG IgGi, IgG2a, IgG2b and IgG3 were 
measured in the serum sixty days after immunisation (protocol described in 
paragraph 3.2.1.1.1). Results are expressed as fold increase in antibody endpoint titre 
compared to titres induced by CGG injected alone.
Figure 3.2 shows that very low titres of CGG-specific IgGi, and virtually no CGG- 
specific IgG2a, IgG2b and IgG3 were present at day 60 in mice previously injected 
with CGG alone. In contrast, most agonists, co-administered sixty days earlier with 
CGG, were able to elicit anti-CGG IgG responses that were still stronger, two 
months after immunisation, than responses in mice injected with CGG alone.
More specifically, at day 60, in mice previously immunised with CGG + zymosan, 
CGG + poly(I:C) or CGG + CpG DNA, CGG-specific antibodies of three or more 
IgG isotypes were still present and at higher titres than in mice previously injected 
with CGG alone (Table 3.3). Responses enhanced by a previous immunisation with 
CGG + R-848 were rather restricted to anti-CGG IgG2b and IgG3 isotypes. At day 
60, CGG-specific antibody titres in mice immunised with CGG + PGN or CGG + 
LPS were not much higher than titres in mice injected with CGG alone.
Table 3.3. Enhancement of long-term anti-CGG antibody responses by TLR agonists.
CGG + 
zymosan
CGG + 
poly(I:C)
CGG + 
R-848
CGG + 
CpG 2216
CGG + 
CpG 1668
IgGi 49.2 ± 13.9
p=0.008
16.0 ± 10.6 8.6 ± 4 .6 12.3 ±3 .5
p=0.011
< 6.0
IgG2a 12.8 ±4 .5  
p=0.023
64.0 ± 18.1
p=0.008
<6 .0 89.6 ± 47.9 22.4 ± 12.0
IgG2b 332.8 ± 220.2 153.6 ± 0 .0
p=0.000
102.4 ±36.2  
p=0.017
281.6 ±237.4 89.6 ± 47.9
IgG3 <6.0 10.7 ±3.8
p=0.022
224.0 ± 207.4 86.7 ±58.5 224.0 ± 207.4
p, statistical significance determined by one-way ANOVA test (titres induced by CGG + agonist 
versus titres induced by CGG alone).
The table shows fold increases in anti-CGG antibody endpoint titres at day 60, compared to titres in 
mice injected with CGG alone, in mice immunised once at day 0 with CGG and TLR agonist (mean ± 
SD, n=3). Only agonists that induced at least a seven-fold enhancement o f fold increase in anti-CGG 
antibody endpoint titres are included in the above table
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Figure 3.2. The effect of TLR agonists on long-term antigen-specific antibody 
responses. C57B1/6 mice were injected i.m. with 100 pg chicken y-globulin (CGG) 
alone or CGG in combination with zymosan (5 mg), peptidoglycan from S. aureus 
(PGN) (200 pg), poly(I:C) (100 pg), LPS from E. coli (10 pg), R-848 (200 pg), CpG 
2216 (20 nmol), CpG 2216 control (20 nmol), CpG 1668 (20 nmol) or CpG 1668 
control (20 nmol). Sixty days after immunisation, serum samples were collected and 
titres of CGG-specific IgGi, IgG2b, IgG2a and IgG3 were measured using ELISA. 
Results are expressed as fold-increase in CGG-specific antibody titre compared with 
titres in mice immunised with CGG alone. Data are represented by mean ± SD for 
three mice per group. * p<0.05 versus CGG immunisation group, by one-way 
ANOVA test.
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3.2.1.2 Secondary response
In order to test the ability o f TLR agonists to generate memory antigen-specific IgG 
responses, titres of anti-CGG IgG isotypes were measured in the serum after 
rechallenge with CGG. Mice were immunised once with CGG alone or with CGG + 
agonist, as described in paragraph 3.2.1.1.1, and rechallenged 61 days later with 
CGG only. In order to assess the mounting of a memory response, rather than a new 
primary response, CGG-specific titres were measured in the serum five days after 
rechallenge, whereas a primary IgG response would necessitate more than seven 
days to form. Endpoint titres of CGG-specific IgGi, IgG2a, IgG2b and IgG3, on the 
day before and five days after rechallenge, are shown in Table 3.4 and Figure 3.3.
Mice that were injected only once with CGG, at day 61, had no anti-CGG antibodies 
at day 66, confirming that mice were not able to mount a primary antibody response 
to CGG within five days, as opposed to the low primary response that developed 
within ten days (see 3.2.1.1.1). CGG-specific IgGi, IgG2a, IgG2b and IgG3 titres 
induced by CGG, injected alone at day 0 first, increased insignificantly after 
rechallenge with CGG on day 61.
In contrast, anti-CGG IgGi titres increased efficiently after antigenic rechallenge in 
mice immunised with CGG + zymosan, CGG + peptidoglycan, CGG + poly(I:C) and 
CGG + CpG 2216. Mice initially immunised with CGG + LPS, CGG + R-848 or 
CGG + CpG 1668 were also able to mount a secondary response.
All agonists except peptidoglycan elicited anti-CGG IgG2a responses that could be 
significantly recalled upon rechallenge. In particular, zymosan, poly(I:C) and CpG 
1668 were very potent inducers of IgG2a memory responses. In mice immunised 
with CGG + R-848, CGG + LPS or CGG + CpG 2216, anti-CGG IgG2a titres after 
rechallenge were over 30 times greater than before rechallenge.
Secondary anti CGG-IgG2b responses were most significant in mice immunised with 
CGG + zymosan and CGG + CpG 2216. Recall responses also developed, though to 
a lesser extent, in mice immunised with CGG + peptidoglycan, CGG + LPS or CGG 
+ CpG 1668. Mice immunised with CGG + R-848 or CGG + poly(I:C) were not able 
to mount a proper secondary anti-CGG IgG2b response.
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Figure 3.3. The effect of TLR agonists on secondary antigen-specific antibody 
responses. C57B1/6 mice were injected i.m. with PBS or 100 pg chicken y-globulin 
(CGG) alone or CGG in combination with zymosan (5 mg), peptidoglycan from S. 
aureus (PGN) (200 pg), poly(I:C) (100 pg), LPS from E. coli (10 pg), R-848 (200 
pg), CpG 2216 (20 nmol), CpG 2216 control (20 nmol), CpG 1668 (20 nmol) or 
CpG 1668 control (20 nmol). Sixty-one days after immunisation, mice were 
rechallenged i.p. with 100 pg CGG. Six days later, serum samples were collected and 
titres of CGG-specific IgGi, IgG2a, IgG2b and IgG3 before rechallenge (■ ) and 
after rechallenge (ODBI) were measured using ELISA. Results are expressed as 
CGG-specific antibody endpoint titre. Data are represented by mean ± SD for three 
mice per group. * p<0.05 versus CGG immunisation groups (before and after 
challenge), by ANOVA General Linear Model test.
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Secondary anti-CGG IgG3 were also most significant in mice immunised with CGG 
+ zymosan and CGG + CpG 2216. Titres increased more than ten times in mice 
immunised with CGG + R-848. Recall responses were moderate in mice immunised 
with CGG + poly(I:C) or CGG + CpG 1668, but absent in mice immunised with 
CGG + peptidoglycan or CGG + LPS.
Overall, all agonists were able to induce significant recall anti-CGG IgG responses, 
of one or more isotypes.
Table 3.4. Enhancement of memory anti-CGG antibody responses by TLR agonists.
CGG + 
zymosan
CGG + 
PGN
CGG + 
poly(I:C)
CGG + 
LPS
CGG + 
R-848
CGG + 
CpG2216
CGG + 
CpG 1668
IgGi I 53 ±15 53 ± 1 9 17 ± 11 0.6 ± 0.3 9.3 ± 5 .0 13 ± 4 3.3 ±0 .9
II 1024 ± 0 171 ± 6 0 768 ± 362 19 ± 10 149 ± 80 3 4 1 ± 121 256 ± 18
p=0.000 p=0.005 p=0.019 p=0.005
IgG2a I 1.6 ±0 .0 0.1 ±0 .0 4.3 ± 1.5 0.1 ±0 .0 0.7 ± 0.2 6.4 ± 0.0 2.4 ± 1.1
II 307 ± 145 1.7 ± 1.1 307 ± 145 5.3 ± 1.5 34 ± 12 307 ± 145 341 ± 9 7
p=0.018 p=0.018 p=0.001 p=0.004 p=0.018 p=0.001
IgG2b I 17 ± 11 1.2 ±0 .6 55 ±53 0 ± 0 8 ± 0 19 ± 10 8.7 ±5 .7
II 384 ± 181 6.7 ± 1.9 96 ±45 2.3 ± 1.2 19 ± 10 171 ± 6 0 64 ±45
p=0.021 p=0.008
IgG3 I 0.3 ±0.1 0.2 ± 0.0 0.8 ±0.8 0.2 ± 0.0 0.5 ± 0.3 0.3 ±0.1 0.5 ±0.3
II 4.7 ±2.3 0.2 ± 0.0 2.8 ±3 .6 0.2 ± 0.0 5.8 ±7.3 4.7 ±2.5 1.8 ± 1.5
p=0.037 p=0.04
I, antibody titres at day 60. II, antibody titres at day 66. p, statistical significance determined by 
ANOVA General Linear Model test (titres induced by CGG + agonist at day 66 compared to day 60 
versus titres induced by CGG alone at day 66 compared to day 60).
The table shows anti-CGG antibody endpoint titres at day 60 (before rechallenge) and at day 66 (after 
rechallenge) in mice immunised once at day 0 with CGG and TLR agonist (mean xlO3 ± SD, n=3).
In summary, all the TLR agonists tested were able to induce primary and secondary 
antigen-specific IgG responses, with both responses characterised by isotype 
switching. Thus, all have adjuvant properties in the induction o f humoral responses. 
Overall, the addition o f zymosan, poly(I:C) or CpG DNA to a soluble protein antigen 
generated or increased primary and memory IgG responses of all isotypes, while 
LPS, R-848 and peptidoglycan had a more restricted effect.
In addition to studying the effects o f TLR agonists on the enhancement of adaptive 
humoral responses, a major aim of this work was to investigate the effect o f TLR 
agonists on CD8+ T cell responses, more precisely their potential to induce cross­
priming.
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3.2.2 Effect of TLR agonists on induction of antigen-specific 
CD8+ T cell responses
As described in Chapter 1.2.2.3.2, cross-priming refers to the generation of  
functional CD8+ T cell responses against an exogenous antigen. The ability of TLR 
agonists to induce cross-priming against a soluble antigen was assessed here. 
Ovalbumin (OVA) was chosen as a model protein antigen to test the capacity o f TLR 
agonists to stimulate antigen-specific CD8 T+ cell responses. OVA is a poorly 
immunogenic protein, which constitutes an efficient tool to follow antigen-specific 
CD8+ T cell as well as CD4+ T cell responses. Indeed, dominant epitopes have been 
described for mouse MHC I (OVA 2 5 7 - 2 6 4 )  and MHC II (OVA 3 2 3 - 3 3 9 )  and transgenic 
mice, with TCR specific for each MHC-peptide complex, have been engineered. 
OVA was thus chosen as a model soluble protein antigen, to study antigen-specific 
CD8+ and CD4+ responses
L
C57B1/6 mice, which have a H-2 haplotype, received a single injection i.m. with 
OVA either alone or in combination with a TLR agonist. To first assess whether TLR 
agonists were able to induce expansion of OVA-specific CD8+ T cells, the frequency 
of CD8+ T cell bearing SIINFEKL-specific TCR was measured in spleen eight days 
after immunisation, using H-2Kb-SIINFEKL tetramers and FACS analysis (see
2.6.1). Representative FACS analysis dot plots are shown in Figure 3.4A. No 
tetramer-positive (Tet+) cells could be detected in naive mice or mice injected with 
OVA (Figure 3.4B). Similarly, zymosan, peptidoglycan, LPS or R-848 could not 
induce any detectable OVA-specific CD8+ T cells population. In contrast, co­
administration o f poly(I:C) or CpG DNA (CpG 2216) with OVA induced expansion 
of SIINFEKL-specific CD8+ T cells: 1.2 % Tet+ ± 0.4 and 0.6% ±0.1 , respectively.
As a first approach to assess the generation of functional OVA-specific CD8+ T cells, 
SIINFEKL-specific CD8+ T cells able to produce IFN-y were enumerated ex vivo 
after restimulation in vitro, using IFN-y ELISPOT assay (see 2.6.2). Spots were 
counted to evaluate the frequency (/) o f OVA-specific CD8+ T cells producing IFN- 
y;/ was expressed as the number o f IFN-y spots per 106 CD8+ T cells (Figure 3.4C).
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Figure 3.4. TLR 3 and TLR 9 agonists induce functional cross-priming against 
OVA. C57B1/6 mice were injected i.m. with 500 pg ovalbumin (OVA) alone or 
OVA in combination with zymosan (500 pg), peptidoglycan from S. aureus (PGN) 
(100 pg), poly(I:C) (100 pg), LPS from E. coli (10 pg), R-848 (50 nmol), CpG 2216 
(20 nmol) or CpG 2216 control (20 nmol). (A,B) Eight days after immunisation, 
SIINFEKL-specific CD8+ T cells in spleens were quantified using Kb-SIINFEKL 
tetramer staining. (A) Representative FACS dot plots of tetramer staining. The value 
in the right comer o f each panel represents the percentage o f tetramer-positive (Tet+) 
cells among CD8+ T cells. (B) Percentage o f Tet+ cells gated on CD8+ T cells. Data 
are represented by mean ± SD for three mice per group. (C) Eight days after 
immunisation, splenic CD8+ T cells were assessed for SIINFEKL-specific IFN-y 
secretion by ELISPOT assay. Results are expressed as the number o f spots per 106 
CD8+ T cells. Data are represented by mean ± SD for three mice per group.
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No spots could be detected after stimulation in the absence o f peptide. An increase in 
the number o f spots, in comparison to naive mice (2 spots ± l ,/= 2 7  ± 12) or mice 
injected with OVA alone (3 spots ± 2,7=42 ± 25), was only detectable from mice 
immunised with OVA + poly(I:C) (124 spots ± 29,/=1861 ± 564) or OVA + CpG 
2216 (47 spots ± 18,7=703 ± 255).
Results from tetramer staining and ELISPOT assay showed that immunisation with 
OVA in combination with poly(I:C) or CpG DNA induced OVA-specific CD8+ T 
cell responses, and that some of the antigen-specific CD8+ T cells generated had 
differentiated into effector cells producing IFN-y.
To characterise further the functional properties o f OVA-specific CD8+ T cells 
generated in the presence o f TLR stimuli, the cytotoxic potential o f these cells was 
assessed.
The principal mechanism used by cytotoxic CD8+ T cells to induce apoptosis of 
target cells is the secretion of lytic granules into the immunological synapse. Since 
granzymes, cell-death-inducing enzymes, are essential components of the granules, it 
was of interest to measure their expression in antigen-specific CD8+ T cells 
generated in the presence TLR stimuli. However, reagents to detect any of the 
murine granzymes species were not commercially available, and only the anti-human 
granzyme B antibody provided by Caltag Laboratories (Burlingame, CA, USA) was 
known to cross-react with mouse granzyme B. Expression of granzyme B by OVA- 
specific CD8+ T cells was thus examined by intracellular staining (see 2.6.1) and 
FACS analysis (Figure 3.5). Representative FACS analysis histograms are shown in 
Figure 3.5A. The shift in fluorescence intensity illustrated the expression of 
granzyme B by OVA-specific CD8+ T cells, in mice immunised with OVA + 
poly(I:C) or OVA + CpG DNA. Distribution o f granzyme B expression, in the 
CD8+/Tet+ cell population, was also examined (Figure 3.5B). Results showed that 
20.3% ± 3.2 o f OVA-specific CD8+ T cells expressed granzyme B after 
immunisation with OVA + poly(I:C), and 35.1% ± 6.0 after immunisation with OVA 
+ CpG DNA.
Expression o f granzyme B is another indication that antigen-specific CD8+ T cells, 
primed in the presence of poly(I:C) or CpG DNA, have differentiated into effector 
cells that are potentially cytolytic.
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Figure 3.5. TLR 3 and TLR 9 agonists induce the production of cytolytic 
enzymes in antigen-specific CD8+ T cells. C57B1/6 mice were injected i.m. with 
OVA (500 pg) in combination with poly(I:C) (100 pg) or CpG 2216 (20 nmol). 
Eight days after immunisation, splenic CD8+ T cells were stained with K - 
SIINFEKL tetramer and for intracellular granzyme B. (A) Representative FACS 
histograms of splenocytes from a mouse immunised with OVA + poly(F.C) or OVA 
+ CpG 2216. Splenocytes, enriched in CD8+ T cells, were stained with anti-
granzyme B antibody ( — ) or isotype control ( ---- ). Events were gated on CD8+
tetramer-positive (Tet+) T cells. (B) Results are expressed as percentage of granzyme 
B-positive cells (GrB*), with events gated on CD8+ Tet+ cells. Data are represented 
by mean ± SD for three mice per group.
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Figure 3.6. TLR 3, TLR 4 and TLR 9 agonists induce antigen-specific 
cytotoxicity in vivo. C57B1/6 mice were injected i.m. with 500 pg OVA alone or 
OVA in combination with zymosan (5 mg), peptidoglycan from S. aureus (PGN) 
(180 pg), poly(I:C) (100 pg), LPS from E. coli (10 pg), R-848 (260 nmol), CpG 
2216 (20 nmol), CpG 2216 control (20 nmol), CpG 1668 (20nmol) or CpG 1668 
control (20 noml). Nine days after immunisation, SIINFEKL-specific CD8+ T cell 
cytotoxic activity was determined by in vivo CTL assay: naive splenocytes were 
pulsed with SIINFEKL, labelled with CFSElow and co-injected i.v., in a 1:1 ratio, 
with CFSEhlgh control splenocytes, into immunised and control mice. (A) 
Representative FACS histograms o f CFSE-positive cells recovered from the spleen 
of immunised and control mice, 18 h after i.v. injection. The value in the left comer 
of each panel represents the percentage of SIINFEKL-specific cytotoxicity. (B) 
Results are expressed as percentage of SIINFEKL-specific lysis for three individual 
mice per group; horizontal lines represent the mean percentage of lysis for each 
group. * p<0.05 versus control by one-way ANOVA test.
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To specifically test the cytotoxic function of OVA-specific CD8+ T cells, CTL assays 
were performed in vivo (see 2.6.3). Representative FACS analysis histograms, 
showing loss of SIINFEKL-pulsed targets cells in a mouse immunised with OVA + 
poly(I:C), compared to a control mouse and as opposed to a mouse injected with 
OVA alone, are presented in Figure 3.6A. Data from the in vivo CTL assay are 
presented as percentage o f SIINFEKL-specific lysis (see 2.6.3.2) (Figure 3.6B). 
OVA injected on its own did not generate OVA-specific CTL. Only four agonists 
were able to. In mice immunised with OVA and LPS, 11.1% ± 4.6 (p=0.035) of 
targets were killed. That percentage was 59.9 ± 10.7 (p=0.013) in mice immunised 
with OVA + poly(I:C), 20.5 ± 6.5 (p=0.002) with OVA + CpG 2216, and 41.3 ± 8.8 
(p=0.003) with OVA + CpG 1668. No lysis, or less than an average o f 5% lysis 
occurred in mice immunised with OVA and the other agonists.
In summary, of all TLR agonists tested, only poly(I:C), LPS and CpG DNAs were 
able to induce functional antigen-specific CD8+ T cell responses.
3.3 Induction of adaptive immune responses by non- 
classical lipopolysaccharides
Lipopolysaccharides (LPSs) are glycolipids synthesised by Gram-negative bacteria 
and integrated in the bacteria outer membrane. Although the precise chemical 
structure of LPSs varies among bacteria species and strains, LPSs generally contain 
the following three major components: lipid A, which is the endotoxin moiety of  
LPS (Galanos et al., 1985), the core polysaccharide, and the polysaccharide side 
chains, also called O-polysaccharide or O-antigen. Lipid A is a disaccharide that 
carries negatively charged phosphate groups and acylated fatty acids. The exact 
nature of the disaccharide, the degree of phosphorylation and number/location of  
negative charges, and the structure, position and number of hydrophobic acyl side- 
chains contribute to defining the shape of lipid A (Rietschel et al., 1994). For 
example, lipid A with six and possibly seven acyl chains, such as lipid A from E. coli 
or Klebsiella pneumoniae, form a conical structure, while lipid A with five acyl 
chains, such as from P. gingivalis, form a predominantly cylindrical structure 
(Schromm et a l , 1998; Schromm et a l,  2000). Importantly, it is thought that 
immunological properties of LPS may depend on lipid A conformation (Brandenburg
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et a l ,  1993; Schromm et a l ,  1998; Schromm et a l,  2000; Netea et a l,  2002; Stover 
et a l,  2004).
The identification o f endotoxin-tolerant C3H/HeJ and C57Bl/10ScCr mouse strains 
(Sultzer, 1968; Watson et a l ,  1974; Coutinho et a l,  1977; Hoffmann et a l ,  1977; 
Michalek et a l ,  1980) and characterisation of a single gene (Lps) mutation 
encouraged the search for the endotoxin receptor(s) (Watson et a l ,  1978). When the 
innate immune receptor TLR4 was described (Rock et a l ,  1998), and assigned to a 
chromosomal region that corresponded to the location of Lps, it was postulated that 
TLR4 was the receptor for endotoxin/LPS. After cloning o f the mouse tlr4 gene, the 
exact mutation responsible for the phenotype o f C3H/Hej and C57Bl/10ScCr mice 
was characterised (Poltorak et a l,  1998; Qureshi et a l ,  1999), and the generation and 
study of TLR4-deficient mice confirmed that immunological responses to endotoxin 
depended on TLR4 (Hoshino et a l ,  1999).
TLR4, within the CD14-TLR4-MD-2 complex, is generally considered as the 
receptor for LPS. The majority of studies investigating the role of TLR4 in 
recognition o f and signalling to endotoxin/LPS have used LPS from E. coli or 
Salmonella spp. as prototypic LPSs. However, LPSs from non-enterobacterial 
organisms, such as LPSs from periodontal bacteria P. gingivalis and Prevotella 
intermedia (Kirikae et a l ,  1999; Hirschfeld et a l,  2001; Pulendran et a l,  2001), or 
LPS from atypical spirochete Leptospira interrogans (Werts et a l ,  2001) have been 
shown to activate immune responses independently of TLR4. P. gingivalis lipid A 
was shown to activate immune cells from endotoxin-tolerant mice (Ogawa et a l,  
1996; Tanamoto et a l ,  1997) and it has been hypothesised that the lipid A 
structure/conformation may be responsible for the fact that LPS from P. gingivalis 
and other TLR4-independent LPSs have a different agonist-receptor specificity 
(Werts et a l ,  2001; Erridge et a l ,  2004).
Neisseria meningitidis synthesise and transport to their outer membrane a glycolipid 
called lipooligosaccharide (LOS). LOS is analogous to LPS as it shares similar lipid 
A structures and core polysaccharide, although LOS lacks O-antigen units (Preston et 
a l,  1996). N. meningitidis lipid A is hexa-acylated, and its LOS was shown to induce 
cytokines and chemokines production through CD14/TLR4 signalling pathways 
(Mirlashari et a l ,  2003; Moller et a l ,  2003; Zughaier et a l ,  2004). LOS from N.
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meningitidis is often put into the same category as LPS. While still recognising that 
LOS presents singularities, LOS will be referred to as LPS in the work reported here.
While the effects o f various LPS structures on stimulation o f innate inflammatory 
responses have been investigated (Hirschfeld et a l,  2001; Werts et a l ,  2001; 
Zughaier et a l ,  2005), little has been reported on the effect of glycolipids with 
different conformation on adaptive immune responses (Pulendran et a l,  2001).
The aim o f the studies presented in this section was to determine the capacity of  
LPSs from different bacteria species to induce functional cross-priming against a 
soluble protein antigen. LPSs included in this study were from E. coli, from K. 
pneumoniae, from N. meningitidis and from P. gingivalis.
3.3.1 Preparation of lipopolysaccharides
The LPSs prepared are dispersable in aqueous solvents. They could therefore be 
extracted from the bacterial cell wall using hot aqueous phenol (Westphal et a l,  
1965) (see 2.3.3). LPS separate into the aqueous phase, while most protein (Morrison 
et a l,  1976) and nucleic acids (Sambrook et a l ,  1989b) separate into the phenol 
phase. Since it has been reported that protein contaminants can co-purify with lipid A 
and/or LPS, and that these endotoxin proteins may have immune activity (Hirschfeld 
et a l ,  2000), extracted LPSs were further purified using gel filtration 
chromatography, with a detergent-containing buffer (Manthey et a l ,  1994a; Manthey 
et a l ,  1994b; Andersen et a l ,  2002). Sodium deoxycholate in the chromatography 
running buffer helps dissociating LPS micelles and separate potential endotoxin- 
associated proteins.
A representative gel filtration elution profile and SDS-PAGE migration pattern are 
illustrated in Figure 3.7. Chromatograms, obtained from monitoring the absorbance 
(OD) and refractory index (RI) (Figure 3.7A), show that components with a high OD 
(above 1.00 AU) and low RI (under 5,000 MV) eluted from the column between 135 
min and 150 min after injection. Components with a high RI (above 40,000 MV) but 
with hardly any OD (less than 0.005) eluted between 230 min and 250 min after 
injection. Elution fractions with the highest RI contained LPS, while proteins and 
nucleic acids, carried over from the phenol-extraction procedure, had a high OD but 
very low RI. More importantly, they eluted 100 min earlier than LPS.
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Figure 3.7. Purification and characterisation of lipopolysaccharides: 
representative chromatography and electrophoresis profiles. After hot-phenol 
extraction from bacteria, LPSs were purified by gel filtration in sodium deoxycholate 
dissociating buffer, and characterised by SDS-PAGE. (A) HPLC elution profile of 
LPS from K. pneumoniae K52 (Kp K52), using a Superdex 75 column. The upper 
panel represents absorbance at 280 nm and the lower panel shows the refractive 
index (RI). The arrow ( hH ) indicates the range of elution fractions that were 
collected and pooled. (B) Electrophoretic mobility in 12% SDS-polyacrylamide gel 
of HPLC-purified LPS from E. coli 055:B5 (Ec 055:B5) and from K. pneumoniae 
K52 (Kp K52), as visualized by silver staining.
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%Thus, the chromatograms described above show that major known contaminants 
were successfully separated from the LPS fraction.
LPSs have characteristic electrophoresis migration patterns, which are in relation to 
the LPS structure. Lipid A is the lipid fraction of LPS; it is a disaccharide to which 
fatty acids are linked (Raetz, 1990). The polysaccharide fraction o f LPS consists of a 
core polysaccharide that is connected to the O-polysaccharide, which contains 
repeating units of sugar sequences that may be branched. The size o f the O-antigen 
affects the size and electrophoretic characteristics of LPS. LPS, such as LPS from E. 
coli 0 5 5 :B5 (Figure 3.7B), thereby generally displays a migration pattern where 
medium molecular weight ladder-like bands represent different degrees of 
glycosylation of the O-antigen. The lipid A attached to the core polysaccharide 
appears as a broad small molecular weight band (Lei et al., 1991). In contrast, some 
LPSs have no O-antigen, and LPS from K. pneumoniae K52 is one example. 
Consequently, LPS K52 banding pattern on SDS-PAGE (Figure 3.7B) shows the 
migration o f a broad band of small molecular weight molecules, which consist of the 
lipid A plus core polysaccharide moiety only.
3.3.2 Effect of different lipopolysaccharides on antigen- 
specific CD8+ T cell responses
To test the ability o f different LPSs to induce antigen-specific CD8+ T cell responses, 
MHC I-restricted antigen-specific cytotoxicity was assessed in vivo. C57B1/6 mice 
were injected i.m. with OVA alone or in combination with various LPSs. An in vivo 
CTL assay was performed nine days after immunisation (Figure 3.8). Results are 
expressed as percentage of SIINFEKL-specific lysis of target cells. No lysis was 
triggered in mice injected with OVA alone. With the exception of LPS from P. 
gingivalis, all LPSs were able to induce SIINFEKL-specific lysis: 31.4% ± 11.7 with 
LPS from E. coli, 51.4% ± 19.9 with LPS from K. pneumoniae, and 46.3% ± 20.6 
with LPS from N. meningitidis.
In summary, LPSs from other bacteria species than E. coli, such as K. pneumoniae, 
and N. meningitidis, also have the capacity to elicit functional antigen-specific CD8+ 
T cell responses. However, not all LPSs share that adjuvant property, since LPS from 
P. gingivalis was not able to induce antigen-specific CD8+ T cell responses.
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Figure 3.8. Lipopolysaccharides from different bacteria species induce 
functional cross-priming. C57B1/6 mice were injected i.m. with 500 pg OVA alone 
or OVA in combination with LPS from E. coli 0 5 5 :B5 (Ec 055) (10 pg), LPS from 
K. pneumoniae K52 (Kp K52) (10 pg), LPS from N. meningitidis 44/76 (Nm 44/76) 
(10 pg) or LPS from P. gingivalis (Pg) (10 pg). Nine days after immunisation, OVA- 
specific CD8+ T cell cytotoxic activity was determined by in vivo CTL assay. Results 
are expressed as percentage of SIINFEKL-specific lysis. Data are represented by 
mean ± SD for three mice per group.
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3.4 Conclusions and discussion
The aim of the studies in this chapter was to characterise further the effect of 
individual TLR stimulus on antigen-specific humoral and cellular responses, in a 
study where a range a representative TLR agonists would be assessed in parallel, 
using the same model.
Results demonstrated that all the TLR agonists tested were able to enhance specific 
IgG antibody responses to a soluble protein antigen, but that only some agonists were 
able to induce specific CD8+ T cell responses against an exogenous soluble protein 
antigen.
Zymosan, poly(I:C) and CpG DNA were efficient humoral adjuvants. Firstly, they 
greatly enhanced the primary IgG response to a protein antigen. The response they 
stimulated was characterised by the production of most IgG isotypes, and in 
particular all three agonists increased levels of antigen-specific IgG2a antibodies. 
Secondly, zymosan, poly(I:C) and CpG DNA enhanced and maintained long-term 
IgG responses, since antigen-specific IgG antibodies of at least three different 
isotypes, including IgG2a and IgG2b, were still present two months after initial 
priming, without additional injection of antigen or adjuvant. Finally, zymosan, 
poly(I:C) and CpG DNA stimulated the generation of memory IgG responses. 
Indeed, five days after rechallenge with antigen only, antigen-specific antibody 
responses were enhanced, compared to responses before rechallenge, in mice that 
had been immunised once, two months earlier, with TLR agonist + antigen. 
Antibody responses were measured within five days after rechallenge, in order to 
exclude the contribution of antibodies produced by newly primed B cells. 
Enhancement o f antigen-specific IgG2a responses was again a common feature.
In comparison with work related to the adjuvanticity of CpG DNA, few studies have 
reported on the effect of zymosan and poly(I:C) on the enhancement of antigen- 
specific antibody responses. Results presented here however confirm that zymosan 
and poly(I:C) augmented IgG2a and IgGi responses (Wilder et a l , 1996; Ara et a l , 
2001; Le Bon et a l , 2001).
The two CpG DNA sequences used belong to two distinct classes. CpG 2216 is a D- 
type sequence (A-class), which is characterised by a mixed phosphodiester- 
phosphorothioate oligodeoxynucleotide backbone. CpG 1668 is a K-type sequence
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(B-class), which has a phophorothioate backbone. A-class CpG sequences have been 
reported to stimulate plasmacytoid DC and NK cells functions in particular (Balias et 
a l,  1996; Krug et al., 2001), while B-class CpG sequences have been reported to 
primarily stimulate B cell proliferation (Krieg et a l,  1995). In contrast to the 
statement that A-class CpG DNA (CpG 2216) stimulate weaker antigen-specific 
antibody responses than B-class CpG DNA (CpG 1668) (Krieg, 2002), both CpG 
DNA sequences were found here to have similar potent effects on antibody responses 
against CGG. CpG 2216 even promoted a broader range of IgG isotypes. It is 
possible that A-class CpG DNA poly(G) motifs, which stabilise A-class CpG DNA 
conformation (Kerkmann et al., 2005) and may mediate CpG DNA binding to 
various receptors and chaperones (Verthelyi et a l,  2003; Kerkmann et a l ,  2005), 
may be responsible for CpG DNA increased endosomal retention (Honda et a l,  
2005a), which increases the stimulation of MyD88-IRF-7 signalling. This may 
represent an advantage for CpG 2216 in enhancing antigen-specific antibody 
responses and isotype switching.
LPS and R-848 were also able to enhance primary and memory antigen-specific IgG 
responses and both promoted the production of IgG2a antibodies, as opposed to 
peptidoglycan, which only weakly enhanced antibody responses against the protein 
antigen. Augmented antigen-specific IgGi, IgG2a and IgG2b titres in response to 
peptidoglycan have been reported, but three weekly-apart injections of peptidoglycan 
were required (Tomasic et a l,  2000). If TLR2 is involved in responses to 
peptidoglycan (Netea et a l ,  2004; Watanabe et a l,  2004), then differences observed 
between the adjuvant effects o f zymosan and peptidoglycan on the enhancement of 
antigen-specific antibody responses may show that TLR are able to differentially 
respond to stimuli, probably through different combinations of cooperating receptors, 
such as TLR2 with dectin-1 for detection o f zymosan, and possibly TLR2 with Nod- 
2 for detection of peptidoglycan from Gram-positive bacteria (Brown et a l,  2003; 
Gantner et a l,  2003a; Girardin et a l ,  2003).
The adjuvant activity of zymosan, poly(I:C), LPS, R-848 and CpG DNA on the 
enhancement of antigen-specific IgG responses was characterised by the promotion 
of various isotypes, which have different functions, although all isotypes generally 
contribute to preventing harmful attachment of the antigen-carrier to cells by 
neutralising the antigen. Every agonist promoted the production of antigen-specific
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IgG2a antibodies, which are characterised by a particular capacity to induce 
antibody-mediated cellular cytotoxicity (ADCC) by NK cells and macrophages 
(Adams et al., 1984; Herlyn et al., 1985; Koh et al., 2000). IgG2a antibodies, along 
with IgGi, can also induce complement-mediated cytotoxicity (CMC) (Klaus et a l , 
1979; Herlyn et al., 1985; Sensel et al., 1997), and are efficient activators of the 
complement classical pathway, which assists antigen removal. Zymosan and soluble 
yeast P-glucan, for instance, were shown to induce CMC-dependent tumour rejection 
in a mouse model (Yan et al., 1999; Hong et al., 2003). Antigen elimination is also 
helped by IgG2a and IgGi acting as opsonising antibodies, which can target the 
antigen to phagocytes. Promotion o f antigen-specific antibody responses that mediate 
ADCC, CMC and/or pathogen neutralisation contributes to protection against 
pathogenesis. For example, the adjuvant effect o f LPS on enhancement of antibody 
responses was applied to improve protection against bacterial and viral diseases in 
mouse models (Berinstein et al., 1993; Nelson et al., 2004). The adjuvant effect of 
CpG DNA on enhancement of specific IgG2a antibodies, against both infectious 
agents and tumours, has been reported in many studies (Weiner et al., 1997; Kwant 
et al., 2004; Hayashi et al., 2005; Shi et al., 2005b). Interestingly, although CpG 
2216 and CpG 1668 were found to enhance antigen-specific IgG responses similarly, 
differences in which effector cell type are activated for ADCC have been reported: in 
the presence of A-class CpG, ADCC was mediated by NK cells, while both NK cells 
and granulocytes were effectors in the presence B-class CpG (van Ojik et al., 2003).
As mentioned above, zymosan, poly(I:C), LPS, R-848 and CpG DNA were able to 
enhance antigen-specific primary and memory IgG responses. Such stimulation of 
specific B cell responses suggests that the agonists provided signals during initial 
priming that were integrated by immune cells and translated into B cell activation 
and antibody class switching, but also stimulated B cell differentiation into memory 
B cells and in some cases long-lived antibody secreting plasma cells (Manz et al., 
2005; Shapiro-Shelef et a l ,  2005). Cognate CD4+ T cell help is known to support B 
cell responses through CD40L/CD40 interactions (Castigli et al., 1994; Ahonen et 
al., 2002; Eaton et al., 2004). This suggests that agonists may have also enhanced the 
generation of antigen-specific CD4+ T cells, and promoted Thl responses that 
stimulated the production of antigen-specific antibodies of the IgG2a isotype. 
Zymosan, LPS from E. coli and R-848 for example were found to increase antigen-
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specific CD4+ T cell responses, which in the case of LPS were directly proven to 
provide help for antigen-specific IgG2a antibody production (Pape et al., 1997; 
Vasilakos et al., 2000; Ara et al., 2001; Wille-Reece et al., 2005).
Other cell types may contribute to promoting isotype-switching. Activation of NK 
cells by poly(I:C) can increase antigen-specific IgGi and IgG2a responses (Wilder et 
al., 1996), possibly through IFN-y secretion (Finkelman et al., 1988; Amigorena et 
a l,  1990). Indeed, antigen-specific IgG2a antibody production in response to R-848 
and CpG DNA for example has been shown to be dependent on IFN-y (Vasilakos et 
al., 2000; Van Uden et a l ,  2001), and DC-NK cells cross-talk may stimulate IFN-y 
production, through cytokines such as IFN-a/p, IL-18 and IL-12 (Van Uden et a l, 
2001; Kamath et al., 2005). Induction o f antigen-specific IgG2a production by 
microbial products such as CFA, poly(I:C), R-848 and CpG DNA was found to be 
IFN-a/p-dependent, and IFN-a/p were shown to promote antigen-specific isotype 
switching and long-term and memory antibody responses (Finkelman et al., 1991; 
Vasilakos et al., 2000; Le Bon et al., 2001; Van Uden et al., 2001). Direct DC-B cell 
interactions may also promote antigen-specific IgG2a responses (Wykes et al., 
1998). There is also evidence that direct B cell activation by PAMPs, more 
specifically CpG DNA, could promote IgG2a isotype switching, through TLR 
activation, TLR9 in the case of CpG DNA (Peng et al., 2003; Lin et al., 2004).
Adjuvant activities o f LPS from E. coli on enhancement o f antigen-specific antibody 
responses were found to be dependent on TLR4 (Skidmore et al., 1976), but the 
contribution of other TLR receptors, such as TLR2, TLR3 and TLR7 in the adjuvant 
effect of zymosan, poly(I:C) and R-848, respectively, remains to be assessed.
Zymosan, poly(I:C), LPS from E. coli, R-848 and CpG DNA are PAMPs from 
various microbial origin. The present study demonstrated that these TLR agonists, 
even though known to stimulate innate responses through activation of different 
TLRs, were all able to enhance antigen-specific humoral responses. Mechanisms 
controlling the adjuvant activities of the different TLR agonists on antigen-specific 
antibody responses would need to be investigated, in order to understand how the 
immune system translates the detection of various microbial stimuli into a particular 
adaptive immune response.
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Immune responses against pathogens are mediated by both humoral and cellular 
adaptive responses. Having determined that agonists o f a range o f TLRs were able to 
enhance antigen-specific antibody responses, the effect of various TLR agonists on 
the in vivo generation o f antigen-specific CD8+ T cell responses, focussing on 
induction of cross-priming against a soluble protein antigen, was also assessed.
Results showed that functional CD8+ T cell responses were generated against OVA 
when OVA was administered in the presence of poly(I:C), CpG DNA and to a lesser 
extent LPS from E. coli. Since cross-tolerance normally develops against cross­
presented exogenous antigens (Kurts et a l , 1997; Bonifaz et a l , 2002), induction of 
cross-priming in the presence of some TLR stimuli demonstrated that these agonists 
were able to stimulate immune responses that licensed the generation o f functional 
antigen-specific CTL responses. Indeed, some microbial products and bacteria were 
found to overcome the induction of cross-tolerance (Mazzaccaro et a l , 1996; Bennett 
e ta l ,  1997; Simmons e ta l ,  1999).
Results confirmed the adjuvant activity of CpG DNA on the induction o f cross­
priming (Cho et a l , 2000). Both A- and B-class CpG DNA sequences induced 
functional antigen-specific CD8+ T cells, and contrary to what was reported (Krieg, 
2002), CpG 2216 (A-class) was not found to promote stronger CTL activity than 
CpG 1668 (B-class).
LPS from E. coli, but also LPS from other enterobacteria, such as K. pneumoniae and 
N. meningitidis, were found to induce cross-priming. In contrast, LPS from P. 
gingivalis, was unable to stimulate the generation of antigen-specific CD8+ T cell 
responses. Differences in the effect o f LPSs on the immune system had been 
observed, where LPS from P. gingivalis stimulated responses in C3H/HeJ mice 
(Joiner et a l , 1982), which are hyporesponsive to LPS from many bacteria, including 
E. coli and Salmonella spp. (Bradford Hill et a l , 1940; Sultzer, 1968). LPS from P. 
gingivalis and other bacteria, such as L. interrogans, activate intracellular immune 
pathways and cytokine expression patterns different to those triggered by LPS from 
E. coli (Hirschfeld et a l , 2001; Werts et a l , 2001). Interestingly, in a model of 
adoptive transfer o f CD8+ TCR transgenic T cells, LPS from E. coli was also shown 
to promote secretion of IFN-y, from antigen-specific CD8+ T cells, after antigen- 
restimulation in vitro, while LPS from P. gingivalis was unable to do so (Pulendran 
et a l ,  2001). Those data reflect the fact that LPS from P. gingivalis stimulates the
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activation o f immune programs that may not support the development of adaptive 
responses, which may explain its inability to induce cross-priming.
In fact, it was demonstrated that LPS from bacteria such as E. coli and N. 
meningitidis stimulated cytokine responses through activation o f TLR4, while LPS 
from P. gingivalis activated TLR2 (Pulendran et a l , 2001; Zughaier et a l , 2004). 
TLR2 agonists for instance fail to induce IFN-a/p (Toshchakov et a l , 2002; Siren et 
a l , 2005), which is one o f the stimuli that licenses the induction o f cross-priming (Le 
Bon et a l ,  2003). Therefore it is possible that, in a similar way to LPS from P. 
gingivalis, zymosan and peptidoglycan activate intracellular immune pathways that 
cannot translate into the generation of CD8+ T cell responses against an exogenous 
antigen. R-848 is a strong immunomodulator that can stimulate innate and Thl 
cytokine production, and lymphocyte activation (Ahonen et a l ,  1999; Wagner et a l,  
1999; Bishop et a l ,  2000; Caron et a l,  2005; Gautier et a l ,  2005). R-848 was 
however unable to induce cross-priming against a soluble protein, when co-injected 
once with the antigen. The effect of R-848 and other imidazoquinolines on induction 
of cross-priming have been tested since and R-848, even when co-administered with 
the antigen three times, was found to be a poor inducer of antigen-specific CD8+ T 
cell responses (Wille-Reece et a l,  2005), while imidazoquinoline S-27609 could 
only enhance the adjuvant effect of anti-CD40 stimuli (Ahonen et a l,  2004). R-848 
lack of efficiency in inducing cross-priming may be due to the lack of expression of 
TLR7 on murine CD8+ DC (Edwards et a l,  2003), which are thought to play an 
important role in cross-priming (den Haan et a l,  2000). R-848 and other TLR7 
stimuli may in fact promote innate immune programs that favour IL-12-mediated 
CD4+ T cell activation and Thl responses that stimulate antibody- and non-CD8+ T 
cell-mediated responses. A new compound was reported to be able to induce cross­
priming, however it was conjugated to the antigen and injected three times. It was 
proposed that conjugates may have mediated cross-priming by activating other DC 
types than CD8+ DC, such as myeloid and/or plasmacytoid DC (Wille-Reece et a l , 
2005).
Zymosan, poly(I:C), LPSs from the three enterobacteria species tested, R-848 and 
CpG DNA were thus shown to enhance adaptive immune responses. The effect of 
some agonists, such as zymosan and R-848 were restricted to the enhancement of
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antigen-specific humoral responses, while LPS, poly(I:C) and CpG DNA were also 
able to induce CD8+ T cell responses against an exogenous soluble protein antigen.
Overall, these agonists augmented particular responses that would promote cytotoxic 
mechanisms, both CD8+ T cell- and non-CD8+ T cell mediated. These TLR stimuli 
thereby displayed properties that make them potential adjuvants against intracellular 
pathogens in particular, against which cytotoxic mechanisms are essential.
Immune pathways that trigger the licensing of cross-priming are still being 
investigated. IFN-a/p, which play an important role in activation o f immune 
pathways by poly(I:C), LPS and CpG DNA, have been shown to be a major cross­
priming licensing stimulus. In order to characterise how the immune system 
translates TLR agonist stimulation into cross-priming licensing, the contribution of 
the IFN-a/p signalling pathway in induction of cross-priming by poly(I:C), LPS 
from enterobacteria, and CpG DNA was assessed, and results are presented in 
Chapter 5.
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Chapter 4
Effects of high-mannose carbohydrate 
structures on adaptive immune responses
4.1 Introduction
Carbohydrates make up most of organic matter and form major structural 
components o f microorganisms such as bacteria, yeast and viruses. Polysaccharides 
were long thought rather innocuous, yet interest in studying the immunological 
contribution of carbohydrate fractions from pathogens developed; and the 
antigenicity of many polysaccharides was established. For example, capsular 
polysaccharides o f bacteria such as pneumococci and meningococci (Bruyn et a l , 
1992; Mandrell et al., 1995), and Candida albicans cell wall polysaccharides (Cutler, 
2005) induce opsonising and neutralising antibodies, which are critical in controlling 
dissemination during infection. High-density oligomannose clusters on HIV-1 gpl20 
are also target epitopes (Sanders et al., 2002; Scanlan et a l,  2002).
Interestingly, certain polysaccharides have been found to display non-specific 
immunomodulatory activities. Yeast cell wall p-glucans for example were typically 
exploited, and are readily sold as dietary supplements to potentiate the immune 
system. Experimental studies have demonstrated that p-glucans, isolated from yeasts, 
bacteria and plants, non-specifically enhance humoral and cellular responses. Indeed 
it has been reported that P-glucans stimulate cytokine production (Sherwood et a l , 
1987; Abel et a l ,  1992; Lowe et a l,  2002), complement activation (Schenkein et a l,  
1981; Glovsky et a l ,  1983), phagocytosis (Yun et a l,  2003), lysosomal enzyme 
activity (Sakurai et a l ,  1997) and increase resistance to some bacterial infections 
(Williams et a l,  1983; Estrada et a l ,  1997; Koumikakis et a l,  2003; Li et a l,  2004; 
Rice et a l ,  2005). Immunostimulatory properties of other glucans, such as chitosan, 
are also being investigated (Shibata et a l,  1997; Choi et a l,  2001; Feng et a l,  2004). 
Bacterial capsular polysaccharides, isolated from Bacteroides fragilis or Klebsiella 
pneumoniae for example, also exhibit potent immunostimulatory properties (Ho et 
a l,  2000; Tzianabos et a l ,  2000).
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Many innate receptors that are crucial for controlling adaptive immune responses 
have glycoside specificities. Carbohydrates thereby benefit from an exceptional 
relationship with the immune system, and some are being considered as potential 
adjuvants to improve the immunogenicity of vaccines (Maeda et a l , 2004; Silva et 
al., 2004; Hasegawa et al., 2005). Mannose oligosaccharides, for example, are 
common ligands for a number of lectins that are involved in the innate immune 
response, including mannose-binding lectin MBL and the mannose receptor, and 
high-mannose molecules such as yeast mannan have been shown to modulate 
immune responses. In vitro activation of human B cells by mannan has been reported 
(Mangeney et a l ,  1989). Mannan added to human peripheral blood mononuclear 
cells was also shown to stimulate proliferation, as measured by 3H-thymidine 
incorporation (Ausiello et al., 1986; Durandy et a l , 1986; Podzorski et a l , 1990; 
Savolainen et a l , 2003). Mice injected intraperitoneally with mannan showed an 
increase in number of peritoneal macrophages and polymorphonuclear cells, and 
proliferation of Kupffer cells, which are resident macrophages of the liver that 
participate in the clearance of organisms from the bloodstream by phagocytosis and 
through the initiation o f inflammatory processes (Okawa et a l , 1986; Gregory et a l , 
2002; Okawa et a l , 2002). Expression o f various cytokines in response to mannan 
has been detected in vivo (Wang et a l , 1998). Mannan also induces the production of 
pro-inflammatory cytokine TNF-a (Gamer et a l,  1996), of IL-2, as well as both 
IFN-y and IL-4 (Li et a l ,  1998). These observations have prompted investigations 
into the use o f mannan and mannosides as glycoconjugate adjuvants, to enhance 
adaptive immune responses against microbial and tumour antigens by specifically 
targeting lectin receptors (Okawa et a l,  1992; Toda et a l,  1997; Shiku et a l,  2000; 
Berlyn et a l,  2001; Stambas et a l ,  2005).
A series of studies in particular demonstrated that mannan conjugated to mucin 
tumour antigen MUC1 could induce strong Thl or Th2 type immune responses, 
depending on the conjugation protocol. Mannan coupled to MUC1 under oxidising 
conditions induced complete tumour protection in mice, with antigen-specific 
responses that were characterised by high CTL precursor frequency, IL-12 and high 
IFN-y secretion and a predominant IgG2a antibody response (Apostolopoulos et a l,  
1995; Apostolopoulos et a l ,  1996; Lofthouse et a l,  1997; McKenzie et a l,  1998; 
Lees et a l ,  1999; Pietersz et a l ,  2000). In contrast, MUC1 conjugated to mannan
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under reducing conditions induced Th2 responses, characterised by secretion of IL-4 
and IL-10 but no IFN-y, and a predominant IgGl antibody response. Prophylaxis 
studies were extended into primate models (Vaughan et al., 1999; Vaughan et a l , 
2000), while results from clinical trials with cancer patients showed some increased 
anti-MUCl antibody titres, T-cell proliferation and CTL responses (Apostolopoulos 
et al., 1997; Apostolopoulos et al., 2000).
The literature suggests that mannan-conjugates have adjuvant potential for the 
generation of antigen-specific humoral and cellular responses. Studies investigating 
the effectiveness of modified-mannan conjugates, in enhancing cytotoxic T-cell 
activity especially, have focussed on inducing responses against one particular 
antigen, mucin MUC1. Conjugation of oxidised mannan to other peptide antigens has 
only been mentioned briefly (McKenzie et al., 1998). It was therefore of interest to 
explore further the ability o f mannan, conjugated to or co-administered with other 
antigens, to promote functional antigen-specific cellular and humoral responses.
The work presented in this chapter addresses the following question: Do mannan, 
modified-mannan conjugates and more generally high-mannose structures exhibit a 
consistent ability to generate adaptive immune responses against an exogenous 
soluble antigen?
4.2 Effect of modified-mannan protein conjugates on 
induction of antigen-specific CD8+ T cell 
responses
Studies published by Apostolopoulo and McKenzie demonstrated that oxidised- 
mannan conjugated to mucin MUC1 produced strong CTL responses in vitro and led 
to tumour rejection, in mice immunised with three intraperitoneal (i.p) doses of 
conjugates. Firstly, in order to verify whether the adjuvant effect of modified- 
mannan was applicable to any other protein antigen, OVA, a well characterised 
antigen, was used. Secondly, in order to analyse the elementary adjuvant influence of  
mannan on promoting primary responses, single injection protocols were carried out. 
Finally, intramuscular injection was chosen, as a route relevant for vaccination.
The aim o f the work presented below was to examine whether oxidised-mannan and 
reduced-mannan, when conjugated to OVA, could induce functional primary CD8+ T 
cell responses against OVA, after a single intramuscular injection. C57B1/6 mice
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were injected i.m. with OVA alone, or OVA in combination with mannan from 
Saccharomyces cerevisiae, or OVA conjugated to oxidised-mannan (OVA-oxMan) 
or reduced-mannan (OVA-redMan) (see 2.3.4.1).
To first assess whether modified-mannan-OVA conjugates were able to induce 
proliferation o f OVA-specific CD8+ T cells, the frequency o f CD8+ T cell bearing 
SIINFEKL-specific TCR was measured in spleen eight days after immunisation, 
using H-2Kb-SlINFEKL tetramer staining followed by FACS analysis (see 2.6.1). 
Representative FACS analysis dot plots are shown in Figure 4.1 A. No tetramer- 
positive (Tet+) cells could be detected in nai've mice or mice injected with OVA 
(Figure 4 .IB). Surprisingly, neither OVA-oxMan nor OVA-redMan could induce 
any detectable OVA-specific CD8+ T cell population, while co-administration of 
intact mannan with OVA induced expansion of SIINFEKL-specific CD8+ T cells 
(0.7 % Tet+ ± 0.5).
In order to determine whether SIINFEKL-specific CD8+ T cells, generated in the 
presence of mannan-OVA conjugates, had the characteristics of effector cells, their 
ability to produce IFN-y was assessed, using IFN-y ELISPOT assay, as described 
previously. Eight days after immunisation, the ability o f SIINFEKL-specific splenic 
CD8+ T cells to produce IFN-y upon restimulation in vitro was determined and the 
frequency if) of OVA-specific CD8+ T cells was expressed as a number of IFN-y 
spots per 106 CD8+ T cells (Figure 4.1C). No spots could be detected after 
restimulation in the absence o f SIINFEKL peptide. OVA-oxMan (11 spots ± 4, 
j=  141 ± 49) and OVA-redMan (16 spots ± 6,^=208 ± 80) were not able to induce an 
increase in number of spots, in comparison to naive mice (8 spots ± 4,/=96 ± 41) or 
mice injected with OVA alone (18 spots ± 3,y=214 ± 38). In contrast, free native 
mannan stimulated the generation o f IFN-y-producing OVA-specific CD8+ T cells 
(110 spots ± 75,/=1338 ± 905).
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Figure 4.1 Modified-mannan OVA conjugates are not able to generate OVA- 
specific CD8+ T cells. C57B1/6 mice were injected i.m. with 500 pg ovalbumin 
(OVA) alone, OVA in combination with mannan from S. cerevisiae (2.8 mg), 
periodate-oxidised mannan conjugated to OVA (OVA-oxMan) or sodium 
borohydride-reduced mannan-Ova conjugates (OVA-redMan); OVA-mannan 
conjugates contained 500 pg OVA and 2.8 mg mannan. (A, B) Eight days after 
immunisation, SIINFEKL-specific CD8+ T cells in spleens were quantified using Kb- 
SIINFEKL tetramer staining. (A) Representative FACS dot plots of tetramer 
staining. The value in the right comer of each panel represents the percentage of 
tetramer-positive (Tet+) cells among CD8+ T cells. (B) Percentage of Tet+ cells, gated 
on CD8+ T cells, for three individual mice per group; horizontal lines represent the 
mean percentage of Tet+ cells for each group. (C) Eight days after immunisation, 
splenic CD8+ T cells were assessed for SIINFEKL-specific IFN-y secretion by 
ELISPOT assay. Results are expressed as the number of spots per 106 CD8+ T cells 
for three individual mice per group; horizontal lines represent the mean number of 
spots for each group.
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Results from tetramer staining and ELISPOT assays correlated and showed that 
modified-mannan conjugated to OVA, delivered once intramuscularly, failed to 
increase the frequency of OVA-specific CD8+ T cells. Co-administration of OVA 
and native mannan, however, induced expansion and differentiation of OVA-specific 
CD8+ T cells.
Oxidised-mannan MUC1 conjugates were shown to target the MHC I presentation 
pathway, leading to cross-priming against MUC1, due to the presence of aldehydes 
from oxidised-mannan (Apostolopoulos et al., 2000). Other aldehyde-containing 
adjuvants have sparked interest, and saponin QS-21, for example, co-administered 
with OVA was found to be as effective as OVA-QS-21 conjugates in inducing 
OVA-specific cytotoxic T-lymphocytes (Soltysik et al., 1995).
Therefore, the possibility that, in the present model, modified-mannan molecules 
required to be unconjugated to OVA to be able to induce CD8+ T cell responses was 
examined. To that effect, C57B1/6 mice were injected i.m. with OVA alone, or OVA 
in combination with mannan, oxidised-mannan, or reduced-mannan. The adjuvant 
capacity of intact and modified-mannan to generate OVA-specific CD8+ T cell 
responses was assessed in spleen using tetramer staining and IFN-y ELISPOT assay 
eight days after immunisation. Tetramer staining (Figure 4.2A) was performed on 
splenic CD8+ T cells. Immunisation with OVA + oxMan or OVA + redMan did not 
result in the generation of an OVA-specific CD8+ T cell population. Consistent with 
results shown in Figure 4.1, an average o f 0.8% of CD8+ T cells were Tet+ in mice 
immunised with OVA + mannan. IFN-y ELISPOT assay (Figure 4.2B) was 
performed with splenic CD8+ T cells. Ox-Man and red-Man were not able to increase 
the frequency of IFN-y-producing SIINFEKL-specific CD8+ T cells. Results 
confirmed firstly that mannan co-administered with OVA induced an increase in the 
frequency of OVA-specific-CD8+ T cells able to produce IFN-y (f= 1410 ± 445, 
compared to fi=\9\ ± 26 with OVA alone), and secondly that OVA-specific CD8+ T 
cells generated in the presence o f native mannan had the capacity to become effector 
cells.
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Figure 4.2. Mannan, but not modified-mannan, induces functional cross­
priming against OVA. C57B1/6 mice were injected i.m. with 500 jug OVA alone or 
OVA in combination with mannan from S. cerevisiae (2.8 mg), periodate-oxidised 
mannan (oxMan) (2.8 mg) or sodium borohydride-reduced mannan (redMan) (2.8 
mg). (A) Eight days after immunisation, SIINFEKL-specific CD8+ T cells in spleens 
were quantified using Kb-SIINFEKL tetramer staining Results are expressed as 
percentage of tetramer-positive (Tet+) cells, gated on CD8+ T cells, in pooled 
splenocytes from three mice per group. (B) Eight days after immunisation, splenic 
CD8+ T cells were assessed for SIINFEKL-specific IFN-y secretion by ELISPOT 
assay. Results are expressed as the number of spots per 106 CD8+ T cells, which were 
purified from pooled splenocytes from three mice per group. Data are represented by 
mean ± SD for three ELISPOT wells per group.
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In summary, oxidised- or reduced-mannan, either conjugated to OVA or co­
administered with OVA, were not able to elicit antigen-specific CD8+ T cell 
responses. Surprisingly, free mannan exhibited adjuvant properties, in inducing 
expansion and differentiation of OVA-specific CD8+ T cells.
A commercial preparation of mannan was used in this study. Specificity was 
confirmed by the manufacturer, according to optical rotation (over +73°, comparable 
to rotation values described by (Masuoka, 2004)) and thin-layer chromatography. 
Nonetheless, the effect of potential p-glucan contaminants was verified, and highly 
purified p-glucans, co-administered with OVA, was not able to induce Kb- 
SIINFEKL-positive CD8+ T cells.
The finding o f this intriguing property of mannan prompted further studies, which 
focussed on native mannan, in an attempt to investigate in more detail a feature of  
free mannan that had not been reported before. Therefore, the ability of free mannan 
to induce antigen-specific adaptive immune responses was characterised further. 
Mannan is a polymannose component of yeast cell wall; in order to assess the 
adjuvant capabilities of high-mannose molecules of organisms that belong to other 
kingdoms, structures originating from bacteria and viruses were included in the 
study.
4.3 Induction of antigen-specific cellular responses 
by mannan and polymannose structures
4.3.1 Antigen-specific CD8+ T cell responses
4.3.1.1 Effect of mannan on induction of antigen-specific CD8+ T cell 
responses
Mannan, co-administered with OVA, consistently indicated an ability to induce 
OVA-specific CD8+ T cell responses. Indeed, in the presence of mannan in vivo, 
OVA-specific CD8+ T cell were primed to proliferate, as measured by H-2Kb- 
SIINFEKL tetramer staining, and were shown to have differentiated into effector 
cells, as assessed by IFN-y ELISPOT assays.
To characterise further the functional properties of OVA-specific CD8+ T cells 
generated in the presence of mannan, the cytolytic potential of these cells was 
assessed. First, expression of granzyme B by OVA-specific CD8+ T cells in the 
spleen was examined by intracellular staining (see 2.6.1) and FACS analysis. A
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representative FACS analysis histogram is shown in Figure 4.3A. Cells stained with 
anti-granzyme B antibody presented a shift in fluorescence intensity (MFI), as cells 
displayed a MFI 3.4 ± 1.4 times greater than MFI of cells stained with isotype 
control (Figure 4.3B). This illustrated expression of granzyme B by OVA-specific 
CD8+ T cells. Distribution of granzyme B expression, in the CD8+/Tet+ cell 
population, was also examined (Figure 4.3C). Results showed that 19.3% ± 10.3 of 
OVA-specific CD8+ T cells expressed granzyme B after immunisation with OVA + 
mannan.
Expression o f granzyme B is another indication that antigen-specific CD8+ T cells, 
primed in the presence of mannan, are armed for effective cell killing.
To test specifically the cytotoxic function of OVA-specific CD8+ T cells, in vivo, 
CTL assays were performed (see 2.6.3). Data from the in vivo CTL assay are 
presented as percentage of SIINFEKL-specific lysis (see 2.6.3.2) (Figure 4.3D). 
OVA injected on its own did not generate OVA-specific CTL. In mice immunised 
with OVA + mannan, 31.9% ± 18.6 of target cells were killed.
In summary, mannan was able to induce fully functional antigen-specific CD8+ T cell 
responses.
4.3.1.2 Induction of antigen-specific CD8+ T cell responses by high- 
mannose molecules
High-mannose PAMPS are ubiquitous (Prehm et al., 1976; Jansson et al., 1985; 
Geyer et al., 1988; Domer et al., 1989; Kohl et al., 2004). Given that the adjuvant 
capacity of mannan was established, it was of interest to investigate whether other 
high-mannose microbial structures shared this property o f inducing antigen-specific 
CD8+ T cell responses.
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Figure 4.3. Mannan induces antigen-specific cytotoxicity in vivo.
C57B1/6 (B6) mice were injected i.m. with OVA (500 pg) in combination with 
mannan from S. cerevisiae (2.8 mg). Eight days after immunisation, splenic CD8+ T 
cells were stained with Kb-SIINFEKL tetramer and for intracellular granzyme B. (A) 
Representative FACS histogram o f splenocytes from a mouse immunised with OVA 
+ mannan. Splenocytes, enriched in CD8+ T cells, were stained with anti-granzyme B 
antibody ( ^ —) or isotype control ( — ). Events were gated on CD8+ tetramer- 
positive (Tet+) T cells. (B) Results are expressed as percentage o f  increase in the 
mean fluorescence intensity (MFI) o f  cells stained with anti-granzyme B antibody 
compared to cells stained with isotype control. Data are represented by mean ± SD 
for three mice per group. (C) Results are expressed as percentage o f  granzyme B- 
positive cells (GrB+), with events gated on CD8+ Tet+ cells, for three individual 
mice; horizontal lines represent the mean percentage o f GrB+ cells for each group. 
(D) B6 mice were injected i.m. with 500 pg OVA alone or OVA in combination with 
mannan from S. cerevisiae (2.8 mg). Nine days after immunisation, OVA-specific 
CD8+ T cell cytotoxic activity was determined by in vivo CTL assay. Results are 
expressed as percentage o f  SIINFEKL-specific lysis. Data are represented by mean ± 
SD for three mice per group.
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4.3.1.2.1 Effect of polymannose lipopolvsaccharides
Lipopolysaccharides (LPSs) are heterogenous molecules generally consisting of 
three main parts: a relatively conserved phosphoglycolipid called lipid A, a core 
oligosaccharide and a polymorphic polysaccharide O-antigen (Raetz, 1990). Some 
bacteria, such as Klebsiella pneumoniae serotypes 03  and 05 , produce polymannan 
O-antigens (Lindberg et a l , 1972; Curvall et al., 1973). Early studies, analysing the 
adjuvant properties of LPSs, illustrated that polymannan LPSs exhibited a particular 
strong activity (Kido et al., 1985a). Specific adjuvanticity of the high-mannose O- 
antigen, in inducing BSA- or OVA-specific antibody responses and delayed-type 
hypersensitivity, was later demonstrated (Kido et al., 1985b; Ohta et al., 1985; Ohta 
et al., 1987; Paeng et a l,  1996).
In order to investigate further the particular adjuvant characteristics of polymannan 
LPSs, the ability o f polymannose LPS from K. pneumoniae 03.K55 to induce 
antigen-specific CD8+ T cell responses, in comparison with LPS from K. 
pneumoniae 0-:K52, which lacks the O-antigen, was examined.
LPS from K. pneumoniae K55 (LPS Kp K55) and K52 (LPS Kp K52) were extracted 
from bacteria and prepared as described in paragraph 2.3.3. C57B1/6 mice were 
immunised i.m. with OVA alone, or OVA in combination with mannan, LPS Kp 
K55, or LPS Kp K52. Eight days after immunisation the frequency of SIINFEKL- 
specific CD8+ T cell was measured in spleen, using H-2Kb-SIINFEKL tetramers (see 
2.6.1) (Figure 4.4A). LPS Kp K55 induced the expansion of a SIINFEKL-specific 
CD8+ T cell population (0.5% ± 0.2), and so did LPS Kp K52 (0.14% ± 0.0, p=0.03). 
Mannan also stimulated expansion of OVA-specific CD8+ T cells significantly 
(p=0.024). The cytolytic potential of these cells was assessed by conducting CTL 
assays in vivo (see 2.6.3) (Figure 4.4B). Results show that OVA ± LPS Kp K55 
induced 78.6% ±1.1  SIINFEKL-specific lysis (p=0.000), and OVA + LPS Kp K52 
induced 63.0% ±13.8 lysis (p=0.003). In mice immunised with OVA ± mannan, 
18.9% ± 7.6 targets were killed (p=0.032).
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Figure 4.4. The effect of polymannose lipopolysaccharide on induction of cross­
priming against OVA. C57B1/6 mice were injected i.m. with 500 pg OVA alone or 
OVA in combination with mannan from S. cerevisiae (2.8 mg), LPS from K. 
pneumoniae 03:K55 (Kp K55) (10 pg) or LPS from K. pneumoniae K52 (Kp K52) 
(10 pg). (A) Eight days after immunisation, SIINFEKL-specific CD8+ T cells in 
spleens were quantified using Kb-SIINFEKL tetramer staining. Results are expressed 
as percentage of tetramer-positive (Tet+) cells, gated on CD8+ T cells, for three 
individual mice per group; horizontal lines represent the mean percentage of Tet+ 
CD8+ cells for each group. (B) Nine days after immunisation, SIINFEKL-specific 
CD8+ T cell cytotoxic activity was determined by in vivo CTL assay. Results are 
expressed as percentage of SIINFEKL-specific lysis. Data are represented by mean ± 
SD for three mice per group.
* p<0.05 versus control by one-way ANOVA test.
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In summary, both polymannose-LPS Kp K55 and rough LPS Kp K52 were able to 
elicit the generation of OVA-specific CD8+ T cells that were cytotoxic.
The ability of a viral high-mannose protein to induce antigen specific CD8+ T cell 
responses was next examined.
4.3.1.2.2 Effect of hemagglutinin from Influenza virus
Many enveloped viruses, including Influenza virus, Herpes simplex virus (HSV) and 
HIV, display high-mannose glycoproteins (Schwarz et al., 1977; Basak et a l,  1981; 
Mizuochi et al., 1990; Brunetti et al., 1994; Bolmstedt et al., 2001). Influenza virus 
hemagglutinin (HA) is a major glycoprotein on the surface of influenza viruses. It 
mediates attachment and entry of the virus into hosts cells, through interactions with 
lectin receptors (Wiley et al., 1987; White et a l,  2005). HA may be involved in 
triggering the production of IFN-a/p (Miller et al., 2003). Therefore, given Influenza 
HA structure and connection with key elements of the innate immune system, the 
adjuvant potential of HA was investigated. HA structure varies depending on the 
virus strain and which cell type Influenza was grown in, and egg-grown HA3 viruses 
were found to interact better with collectins and to induce higher levels of IFN-a 
than HA1 viruses for example (Reading et a l,  1997; Miller et al., 2003). Egg-grown 
Influenza X:31 (H3N2) was thus chosen as a source of HA to study its capacity to 
generate antigen-specific CD8+ T cell responses.
HA was separated from sucrose gradient-purified Influenza X:31 A/Aichi/68 (H3N2) 
using enzymatic digestion with bromelain, followed by ultracentrifugation (see 
2.3.4.3). The bromelain-released HA (B-HA) preparation was characterised by SDS- 
PAGE in non-reducing conditions (Figure 4.5A). B-HA migration profile showed a 
band for bromelain-released HA monomer (approximately 80 kDa) (Braakman et al., 
1991; Epand et al., 2002) and a band showing carried-over bromelain.
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Figure 4.5. The effect of a high-mannose viral protein on induction of cross­
priming against OVA. C57B1/6 mice were injected i.m. with OVA (500 pg) in 
combination with NaCl-inactivated bromelain (20pg), bromelain-released 
heamagglutinin (B-HA) from Influenza X:31 A/AICHI/68 (20pg) or OVA (500pg) 
in combination with B-HA (20pg). (A) SDS-PAGE characterisation o f bromelain- 
released HA (B-HA). B-HA was visualised by silver staining after electrophoretic 
migration in a 12% SDS-polyacrylamide gel, under non-reducing conditions, 
alongside Influenza virus X:31 (X:31) it was purified from, bromelain (B), the 
enzyme used to separate HA from X:31, and molecular weight markers (MWM). (B) 
Nine days after immunisation, SIINFEKL-specific CD8+ T cell cytotoxic activity 
was determined by in vivo CTL assay. Results are expressed as percentage o f  
SIINFEKL-specific lysis. Data are represented by mean ± SD for three mice per 
group. * p<0.05 versus control by one-way ANOVA test.
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The capacity of B-HA from Influenza to induce OVA-specific CD8+ T cell responses 
was determined by performing a CTL assay in vivo (Figure 4.5B). C57B1/6 mice 
were immunised i.m. with OVA in combination with B-HA. Since Influenza had 
been grown in eggs by the manufacturer, a group of mice was injected with B-HA 
alone, in order to test whether the presence of traces of OVA, which might have been 
carried through the preparation of B-HA, could have an effect in the assay. A group 
of mice was injected with OVA in combination with bromelain, to account for the 
presence of the enzyme in the preparation. Data showed that OVA + B-HA was able 
to induce 18.6% ± 8.7 SIINFEKL-specific lysis (p=0.043), while lysis was negligible 
in mice immunised with OVA + bromelain (4.4% ± 1.8) or B-HA alone (2.5% ± 
2 .2).
In summary, it was shown that HA, a high-mannose viral glycoprotein, was able, 
even though to moderate levels, to elicit antigen-specific CD8+ T cell-mediated 
cytotoxicity.
Many studies have investigated the relevance of CD4+ T cell help in CD8+ T cell 
responses. There has been a strong consensus that CD4+ T cell responses are indeed 
important in many aspects of CD8+ T cell responses (Rocha et al., 2004; Smith et al., 
2004). Since mannan and polymannose LPS Kp K55 were shown to elicit antigen- 
specific CD8+ T cell responses, their capacity to induce OVA-specific CD4+ T cell 
responses, which could support the CD8+ T cell responses observed, was in turn 
examined.
4.3.2 Antigen-specific CD4+ T cell responses
The effect of mannan, polymannose LPS Kp K55 and rough LPS Kp K52 on 
expansion of OVA-specific CD4+ T cells, and on the expression profile of cytokines 
from T-helper cells, was studied.
4.3.2.1 Effect of high-mannose structures on proliferation of antigen- 
specific CD4+ T cells
OVA-specific CD4+ T cell proliferation was characterised using a model of adoptive 
transfer of cells from OT II RAG-deficient mice. OT II RAG_/‘ mice (CD45.2+) have 
all CD4+ T cells expressing a TCR specific for the MHC II I-Ab restricted OVA(3 2 3 - 
3 3 9 ) peptide. At the time of immunisation with OVA and polymannose structures,
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C57B1/6 mice (CD45.1+) were also injected with OVA-specific OT II cells. 
Expansion of the OVA-specific CD4+ T cell population was measured using FACS 
analysis, after staining cells from recipient mice with both anti-CD4 and anti- 
CD45.2.
Accordingly, C57B1/6 (CD45.1+) mice were immunised subcutaneously with OVA 
alone, or OVA in combination with mannan, LPS Kp K55, or LPS Kp K52. The 
mice were also injected intravenously with OT II lymph node cells, composed of 
over 85% CD4+ T cells. Ten days after immunisation, draining inguinal lymph nodes 
were collected and single cell suspensions were prepared. Cells were labelled with 
fluorescent anti-CD4 and anti-CD45.2 and their frequency was measured using 
FACS analysis; representative FACS analysis dot plots are shown in Figure 4.6A. 
Numbers of OVA-specific CD4+ T cells per draining lymph node (dLN) were 
calculated from the frequency of CD45.2+ CD4+ cells and dLN cell counts (Figure 
4.6B). At day 10, OT II CD4+ T cells, in mice injected with OVA alone, were hardly 
detectable, probably because the peak of proliferation occurred in the first few days 
and the population contracted then on. The effect of adjuvants on antigen-specific 
CD4+ T cells was examined at day 10, thereby after the expected peak in 
proliferation, because LN cells were also to be restimulated in vitro to measure 
cytokine production, and CD4+ T cells may be killed by restimulation during their 
early activation phase. In mice immunised with OVA + mannan, the average number 
of OVA-specific CD4+ T cells increased 9-fold compared to numbers in control 
mice. In mice immunised with LPS Kp K55 and LPS Kp K52, the OVA-specific 
CD4+ T cell population expanded more than 10-fold, to 3.2x104 cells ± 2.1 xlO4 and 
1.1 x 104 cells ± 0 .7xl04, respectively, compared to 0.08xl04 cells ± 0.06xl04 in 
control mice.
Mannan and both LPS Kp K55 and LPS Kp K52 were thus shown to enhance 
proliferation/survival of OVA-specific CD4+ T cells in vivo.
The pattern of cytokine expression of these OVA-specific CD4+ T cells was next 
studied ex vivo, after restimulation in vitro with OVA peptide.
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Figure 4.6. The effect of mannan and polymannose lipopolysaccharide on 
proliferation of antigen-specific CD4+ T cell. C57B1/6 (CD45.1+) mice were 
injected s.c. with 500 pg OVA alone or OVA in combination with mannan from S. 
cerevisiae (2.8 mg), LPS from K. pneumoniae 03:K55 (Kp K55) (10 pg) or LPS 
from K. pneumoniae K52 (Kp K52) (10 pg). The mice were also injected i.v. with 
1.5xlO6 cells prepared from lymph nodes of OT II (CD45.2+) mice. OVA-specific 
CD4+ T cell proliferation was assessed ten days after immunisation by counting cells 
recovered from the draining lymph node and determining the proportion of OT II 
cells using flow cytometry. (A, B) Ten days after immunisation, cells from the 
draining lymph node were stained with anti-mouse CD4 and anti-mouse CD45.2 
antibodies. (A) Representative FACS dot plots of CD45.2 staining. The value in the 
right comer of each panel represents the percentage of OT II cells (CD45.2+) among 
CD4+ T cells. (B) Results are expressed as absolute number of OVA-specific CD4+ 
OT II cells recovered from the draining lymph node (dLN). Data are represented by 
mean ± SD.
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4.3.2.2 Cytokine production by CD4+ T ceils primed in the presence of 
high-mannose molecules
CD4+ T cells, purified from lymph nodes ten days after immunisation, were cultured 
with syngeneic stimulator cells, in the presence or absence of 5 pM OVA(3 2 3 -3 3 9 > 
peptide (see 2.7.2). Culture supernatants were collected 72 h later and assayed for the 
presence of prototypic ThO (IL-2), Thl (IFN-y) and Th2 (IL-4 and IL-5) cytokines 
(Figure 4.7). It is to note that no cytokines were detectable in wells where stimulator 
cells were cultured on their own, both in the presence or absence of OVA peptide. 
The cytokine array data were expressed as cytokine concentration produced per 105 
OT II CD4+ T cells. Antigen-specific CD4+ T cells from both control and OVA- 
injected mice exclusively produced IL-2. In contrast, mannan, LPS Kp K55 and LPS 
Kp K52 induced the production of IFN-y, in addition to IL-2. Mannan stimulated 
predominantly the production of IL-2, while LPS Kp K55 induced more IFN-y than 
IL-2. LPS Kp K52 induced relatively equivalent levels of IL-2 and IFN-y. Mannan, 
LPS Kp K55 and LPS Kp K52 elicited no, or negligible, production of IL-4 and IL-5. 
Thus, data showed that mannan, LPS Kp K55 and LPS Kp K52 induced similar 
mixed ThO/Thl cytokine expression profiles from OVA-specific CD4+ T cells, 
though cytokine levels varied.
In summary, mannan and both polymannose-LPS Kp K55 and rough LPS Kp K52 
were able to induce antigen-specific CD4+ T cell responses, as they stimulated 
proliferation of OVA-specific CD4+ T cells and instructed the production of ThO and 
Thl cytokines from those cells, specifically in response to OVA.
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Figure 4.7. Cytokine production from antigen-specific CD4+ T cells primed in 
the presence of mannan and polymannose lipopolysaccharide. C57B1/6 
(CD45.1+) mice were injected s.c. with 500 pg OVA alone or OVA in combination 
with mannan from S. cerevisiae (2.8 mg), LPS from K. pneumoniae 03:K55 (Kp 
K55) (10 pg) or LPS from K. pneumoniae K52 (Kp K52) (10 pg). The mice were 
also injected i.v. with 1.5xlO6 lymph nodes cells from OT II (CD45.2+) mice. Ten 
days after immunisation, CD4+ T cells were purified from the draining lymph node 
and seeded at lxlO6 cells / mL with 5><106 / mL syngeneic T-depleted splenocytes, in 
the presence or absence of 5 pM OVA(3 2 3 -3 3 9) peptide. Culture supernatants were 
collected after 72 h incubation, and cytokine concentration was determined using 
flow cytometry array (mouse Thl/Th2 cytometric bead array; BD Biosciences). 
Results are expressed as concentration of cytokine produced per 105 CD4+ OT II 
cells; concentration of cytokine produced in the absence of OVA peptide was 
subtracted. Data are represented by mean ± SD.
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The adjuvant properties of high-mannose structures were characterised further by 
studying their effect on the generation of antigen-specific B-cell responses.
4.4 Induction of antigen-specific humoral responses 
by high-mannose structures
In order to test whether polymannose molecules are able to elicit humoral responses 
against a soluble protein antigen, and to evaluate the quality o f this response, titres of 
antigen-specific immunoglobulin G were measured in serum, and antibodies were 
isotyped. IgG responses were characterised first during an early and a late primary 
response, then during a secondary response. The high-mannose structures studied 
were mannan and LPS Kp K55. LPS Kp K52 was included, to represent a K. 
pneumoniae LPS structure that lacked the polymannose O-antigen. CGG was used as 
a model protein antigen.
4.4.1 Primary response
4.4.1.1 Early immunoglobulin G responses
C57B1/6 mice were injected once intramuscularly (i.m.) with CGG alone, or CGG in 
combination with mannan, LPS Kp K55, or LPS Kp K52. Titres of CGG-specific 
IgGl, IgG2a, IgG2b and IgG3 were measured in the serum ten days later, using 
ELISA (see 2.5.2).
CGG induced weak IgG responses, which consisted mainly of IgGl (37,333 ± 
19,956) and very little, if  any, IgG2a (50 ± 0), IgG2b (467 ± 249) or IgG3 (250 ± 0). 
Co-administration of mannan, LPS Kp K55 or LPS Kp K52 increased CGG-specific 
responses, with the production of all IgG isotypes being enhanced (Figure 4.8). 
Results are expressed as fold increase in antibody endpoint titre compared to titres 
induced by CGG on its own.
Titres of anti-CGG IgGl were higher in mice immunised with CGG + mannan (11.4- 
fold ± 3.2, p=0.011), CGG + LPS Kp K55 (22.9-fold ± 6.5, p=0.009) and CGG + 
LPS Kp K52 (13.7-fold ± 0.0, p=0.000), compared to IgGl titres in mice injected 
with CGG alone.
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Figure 4.8. The effect of mannan and polymannose lipopolysaccharide on 
primary antigen-specific antibody responses. C57B1/6 mice were injected i.m. 
with 100 jug chicken y-globulin (CGG) alone or CGG in combination with mannan 
from S. cerevisiae (2.8 mg), LPS from K. pneumoniae 03:K55 (Kp K55) (10 pg) or 
LPS from K. pneumoniae K52 (Kp K52) (10 pg). Ten days after immunisation, 
serum samples were collected and titres of CGG-specific IgGl, IgG2b, IgG2a and 
IgG3 were measured using ELISA. Results are expressed as fold-increase in CGG- 
specific antibody titre compared with titres in mice immunised with CGG alone. 
Data are represented by mean ± SD for three mice per group. * p<0.05 versus CGG 
immunisation group, by one-way ANOVA test.
117
Mannan, LPS Kp K55 and LPS Kp K52 induced extremely potent anti-CGG IgG2a 
responses: 427-fold increase ±121 (p=0.008), 3413-fold ± 965 (p=0.007), and 1024- 
fold ± 0, (p=0.000), respectively. It is to note that LPS Kp K55 generated a response 
3 times greater than LPS Kp K52 (p=0.025).
Anti-CGG IgG2b responses were also enhanced significantly. Mannan induced an 
increase in titre o f 256-fold ± 137, and both LPS Kp K55 and LPS Kp K52 induced 
an equal increase of 585-fold ± 207 (p=0.016).
To a similar extent, all three compounds enhanced anti-CGG IgG3 responses. Titres 
increased 85-fold ± 30 (p=0.017) with CGG + mannan, 427-fold ± 121 (p=0.008) 
with CGG + LPS Kp K55, and 299-fold ± 160 with CGG + LPS Kp K52.
4.4.1.2 Long-term immunoglobulin G responses
In order to test whether polymannose molecules could generate a long-lasting CGG- 
specific primary IgG response, titres of anti-CGG IgGl, IgG2a, IgG2b and IgG3 
were measured in the serum sixty days after the single immunisation protocol 
described in paragraph 4.4.1.1 (Figure 4.9). Results are expressed as fold increase in 
antibody endpoint titre compared to titres induced by CGG injected alone.
At day 60, in comparison with anti-CGG IgGl titres in mice immunised with CGG 
alone, titres in mice previously immunised with CGG + LPS Kp K55 were higher by 
24.0-fold ±11.3 (p=0.045). Mannan and LPS Kp K52 induced IgGl titres that were 
only higher by 7.3-fold ± 6.2 and 5.3-fold ±1 .9  (p=0.031), respectively.
Anti-CGG IgG2a titres, in mice previously immunised with the CGG ± adjuvant 
were also higher than titres in mice injected with CGG alone. Fold-increases in 
antibody titres in mice immunised with mannan, LPS Kp K55 or LPS Kp K52 were 
34.7-fold ± 22.9, 512-fold ± 0 (p=0.000), and 213 ± 60 (p=0.008), respectively. The 
response induced by LPS Kp K55 was more than twice greater than the response 
induced by LPS Kp K52 (p=0.002).
In mice previously immunised with CGG ± mannan, titres of anti-CGG IgG2b at day 
60 were 32-fold ± 0 (p=0.000) higher than titres in mice injected with CGG alone. 
Fold-increases in CGG-specific IgG2b titres induced by CGG ± LPS Kp K55 and 
CGG + LPS Kp K52 were 149 ± 80 and 85 ± 30 (p=0.017), respectively.
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Figure 4.9. The effect of mannan and polymannose lipopolysaccharide on long­
term antigen-specific antibody responses. C57B1/6 mice were injected i.m. with 
100 pg chicken y-globulin (CGG) alone or CGG in combination with mannan from 
S. cerevisiae (2.8 mg), LPS from K. pneumoniae 03:K55 (Kp K55) (10 pg) or LPS 
from K. pneumoniae K52 (Kp K52) (10 pg). Sixty days after immunisation, serum 
samples were collected and titres of CGG-specific IgGl, IgG2b, IgG2a and IgG3 
were measured using ELISA. Results are expressed as fold-increase in CGG-specific 
antibody titre compared with titres in mice immunised with CGG alone. Data are 
represented by mean ± SD for three mice per group. * p<0.05 versus CGG 
immunisation group, by one-way ANOVA test.
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At day 60, titres o f CGG-specific IgG3 induced by mannan were in fact comparable 
to titres in mice previously injected with CGG alone (12.3-fold increase ± 14) 
Responses elicited by LPS Kp K55 and LPS Kp K52 were low: 5.3-fold ± 1.9 
(p=0.031) and 4.7 ± 2.5, respectively.
In summary, mannan, LPS Kp K55 and LPS Kp K52 were all able to enhance 
primary CGG-specific IgG responses. All three compounds induced very potent early 
responses. LPS Kp K55 and LPS Kp K52 were able to elicit anti-CGG IgG responses 
that were still generally strong two months after immunisation, while mannan was 
only able to generate a long-term IgG2b response.
In particular, LPS Kp K55 induced a better CGG-specific IgG2a primary response 
than LPS Kp K52.
4.4.2 Secondary response
In order to test whether polymannose molecules were able to generate memory 
antigen-specific IgG responses, while minimising the contribution of a new primary 
response, titres of anti-CGG IgG isotypes were measured in the serum five days after 
rechallenge with CGG, in mice, which had been immunised once as described in 
paragraph 4.4.1.1 and rechallenged at day 61. Endpoint titres o f CGG-specific IgGl, 
IgG2a, IgG2b and IgG3, on the day before and 5 days after rechallenge, are shown in 
Figure 4.10.
Titres of CGG-specific IgG, of all isotypes, induced by CGG on its own were 
identical before and after challenge.
In mice immunised with OVA + mannan, anti-CGG IgGl titres more than doubled 
after rechallenge, from 58,667 ± 49,459 to 149,333 ± 78,822. In mice immunised 
with LPS Kp K55 (p=0.002) or LPS Kp K52, titres increased more than ten times 
after challenge, though LPS Kp K55 induced a greater secondary response than LPS 
Kp K52 (p=0.006).
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Figure 4.10. The effect of mannan and polymannose lipopolysaccharide on 
secondary antigen-specific antibody responses. C57B1/6 mice were injected i.m. 
with PBS or 100 pg chicken y-globulin (CGG) alone or CGG in combination with 
mannan from S. cerevisiae (2.8 mg), LPS from K. pneumoniae 03:K55 (K55) (10 
pg) or LPS from K. pneumoniae K52 (K52) (10 pg). Sixty-one days after 
immunisation, mice were rechallenged i.p. with 100 pg CGG. Five days later, serum 
samples were collected and titres of CGG-specific IgGl, IgG2a, IgG2b and IgG3 
before rechallenge ( I )  and after rechallenge (ODDI ) were measured using ELISA. 
Results are expressed as CGG-specific antibody endpoint titre. Data are represented 
by mean ± SD for three mice per group. * p<0.05 versus CGG immunisation groups 
(before and after challenge), by ANOVA General Linear Model test.
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In mice immunised with OVA + mannan, anti-CGG IgG2a titres also more than 
doubled after rechallenge, from 8,667 ± 5.734 to 21,333 ± 7,542, while LPS Kp K52 
was less effective, as titres increased less than two-fold. In contrast, LPS Kp K55 
(p=0.000) was able to elicit stronger secondary responses than LPS Kp K52
(p=0.000).
In mice immunised with any of the three compounds, anti CGG-IgG2b titres were 
more than ten times higher after rechallenge. IgG2b secondary response was most 
significant with LPS Kp K55 (p=0.000).
Mannan and LPS Kp K52 induced little secondary anti-CGG IgG3 responses, while 
LPS Kp K55 was very efficient (p=0.001), and more so than LPS Kp K52 (p=0.004).
In summary, mannan was able to induce primary and secondary antigen-specific IgG 
responses. All IgG isotypes were produced, but IgG2a and IgG2b dominated the 
primary response, and IgG2b prevailed during memory responses. LPS Kp K55 was 
also a potent inducer of antigen-specific IgG responses. IgG2a, IgG2b and IgG3 
isotypes were highly produced during the primary response, and memory responses 
were characterised by even greater levels of IgG2a and IgG2b. Although possessing 
no polymannose O-antigen, LPS Kp K52 elicited the same profile of primary 
antigen-specific IgG response as LPS Kp K55. In contrast, secondary responses were 
dominated by IgG2b only. Overall, LPS Kp K55 was significantly more efficient in 
generating antigen-specific IgG2a responses.
4.5 Conclusions and discussion
Carbohydrates fulfil important biological functions and are indispensable to many 
organisms. Immune systems have evolved to recognise and react adequately to 
carbohydrate structural constituents, from as diverse as lipopolysaccharides from 
bacteria, viral glycoproteins, and yeast p-glucan and mannan. Particular 
immunostimulatory activities displayed by some carbohydrates have led to vaccine 
development studies investigating the use of polysaccharides as adjuvants, capable of 
safely enhancing immune responses against co-administered antigens. The aim of the 
work reported here was to examine the potential of mannan and other microbial high- 
mannose molecules as stimulators of cellular and humoral immune responses against 
soluble protein antigens.
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As an initial approach, mannan was conjugated under oxidising conditions to a 
model protein antigen, OVA. This procedure, applied to tumour antigen MUC1, had 
been shown to generate immunogenic conjugates able to induce antigen-specific 
CD8+ T cell responses in mice (Apostolopoulos et al., 1995). The OVA model 
studied here however showed a different outcome. Indeed, OVA-oxMan conjugates 
were not able to induce cross-priming against OVA, at least during a primary 
response. Aldehydes, produced by oxidation of mannan, were found to be essential 
for the adjuvant functions of MUCl-oxMan conjugates (Apostolopoulos et al., 
2000). Aldehydes had previously been proven to have immunostimulatory and 
adjuvant properties, whether conjugated to a target antigen or simply co-administered 
(Soltysik et al., 1995; Cross et al., 2001). It was therefore hypothesised that oxidised 
mannan and OVA might require to interact with different innate cell types, 
independently, for adjuvant mechanisms to take place. OxMan, co-injected with 
OVA, was not able either to induce cross-priming against OVA, despite presenting 
similar amounts o f aldehydes as described by (Apostolopoulos et al., 2000) (0.27 to 
0.47 jiimol/mg mannan in the present study, determined colorimetrically with 2,4- 
dinitrophenylhydrazine). Adjuvant properties of aldehydes, in generating functional 
antigen-specific CD8+ T cell responses in particular, therefore probably depend on a 
multiple-immunisation course, in addition to the nature of the target antigen. Indeed, 
studies relative to MUC1 -oxMan describe the effect of conjugates after three 
injections in mice, and after four to seven injections in primates (Apostolopoulos et 
al., 1995; Vaughan et al., 1999). Immunisation of mice with three doses of oxMan 
conjugated to a different antigen, Listeria monocytogenes listeriolysin O (LLO), did 
not result either in antigen-specific CTL responses, whether conjugates were 
inoculated intranasally or intraperitoneally (Stambas et al., 2002a; Stambas et al., 
2002b). OxMan conjugates might represent more promising anti-infectious adjuvants 
when integrated into modem immunisation protocols, such as prime-boost strategies, 
and especially those aiming at supporting antibody responses (Stambas et al., 2005).
If the use o f oxidised mannan was not a successful approach for generating primary 
antigen-specific CD8+ T cell responses, free native mannan manifested exciting 
adjuvant properties. Mannan, co-administered with a protein antigen, consistently 
stimulated specific adaptive responses. Mannan’s adjuvant effect was diversified, as 
it affected both cellular and humoral adaptive responses. Cellular responses proved
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to be functional, since clonal expansion of antigen-specific CD8+ and CD4+ T cells 
was accompanied by differentiation into effector cells. Indeed, mannan induced 
functional cross-priming, since antigen-specific CD8+ T cells, generated in the 
presence of mannan, proliferated and were capable of producing IFN-y upon 
restimulation. Effector CD8+ T cells were also armed with granzyme B for cytotoxic 
killing, and demonstrated their ability to lyse target cells in vivo. Antigen-specific 
CD4+ T cells, generated in the presence of mannan, also demonstrated, upon 
restimulation, their capacity to become effector cells. Indeed, some antigen-specific 
CD4+ T cells exhibited a Thl phenotype, characterised by the secretion of IFN-y. 
This indicated that antigen-specific CD4+ T cells generated in the presence of 
mannan had the potential to enhance cellular responses, through induction of 
cytokine production for example (Kipps et a l , 1985; Gracie et al., 1996). This 
interpretation was supported, indirectly, by the presence of serum antigen-specific 
immunoglobulin G of various isotypes. Indeed, it has been established that, in order 
to respond to protein antigens and undergo appropriate antibody class switching, B 
cells require help from antigen-specific CD4+ T cells, through CD40/CD40L 
interactions. IFN-y produced by CD4+ T cells, whilst not indispensable, favours B 
cell responses that can also support cellular responses. This includes, in mice, the 
production of IgG2a antibodies, which are characterised by their strong capacity to 
induce antibody-mediated cellular cytotoxicity (ADCC) by NK cells and 
macrophages, through FcyRI and FcyRIII (Gavin et a l , 1998; Barnes et a l , 2002b; 
Radaev et a l , 2002). In fact, mannan enhanced production of antigen-specific IgG2a, 
which may correlate with the capacity of antigen-specific CD4+ T cells, generated in 
the presence of mannan, to secrete IFN-y. Mannan also stimulated the production of 
antigen-specific IgG of other isotypes (IgGl, IgG2b, IgG3). The antibody isotypes 
enhanced by mannan have a variety of functions, in terms of neutralisation and 
opsonisation. Opsonization allows both FcR targeting on phagocytes, and 
complement fixation. Mannan has been shown for example to promote the secretion 
of neutralising anti-rotavirus antibodies (Franklin et a l ,  2005). IgGl and IgG2a 
antibodies in particular are efficient activators of the complement classical pathway, 
which helps antigen removal. They can also induce complement-mediated 
cytotoxicity (CMC) (Klaus et a l,  1979; Herlyn et a l,  1985).
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With appropriate help from CD4+ Th cells, including CD40L/CD40 ligation, and 
then survival signals in the bone marrow, antigen-specific B cells can differentiate 
and survive as long-lived antibody-secreting plasma cells (McHeyzer-Williams et al., 
2005). Long-term antigen-specific antibody responses were enhanced in mice 
immunised once with antigen + mannan, indicating that during the primary response 
mannan provided signals that were integrated by antigen-specific B cells, and/or 
antigen-specific CD4+ T cells, and/or follicular DC. As a result, some B cells 
differentiated into long-lived plasma cells, which were still producing antigen- 
specific antibodies 60 days after initial priming, without second antigenic or adjuvant 
stimulation. Some B cells can also differentiate into memory B cells, which do not 
secrete antibodies, but are rapidly able to if  their BCR is activated. Five days after 
rechallenge with antigen only, antigen-specific antibody responses were enhanced, 
compared to responses before rechallenge, in mice that had been immunised once, 61 
days earlier, with antigen and mannan. Antibodies could not have been produced 
within five days by newly primed B cells, because B cell differentiation into 
antibody-secreting plasma cells would require at least seven days. This indicated that 
during the primary response, mannan was able to stimulate the instruction of B cell 
differentiation into memory cells. Mannan, co-administered with a protein antigen, 
promoted the generation of long-lived and memory antigen-specific B cells 
characterised by two IgG isotypes in particular: IgG2b and IgG2a, which are isotypes 
that contribute to immune mechanisms most efficient at eliminating intracellular 
pathogens.
Mannan is a complex glycan, and its adjuvant effects may be related to its 
composition. Mannan is a yeast cell wall polysaccharide, composed of mannose 
polymers, such as the linear backbone chain made of a -1,6 mannose units, and 
mannose oligomers, such as the linear or branched side chains of a -1,2 and a -1,3 
mannose units. Other organisms, including some viruses (Deom et al., 1986; Kohl et 
al., 2004; Wang et al., 2004), bacteria (Prehm et al., 1976; Paeng et al., 1996; Tian et 
al., 2000) and plants (Gauntt et a l,  2000) bear high-mannose molecules. While 
polysaccharides in general were suspected early on of having immunomodulatory 
activities (Suzuki et al., 1969a; Suzuki et al., 1969b; Lee et al., 2001), only a few 
studies have reported on adjuvant properties of mannan (Domer et al., 1986; Franklin 
et al., 2005) or other polymannose molecules (Ohta et al., 1982; Kido et al., 1985a).
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Results presented here demonstrated a novel and exciting feature of mannan: its 
ability to induce antigen-specific CD8+ T cell responses. Endotoxin contamination is 
often suspected to account for the activity of purified microbial components. This 
possibility was considered. The endotoxin content of mannan (15 ng/mg) was 
measured by the Limulus amoebocyte assay (see 2.3.4.2). However, this measure can 
be inaccurate, since p—(1,3) glucans, which may have been carried over in small 
amounts during mannan precipitation, activate the clotting enzymes used in the assay 
and therefore bias the readings of endotoxin activity (Ohno et al., 1990). An 
endotoxin-specific Limulus test should have been used. The possible adjuvant 
activity of p-glucan contaminants was excluded, as up to 500 pg of purified p-(l,3) 
glucans were not able to induce cross-priming against soluble OVA. In addition, 
periodate oxidisation, which is often used to test the specific activity of  
carbohydrates, was shown to abrogate the adjuvant effect of free mannan (see Figure 
4.2), while lipid A structures from possible endotoxin contaminants would have been 
resistant to periodate. Furthermore, the activity of mannan (Tada et al., 2002), and 
other polysaccharides (Flo et al., 2002; Saito et al., 2003), was previously shown to 
be resistant to polymyxin B, which binds to lipid A and inhibits its activity. Ideally, 
studies would be performed using compounds synthesised in a controlled 
environment. However, synthesis of complex carbohydrates is only in early stages of 
development.
Influenza HA and LPS from K. pneumoniae K55 both contain immunologically 
relevant polymannose structures (Roberts et al., 1993; Reading et al., 1997; Zhao et 
al., 2002) and since purification methods are well established for these two 
molecules (Bonnafous et al., 2000; Zamze et al., 2002), HA and LPS Kp K55 were 
chosen to examine whether high-mannose compounds also manifested the ability to 
induce cross-priming. HA and LPS Kp K55 were indeed shown to induce antigen- 
specific CD8+ T cell responses. HA and LPS Kp K55 are admittedly hybrid 
molecules, as HA is a glycoprotein and LPS Kp K55 a glycolipid. Therefore, their 
adjuvant effect cannot be irrefutably attributed to their high-mannose fraction, 
although previous studies have illustrated the prominent contribution of the 
polysaccharide moiety in the immunogenicity and/or adjuvanticity of HA and LPS 
Kp K55. Indeed, sodium periodate oxidises adjacent hydroxyls on sugar rings, such 
as found in HA, and strong periodate treatment of influenza virus was shown to
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result in a great reduction of IFN-a/p induction, which was imputed to HA loss of 
conformation (Miller et al., 2003). The present study did not examine the precise 
contribution of the high-mannose structure to the adjuvant effect of HA. One way of  
addressing this in the future would be to destroy or remove HA high-mannose 
fraction, by periodate treatment or mannosidases digestion. Another way would be to 
compare a normally glycosylated HA with HA naturally lacking high-mannose 
(Nakamura et al., 1979; Reading et al., 2000).
LPS Kp K55 marked adjuvanticity has been shown to depend on its polymannose 
fraction. LPS Kp K55 lipid A, separated from the polymannose O-antigen by 
hydrolysis, displayed a great loss of adjuvant activity (Kato et al., 1985), and 
comparative studies with an O-antigen deficient mutant confirmed that the 
polymannose moiety was indispensable to LPS adjuvant effect in inducing delayed- 
type hypersensitivity to OVA, and in augmenting antibody responses to bovine y- 
globulin (Ohta et al., 1987). LPS from E. coli K-12 is a weak enhancer of antigen- 
specific antibody responses; however when E. coli K-12 was transfected with rjb 
genes capable of synthesizing the polymannose O-antigen, its LPS adjuvant activity 
was significantly increased (Paeng et al., 1996). In contrast to polymannose O- 
antigen {Klebsiella serotype 03) in LPS Kp K55, O-antigens with a galactose 
structure in LPS K l:01 and K3:02 did not correlate with an enhanced adjuvant 
activity (Jones, 2004). In the present study, LPS Kp K52, a rough LPS from K  
pneumonia, was used in comparison with LPS Kp K55, in an attempt to determine 
the contribution of the polymannose O-antigen to adjuvanticity, although a O-antigen 
deficient mutant of LPS Kp K55 would have been a better control. If no significant 
difference could be established between the polymannose LPS and the rough LPS in 
their capacity to induce cross-priming, the polymannose LPS displayed a stronger 
activity in enhancing antigen-specific antibody responses. More precisely, LPS Kp 
K55 was able to more strongly promote antigen-specific IgG2a responses, which 
play an important role in protective responses, since IgG2a antibodies are involved in 
assisting and inducing cell-mediated cytotoxicity (CMC and ADCC). Although LPS 
Kp K52 and LPS Kp K55 both enhanced antigen-specific CD4+ T cell proliferation 
and promoted a similar CD4+ T helper cell differentiation pattern, LPS Kp K55 was 
generally over five times more potent than the rough LPS, which is consistent with 
results reported by (Ohta et al., 1987) and (Paeng et al., 1996). LPS Kp K55 greater
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adjuvant effect on augmenting antibody responses, regarding IgG isotype switching 
especially, would also be consistent with greater adjuvanticity on CD4+ T cell 
responses.
Overall, LPS Kp K55 polymannose O-antigen appears to increase the adjuvant effect 
of the lipid A/core moiety on augmenting antigen-specific CD4+ T cell responses, 
and on augmenting a particular type of humoral responses that may be associated 
with CD8+ T cell-non-mediated cytotoxicity.
Mannan and polymannose LPS Kp K55 were thus shown to induce antigen-specific 
CD8+ T cell responses and to enhance antigen-specific CD4+ T cell and antigen- 
specific B cell responses. These carbohydrates thereby displayed properties that 
make them potential adjuvants against intracellular pathogens in particular, against 
which cytotoxic mechanisms are essential. In view of their disparate strength of 
activity, LPS Kp K55 being more potent than mannan, but considering the known 
toxicity of lipid A, engineering a molecule that contains the polymannose fraction 
linked to a less endotoxic lipid A/lipid A analog may constitute a fruitful strategy.
Understanding how mannan and high-mannose molecules trigger the adjuvant 
activities reported here would be pertinent, in order to try to control and make full 
use of their properties, for potential prophylactic/therapeutic ends.
As a first step in that direction, while attempting to define a common mechanism by 
which PAMPs in general induce antigen-specific CD8+ T cell responses against a 
soluble protein antigen, the way(s) mannan and high-mannose molecules license 
cross-priming was examined, as reported in the following chapter.
128
Chapter 5
Mechanisms of induction of cross-priming 
against a soluble protein antigen by pathogen- 
associated molecular patterns
5.1 Introduction
Cross-priming refers to the productive activation of CD8+ T cells against an 
exogenous antigen, meaning an antigen that was not synthesised within the APC it is 
presented by, but was captured. Similarly to classical CD8+ T cell priming against an 
endogenous antigen, cross-priming requires that CD8+ T cells interact with APC that 
not only present the antigen on MHC I, but are also appropriately activated (Bonifaz 
et al., 2002). Indeed, as presentation of endogenous antigen to CD8+ T cells by 
resting DC leads to tolerance, cross-presentation under steady state leads to cross­
tolerance (Guerder et al., 1992; Kurts et al., 1997).
Activation o f DC that allows for cross-priming has been termed licensing (Keene et 
al., 1982; Lanzavecchia, 1998), and to date two major licensing stimuli have been 
described. Cognate CD4+ T cell help has been shown to provide essential/sufficient 
signalling to APC (Bennett et al., 1997), through CD40L/CD40 interactions (Bennett 
et al., 1998; Ridge et a l ,  1998; Schoenberger et al., 1998; Lefrancois et al., 2000), 
for carrying out both cellular cross-priming and cross-priming against soluble 
antigens. More recently, IFNoc/p was identified as a soluble licensing factor, which 
acts independently of CD4+ T cell help and CD40/CD40L ligation (Le Bon et al.,
2003).
Some microbial products, essentially PAMPs, are detected by the innate immune 
system, and this triggers specific intracellular signalling pathways that activate the 
transcription of particular sets of genes, leading to the expression of costimulatory 
molecules and cytokines. Activation pathways stimulated by PAMPs include the NF- 
kB pathway (Takeuchi et al., 1999; Hemmi et al., 2000; Alexopoulou et al., 2001) 
and the IRF pathways (Kawai et a l,  2001; Yamamoto et a l,  2002b; Yamamoto et 
a l,  2003; Kawai et a l ,  2004). There is a potential strong link between PRR
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signalling and PAMP adjuvant activities, which at present has been made clear for 
TLR signalling in particular. Enhancement of adaptive humoral responses by CFA, 
for example, was shown to be mediated by TLR signalling, and also to be dependent 
on IFNa/p signalling (Le Bon et ah, 2001; Schnare et a l , 2001). Hence, PRR 
activation and stimulation of autocrine/paracrine cytokines networks may promote 
CD40/CD40L expression/ligation and/or IFN-a/p secretion, which in turn may 
mediate licensing for cross-priming. dsRNA motifs for instance, are recognised by 
various receptors, including TLR3, PKR, and RNA helicases RIG-1 and mda-5, and 
can induce IFN-a/p production and expression of costimulatory molecules (Diebold 
et al., 2003; Hoebe et al., 2003b; Honda et al., 2003; Oshiumi et al., 2003a; 
Andrejeva et ah, 2004; Kato et al., 2005). LPS from E. coli (TLR4) and CpG DNA 
(TLR9) are also able to induce IFN-a/p and costimulatory molecules (Kaisho et al., 
2001; Hemmi et al., 2003; Oshiumi et al., 2003b; Zhao et al., 2003; Tabeta et al.,
2004).
Having established, in chapters 3 and 4, the ability of various PAMPs to induce 
cross-priming against a soluble protein antigen, it was of importance to investigate 
which licensing pathways were involved. The study o f licensing mechanisms in 
response to TLR agonists was focussed on the stimulation of innate cytokines and the 
role of IFN-a/p in particular, for two reasons. Firstly, the TLR agonists found to 
induce cross-priming (poly(I:C), LPS and CpG DNA) have all been shown to induce 
IFN-a/p that are able to mediate stimulation of T cell responses (Tough et al., 1996; 
Tough et al., 1997; Sun et al., 1998), which may favour adjuvanticity. Secondly, 
IFN-a/p, which those agonists have the capacity to induce, are able to convert a T- 
helper cell-dependent cross-priming into a T-helper cell-independent process (Le 
Bon et ah, 2003). This suggests that poly(I:C) and LPS are probably able to induce 
cross-priming independently of CD4+ T cell, a fact that has already been 
demonstrated for CpG DNA (Cho et ah, 2000; Cho et ah, 2002). Induction of cross­
priming by particular carbohydrate structures, such as high-mannose carbohydrates, 
has not been reported before. The contribution of various known cross-priming 
licensing stimuli, including IFN-a/p signalling since some high-mannose 
glycoproteins have been shown to induce IFN-a production (Mone et ah, 1992; 
Milone et ah, 1998; Miller et ah, 2003; Rong et ah, 2003), needed to be assessed.
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While much progress has been made over the last five years on mapping intracellular 
signalling cascades that are initiated by TLR, and on linking TLR stimulation to 
adaptive responses, characterisation of how other PRRs, such as C-type lectins, 
participate in instructing adaptive immune responses is still in its infancy. 
Cooperation between TLR and C-type lectins has however been reported (Perera et 
a l , 2001; Brown et a l , 2003; Gantner et a l , 2003a; Nagaoka et a l,  2005). As this 
study has shown that lectin ligands have the ability to induce CD8+ T cell responses, 
against an exogenous antigen, it will be of interest to determine the role of lectin 
receptors and TLR in the induction of cross-priming.
Accordingly, the aim of the work presented here was in the first instance to 
determine the relevance of the IFN-a/p licensing pathway in the induction of cross­
priming by TLR agonists. The second part of the work was to investigate both the 
contributions of CD40/CD40L and IFN-a/p licensing pathways in the induction of 
cross-priming by high-mannose molecules. The role of the mannose receptor and of 
TLR4 was also examined.
5.2 Mechanisms of induction of cross-priming by 
Toll-like receptor agonists
Induction of antigen-specific adaptive responses relies on a chain of signals that is 
initiated by the innate immune system. Early events involve the production of innate 
cytokines, which may act directly on adaptive cells, and/or indirectly through 
activation of other innate cells. The production of cytokines in response to TLR 
agonists has mainly been studied in vitro, on bone marrow-derived or purified 
populations of DC. In order to characterise the response to TLR stimuli in an 
integrated system, the production of innate cytokines in vivo was assessed.
5.2.1 Systemic pro-inflammatory mediators
C57B1/6 mice were injected i.m. with individual TLR agonists. Serum levels of 
various pro-inflammatory mediators were measured over a time-course, using flow 
cytometry array (Figure 5.1). In response to most agonists, major pro-inflammatory 
cytokines, such as TNF-a and IL-6, were produced in large quantities as rapidly as 2 
h after injection. Production of TNF-a and IL-6, however, was not sustained, since 
by 12 h, serum concentrations had decreased rather dramatically. All agonists
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induced high levels of macrophage chemoattractant MCP-1, a chemokine critical 
against some bacterial and viral infections (Nakano et al., 1994; Hokeness et a l,  
2005). Production of MCP-1 was long-lasting, especially in the case of poly(I:C), 
LPS from E. coli and CpG 1668, with which chemokine concentration was still 
above 1,000 pg/mL 12 h after injection. The kinetic of MCP-1 induction by CpG 
2216 suggested that this agonist may elicit delayed production of pro-inflammatory 
mediators compared to the other agonists, a trend that was also observed for IL-6 
production. Indeed, IL-6 and MCP-1 concentrations, although much lower than with 
CpG 1668 for example, increased over the 12 h time-course. Serum levels of the 
bioactive form of IL-12p70, a key cytokine in the initiation of effective cellular 
responses, were also measured. Results show that the only high-inducer of IL-12p70 
was CpG 1668. A short lasting production of 100-200 pg/mL was detected in 
response to R-848. IFN-y is also a relevant effector cytokine. Only R-848 and CpG 
2216 seemed to be able to induce appreciable levels of IFN-y. While concentration 
peaked suddenly and briefly at 4 h with R-848, it is not known whether CpG 2216 
would induce higher and/or lasting production of IFN-y beyond 12 h after injection.
In summary, all agonists were able to induce often very high serum levels of pro- 
inflammatory mediators during the first 12 h after injection. However, cytokines 
involved in activation of cellular immune responses were detected systemically in 
response to R-848 and CpG DNA only.
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Figure 5.1. TLR agonists rapidly induce high levels of pro-inflammatory 
mediators in the serum. C57B1/6 mice were injected i.m. with zymosan (5 mg), 
peptidoglycan from S. aureus (PGN) (200 pg), poly(I:C) (100 pg), LPS from E. coli 
(10 pg), R-848 (200 pg), CpG 2216 (20 nmol) or CpG 1668 (20 nmol). Sera were 
collected at 2 h (H ), 4 h (D )  and 12 h (D )  after immunisation. TNF-a, IL-6, MCP- 
1, IL-12p70 and IFN-y were quantified in the serum o f each mouse using flow  
cytometry array (mouse inflammation cytometric bead array; BD Biosciences). Data 
are represented by mean ± SD for three mice per group.
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5.2.2 Systemic IFN-a
IFN-a is an innate cytokine, which has been shown to stimulate antigen-specific 
adaptive immune responses. Serum levels of IFN-a, produced in response to TLR 
agonists, were measured over a time-course, using ELISA (see 2.4.2). Mice were 
immunised as described in paragraph 5.2.1.
Significant concentrations of IFN-a were detected 2 h after injection with poly(I:C), 
LPS, R-848, or CpG DNA, though R-848 and poly(I:C) induced at least 10 times 
more cytokine than LPS or CpG DNA (Figure 5.2). In mice injected with, LPS, R- 
848 or CpG 1668, IFN-a production returned to baseline concentration by 12-24 h 
after injection. In contrast, production was constant for at least 24 h with CpG 2216, 
and lasted between 12 h and 24 h with poly(I:C).
In summary, poly(I:C), LPS, R-848 and CpG DNA were able to induce the 
production o f systemic IFN-a, as opposed to zymosan and peptidoglycan.
It is important to note that levels of IFN-a only were measured. At the time of this 
study, no reagents that enable the measure of serum levels of IFN-p were available. 
Therefore, in order to properly assess the role of IFN-a/p in induction of cross­
priming by TLR agonists, the generation of antigen-specific CD8+ T cell responses 
was examined in mice deficient for the IFN-a/p receptor.
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Figure 5.2. Measurement of serum levels of IFN-a induced by TLR agonists.
C57B1/6 mice were injected i.m. with zymosan (5 mg), peptidoglycan from S. aureus 
(PGN) (200 pg), poly(I:C) (100 pg), LPS from E. coli (10 pg), R-848 (200 pg), CpG 
2216 (20 nmol) or CpG 1668 (20 nmol). Sera were collected at 2 h ( I ) ,  4 h (H ), 12 
h ( 0 )  and 24 h ( □ )  after immunisation. IFN-a was quantified in the serum o f each 
mouse using ELISA. Data are represented by mean ± SD for three mice per group, 
nd, not done.
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5.2.3 Antigen-specific CD8+ T cell responses in the absence 
of IFN-a/p signalling.
5.2.3.1 Responses to Toll-like receptor agonists
In order to characterise more directly the contribution of IFN-a/p signalling pathway 
in the induction of cross-priming by TLR agonists, generation of antigen-specific 
CD8+ T cell responses against model protein antigen OVA was studied in mice 
deficient for the IFN-a/p receptor (IFN-a/pR'7'). Wild-type 129Sv/Ev mice (WT) 
and IFN-a/pR'7' mice were immunised i.m. with OVA in combination with 
individual TLR agonists. Nine days after injection, OVAsiiNFEKL-specific cytotoxicity 
was measured in vivo (see 2.6.3). Data are expressed as the percentage reduction in 
cytotoxicity in IFN-a/pR'7' mice compared to WT mice (see 2.6.3.2) (Figure 5.3A). 
In response to poly(I:C) and LPS, OVA-specific lysis in IFN-a/pR’7' mice was 
reduced by 92.4% ± 7.6 and 100% ± 0, respectively, compared to lysis in WT mice. 
Lysis induced by CpG 2216 was reduced by 66.5% ± 29.1 in IFN-a/pR'7' mice, and 
lysis induced by CpG 1668 was reduced by 57.6% ± 16.8.
In summary, induction of cross-priming by poly(I:C) and LPS was totally or almost 
completely abrogated in the absence of IFN-a/p signalling, while the effect of CpG 
DNA was reduced approximately by half.
5.2.3.2 Responses to non-classical lipopolysaccharides
The role of IFN-a/p in the induction of cross-priming by non-classical 
lipopolysaccharides was also studied. Wild-type 129Sv/Ev mice (WT) and IFN- 
a/pR'7' mice were immunised i.m. with OVA in combination with LPS from E. coli 
(Ec 055:B5), LPS from K. pneumoniae (Kp K52), LPS from N. meningitidis (Nm 
44/76). Nine days after injection, SIINFEKL-specific cytotoxicity was measured in 
vivo. Data are expressed as the percentage reduction in cytotoxicity in IFN-a/pR'7' 
mice compared to WT mice (Figure 5.3B).
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Figure 5.3. Induction of cross-priming by TLR agonists is dependent on the 
IFN-a/p pathway. (A) Wild-type (WT) 129 Sv/Ev mice and IFN-a/pR-deficient 
(IFN-a/pR"7') mice were injected i.m. with 500 pg ovalbumin (OVA) in combination 
with poly(I:C) (100 pg), LPS from E. coli (10 pg), CpG 2216 (20 nmol) or CpG 
1668 (20 nmol). Nine days after immunisation, OVA-specific CD8+ T cell cytotoxic 
activity was determined by in vivo CTL assay. Results are expressed as percentage of 
reduction in SIINFEKL-specific lysis in IFN-a/pR"7" mice compared to WT mice. 
Data are represented by mean ± SD for three mice per group. (B) WT mice and IFN- 
a/pR"7' mice were injected i.m. with 500 pg OVA alone or OVA in combination with 
LPS from E. coli 0 5 5 :B5 (Ec 055) (10 pg), LPS from K. pneumoniae K52 (Kp K52) 
(10 pg) or LPS from N. meningitidis 44/76 (Nm 44/76) (10 pg). Nine days after 
immunisation, OVA-specific CD8+ T cell cytotoxic activity was determined by in 
vivo CTL assay. Results are expressed as percentage of reduction in SIINFEKL- 
specific lysis in IFN-a/pR'7" mice compared to WT mice. Data are represented by 
mean ± SD for three mice per group.
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SIINFEKL-specific lysis induced by each LPS was reduced by over 90% in IFN- 
a/pR'7' mice compared to lysis in WT mice. Induction of OVA-specific cytotoxicity 
by LPSs from various bacterial sources was thus entirely dependent on the presence 
of IFN-a/p signalling.
In summary, poly(I:C), which is a TLR3 agonist, lipopolysaccharides that (most 
probably) are TLR4 agonists, and CpG DNA, which is a TLR9 agonist, are structures 
that induce antigen-specific CD8+ T cell responses, a property that was totally 
abrogated, or partially in the case of CpG DNA, in the absence of IFN-a/p 
signalling.
5.3 Investigation of mechanisms involved in 
induction of cross-priming by mannan and high- 
mannose structures
Experimental data presented in chapter 4 showed that mannan and other high- 
mannose molecules were able to induce functional cross-priming. With the aim of 
characterising the possible mechanisms involved, established licensing pathways, 
such as CD40L/CD40 ligation and IFN-a/p signalling, were investigated. The roles 
of CD4+ T cells and of IL-12, which is a major T helper cell-inducer, were also 
determined. Cross-priming, in response to mannan and high-mannose structures, was 
studied against OVA, using various murine knock-out models.
5.3.1 Licensing pathways
5.3.1.1 The role of CD4* T cell help, IL-12 and CD40/CD40L interaction
Mannan and high-mannose structures were found to act as adjuvants in the 
development of antigen-specific CD4+ T cell responses [see 4.3.2], which may 
constitute an appropriate environment for induction of cross-priming. Furthermore, 
there has been evidence for cross-priming requiring help from CD4+ T cell (Bennett 
et al., 1997), although other models of cross-priming proved not to be dependent on 
CD4+ T cells (Le Bon et al., 2003). Thus, the involvement of CD4+ T cells, and 
potential associated signalling events, in stimulating antigen-specific CD8+ T cell 
responses was evaluated in parallel.
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Since MHC II molecules are required for CD4+ T cells positive selection in the 
thymus, MHC II-deficient mice lack CD4+ T cells. Therefore, in order to determine 
directly the role of CD4+ T cells in induction of cross-priming by high-mannose 
compounds, experiments were conducted using MHC II-deficient mice (Figure 
5.4A). Wild-type C57B1/6 mice (B6) and MHC II-deficient mice (MHC II'7') were 
immunised i.m. with OVA in combination with mannan, polymannose LPS from K. 
pneumoniae K55 (LPS Kp K55) or rough LPS from K. pneumoniae K52 (LPS Kp 
K52). Nine days after injection, SIINFEKL-specific cytotoxicity was measured in 
vivo. Mannan, LPS Kp K55 and LPS Kp K52 were still able to induce OVA-specific 
cytotoxicity in the absence of CD4+ T cells. Lysis of target cells in MHC IF7' mice 
was actually increased, possibly due to a lack of regulatory T cells (Haeryfar et a l ,
2005). Indeed, for example, the percentage lysis induced by mannan was 92.1% ± 
1.7, compared to 18.9% ± 7.6 in B6 mice.
IL-12 is an early innate cytokine that plays a predominant role in the differentiation 
of naive CD4+ T cells into Thl T cells (Macatonia et a l , 1995), and which may also 
promote CTL responses (Sad et a l , 1995; Bianchi et a l , 1996). Furthermore, IL-12 
has been shown to participate in induction of cross-priming against a soluble antigen 
(Van Uden et a l ,  2001; Cho et a l,  2002). In order to test how essential IL-12 is in 
the stimulation of cross-priming by mannan and polymannose LPS Kp K55, 
experiments were conducted in IL-12p35-deficient mice (IL-12p35'7"). Wild-type B6 
mice and IL-12p35‘7" mice were immunised i.m. with OVA in combination with 
mannan or LPS Kp K55. Nine days later, SIINFEKL-specific cytotoxicity was 
measured in vivo (Figure 5.4B). Percentages of OVA-specific lysis were similar in 
wild-type and IL-12p35'7’ mice, for both mannan and LPS Kp K55. Biologically 
active IL-12 (IL-12p70) necessitates the combination of two subunits, including IL- 
12p35; therefore results showed that lack of functional IL-12 did not significantly 
impair the ability of mannan and LPS Kp K55 to induce OVA-specific CD8+ T cell 
responses.
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Figure 5.4. Induction of cross-priming by TLR-agonists does not depend on 
CD4+ T cell help, nor IL-12, nor CD40/CD40L signalling. (A) C57B1/6 (B6) mice 
and MHC II-deficient (H-2-Ab‘7‘) mice were injected i.m. with 500 jug OVA in 
combination with mannan from S. cerevisiae (2.8 mg), LPS from K. pneumoniae 
03:K55 (Kp K55) (10 pg) or LPS from K. pneumoniae K52 (Kp K52) (10 pg). (B) 
B6 mice and IL-12p35-deficient (IL-12p35'7‘) mice were injected as in (A). (C) B6 
and CD40-deficient (CD40'7') mice were injected as in (A). (A, B, C) Nine days after 
immunisation, SIINFEKL-specific CD8+ T cell cytotoxic activity was determined by 
in vivo CTL assay. Results are expressed as percentage of SIINFEKL-specific lysis. 
Data are represented by mean ± SD for three mice per group.
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As described in Chapter 1.2.2.3.2, ligation of CD40L, on T cells, with CD40, on 
APC, may allow DC, which are able to cross-present exogenous antigens, to become 
competent for inducing functional cross-priming. It has been previously reported that 
licensing for cross-priming may be dependent on CD40/CD40L interaction (Bennett 
et al., 1998; Schoenberger et a l , 1998), or not (Cho et a l , 2002; Le Bon et a l , 
2003). Therefore, to test the dependence of high-mannose stimuli on CD40/CD40L 
ligation as a licensing factor, the ability of mannan and LPS Kp K55 to generate 
cross-priming against OVA was tested in mice lacking CD40 molecules (Figure 
5.4C). Wild-type B6 mice and CD40-deficient mice (CD40’/‘) were immunised i.m. 
with OVA in combination with mannan or LPS Kp K55. Nine days later, SIINFEKL- 
specific cytotoxicity was measured in vivo. Results showed that mannan and LPS Kp 
K55 were still able to induce OVA-specific cytolysis in the absence of CD40.
In summary, mannan and both LPS Kp K55 and Kp K52 induced cross-priming 
despite the absence of CD4+ T cells. In addition, mannan and LPS Kp K55 did not 
depend on CD40 or IL-12 to generate antigen-specific CD8+ T cell responses.
5.3.1.2 IFN-a/p signalling
IFN-a/p signalling is a major licensing pathway for the initiation of cross-priming. 
Since induction of cross-priming by mannan and polymannose LPS Kp K55 did not 
depend on other prominent licensing pathways, as shown in paragraph 5.3.1.1, the 
role of the IFN-a/p signalling pathway required to be investigated. In order to test 
whether high-mannose structures were able to induce cross-priming in the absence of 
IFN-a/p signalling, experiments were conducted in IFN-a/pR'^mice (Figure 5.5A).
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Figure 5.5. The role of IFN-a/p in induction of cross-priming by mannan and 
high-mannose compounds. (A, B) Wild-type (WT) 129 Sv/Ev mice and IFN-a/pR- 
deficient (IFN-a/pR‘7') mice were injected i.m. with 500 pg OVA in combination 
with mannan from S. cerevisiae (2.8 mg) or LPS from K. pneumoniae 03:K55 (Kp 
K55) (10 pg). (A) Nine days after immunisation, SIINFEKL-specific CD8+ T cell 
cytotoxic activity was determined by in vivo CTL assay. Results are expressed as 
percentage of reduction in SIINFEKL-specific lysis in IFN-a/pR'7' mice compared to 
WT mice. Data are represented by mean ± SD for three mice per group. (B) WT 
mice and IFN-a/pR’7’ mice were injected i.m. with OVA (500 pg) in combination 
with bromelain-released hemagglutinin (B-HA) from Influenza X:31 A/AICHI/68 
(20pg). Nine days after immunisation, SIINFEKL-specific CD8+ T cell cytotoxic 
activity was determined by in vivo CTL assay. Results are expressed as percentage of 
reduction in SIINFEKL-specific lysis in IFN-a/pR’7" mice compared to WT mice. 
Data are represented by mean ± SD for three mice per group.
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Wild-type 129Sv/Ev mice (WT) and IFN-a/pR"7" mice were immunised i.m. with 
OVA in combination with mannan or LPS Kp K55, and OVA-specific CD8+ T cell 
cytotoxicity was assessed nine days later in vivo. Data are expressed as percentage 
reduction in SIINFEKL-specific lysis in IFN-a/pR’7" mice compared to wild-type 
mice. Results showed that SIINFEKL-specific lysis in response to mannan was 
reduced by 71.8% ± 22.0 in IFN-a/pR’7" mice compared to lysis in WT mice. The 
cytotoxic response induced by LPS Kp K55 was also greatly reduced in IFN-a/pR"7' 
mice (by 88.7%± 11.0).
Hemagglutinin (HA) from Influenza A virus (H3N2) was found to have the adjuvant 
property of inducing cross-priming against a soluble protein antigen (see 4.3.1.2.2). 
The role of IFN-a/p signalling in this process was examined (Figure 5.5B). Wild- 
type 129Sv/Ev mice (WT) and IFN-a/pR'7' were immunised i.m. with OVA in 
combination with HA, and OVA-specific cytotoxicity was determined nine days later 
in vivo. SIINFEKL-specific lysis induced by HA was significantly reduced in IFN- 
a/pR"7' mice (by 96.5% ± 3.4) compared to lysis in WT mice.
In summary, initiation of antigen-specific CD8+ T cell responses by high-mannose 
molecules such as mannan, HA and LPS Kp K55 depended heavily on IFN-a/p 
signalling pathway.
In addition to characterising the contribution of established cross-priming licensing 
pathways, the role of relevant innate receptors, which would be first to recognise the 
high-mannose molecules studied here, was examined.
5.3.2 Role of innate receptors
5.3.2.1 The mannose receptor
The mannose receptor (MR) is the principal mannose-binding receptor (Stahl et al., 
1998; Weis et al., 1998; Geijtenbeek et al., 2004). Ligand-receptor interactions have 
been implicated in the induction of expression and secretion of immunomodulatory 
cytokines, including IFN-a (Gamer et al., 1994; Yamamoto et al., 1997; Milone et 
a l,  1998). Thus, considering the role of MR in key steps of immune responses to 
high-mannose molecules (Sallusto et al., 1995; Prigozy et al., 1997; Martinez- 
Pomares et al., 1998), the MR contribution to the induction of cross-priming by
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mannan and polymannose LPS Kp K55 was assessed. Moreover, with the aim to 
refine the characterisation of polymannose LPS properties, polymannose LPS from 
E. coli 0 9  was included in the study. Indeed, both LPS Ec 0 9  and LPS Kp K55 have 
mannose homopolymer O-antigen polysaccharide chains (Curvall et al., 1973; Prehm 
et al., 1976; Chen et al., 2002). In contrast, LPS Kp K52 and LPS Ec 055 do not 
contain a polymannose O-antigen. Wild-type B6 mice (WT) and MR-deficient mice 
(MR'7') were immunised i.m. with OVA alone or OVA in combination with mannan, 
LPS Kp K55, LPS Kp K52, LPS Ec 0 9  or LPS Ec 055. To first assess whether the 
absence of MR affected the ability of the compounds to induce proliferation of OVA- 
specific CD8+ T cells, the frequency of CD8+ T cell bearing SIINFEKL-specific 
TCR was measured in peripheral blood eight days after immunisation, using H-2Kb- 
SIINFEKL tetramer staining and FACS analysis (Figure 5.6A). Results showed that 
LPS Kp K52, LPS Ec 055 stimulated the expansion of OVA-specific CD8+ T cells 
in both WT and MR'7' mice. Mannan and LPS Ec 0 9  properties were not affected 
either in MR'7' mice compared to WT mice. However, less OVA-specific CD8+ T 
cells were detected in MR'7' mice immunised with OVA + LPS Kp K55, in 
comparison to WT mice (0.86% ± 0.16 in WT compared to 0.39% ± 0.08 in MR'7'; 
p=0.006). In order to test the functional properties of OVA-specific CD8+ T cells 
generated in MR'7' mice, in comparison to WT mice, CTL assays in vivo were 
conducted (Figure 5.6B). Percentages of SIINFEKL-specific lysis induced by LPS 
Kp K52 and LPS Ec 055 in MR'7' mice were not significantly different from 
percentages of lysis measured in WT mice. Similarly, OVA-specific-lysis induced by 
mannan, LPS Kp K55 and LPS Ec 0 9  were statistically comparable in WT and in 
MR'7' mice.
Overall, results showed that lack of MR did not interfere significantly with the 
induction of functional antigen-specific CD8+ T cell responses by high-mannose 
structures.
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Figure 5.6. The mannose receptor is not required for induction of cross-priming 
by mannan and polymannose lipopolysaccharides. C57B1/6 mice and MR- 
deficient (MR"7') mice were injected i.m. with 500 pg OVA alone or OVA in 
combination with mannan from S. cerevisiae (2.8 mg), LPS from K. pneumoniae 
03:K55 (Kp K55) (10 pg), LPS from K. pneumoniae K52 (Kp K52) (10 pg), LPS 
from E. coli 09:K9(L9):H12 (Ec 09) (10 pg) or LPS from E. coli 055:B5 (Ec 055) 
(10 pg). (A) Eight days after immunisation, SIINFEKL-specific CD8+ T cells in 
peripheral blood were quantified using Kb-SIINFEKL tetramer staining. Results are 
expressed as percentage of Tet+ cells gated on CD8+ T cells. Data are represented by 
mean ± SD for three mice per group. (B) Nine days after immunisation, SIINFEKL- 
specific CD8+ T cell cytotoxic activity was determined by in vivo CTL assay. Results 
are expressed as percentage of SIINFEKL-specific lysis. Data are represented by 
mean ± SD for three mice per group.
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5.3.2.2 Toll-like receptors
Toll-like receptors (TLR) are a group of receptors that recognise specific structures 
from, among others, bacteria, fungi, and viruses. Stimulation of TLR signalling 
pathways results in the transcription of precise sets of genes encoding for cytokines 
and costimulatory molecules. TLR4 in particular has been shown to initiate 
signalling cascades that can lead to the production of immunomodulatory cytokines 
such as IFN-p and/or influence the expression of CD40 on APC (Toshchakov et a l, 
2002; Hoebe et a l,  2003b; Nicolle et a l,  2004). Since both mannan and LPS from E. 
coli have been described as TLR4 agonists (Hoshino et a l,  1999; Tada et a l,  2002), 
and TLR4 may participate in the initiation of cross-priming licensing pathways, the 
contribution of TLR4 in induction of antigen-specific CD8+ T cell responses by 
mannan and polymannose LPS Kp K55 was assessed. Wild-type C57B1/10 mice 
(WT) and TLR4-deficient mice (TLR4'7") were immunised i.m. with model protein 
antigen OVA alone, or OVA in combination with mannan, LPS Kp K55 or LPS Ec 
055. Nine days after injection, OVA-specific cytotoxicity was measured in vivo. 
Data from the CTL assay in vivo are expressed as the percentage reduction in 
SIINFEKL-specific lysis in TLR4*7' mice compared to WT mice (Figure 5.7). Results 
showed that OVA-specific lysis in TLR47' mice, in response to mannan or LPS Ec 
055, was reduced by 76.0% ±13. 8  and 89.0% ± 10.1, respectively, compared to 
cytolysis in WT mice. In sharp contrast, OVA-specific lysis generated by LPS Kp 
K55 was at similar levels in both WT and TLR47’ mice.
In summary, induction of antigen-specific CD8+ T cell responses by mannan or LPS 
Ec 055 was TLR4-dependent, whereas induction by LPS Kp K55 was TLR4- 
independent.
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Figure 5.7. The role of TLR4 in induction of cross-priming by mannan and 
lipopolysaccharides. Wild-type (WT) C57Bl/10ScSnJ mice and TLR4-deficient 
(TLR4'7") mice were injected i.m. with 500 pg OVA in combination with mannan 
from S. cerevisiae (2.8 mg), LPS from K. pneumoniae 03:K55 (Kp K55) (10 pg) or 
LPS from E. coli 055:B5 (Ec 055) (10 pg). Nine days after immunisation, OVA- 
specific CD8+ T cell cytotoxic activity was determined by in vivo CTL assay. Results 
are expressed as percentage of reduction in SIINFEKL-specific lysis in TLR4'7' mice 
compared to WT mice. Data are represented by mean ± SD for three mice per group.
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5.4 Conclusions and discussion
Activation of CD8+ T cell cytotoxic programs needs to be controlled to prevent 
autoimmunity. DC licensing constitutes a safety protocol in the initiation of cross­
priming, in the sense that CD8+ T cells can only become functional if  they are 
actively instructed to do so by competent DC. The precise nature and effects of DC 
signals acting on CD8+ T cells have not been fully elucidated, and what a DC 
competent state entails has also not been entirely defined. However, CD40/CD40L 
interactions and IFN-a/p signalling have been shown to be two major upstream 
licensing stimuli, which ultimately allow induction of cross-priming. In chapters 3 
and 4, particular PAMPs were proven to induce cross-priming against a soluble 
protein antigen. The aim of the work presented in this chapter was to investigate the 
nature of the licensing stimuli involved. Results indicate that for PAMPs induction of 
cross-priming against a soluble antigen, the IFN-a/p licensing pathway is dominant.
Of a range of representative TLR agonists, only poly(I:C) (TLR3), LPS from E. coli 
(TLR4) and CpG DNA (TLR9) were found able to induce cross-priming against a 
soluble protein antigen (see Chapter 3). The hypothesis tested in the present chapter 
was that IFN-a/p played an essential part in the licensing process.
TLR agonists, as PAMPs in general, are known to be detected rapidly, and part of the 
response they elicit is the production of cytokines, which act as alarm signals and 
activation mediators. Indeed, all TLR agonists tested in vivo stimulated systemic 
release of high levels of cytokines as early as 2 h after intramuscular injection. 
However, while poly(I:C) could induce the production of over 2 ng/mL IFN-a, LPS 
and CpG DNA generated a substantial (up to 250 pg/mL) yet much lower response. 
On the other hand, R-848, a TLR7 agonist that was shown to be unable to generate 
antigen-specific CD8+ T cell responses against a soluble protein antigen (see Chapter 
3), nevertheless briefly induced very high serum levels of IFN-a (2 ng/mL) 2 h after 
injection. If secretion of IFN-a did not seem to define a specific connection between 
IFN-a/p and the ability of poly(I:C), LPS and CpG DNA to induce cross-priming, 
experiments with knock-out mice lacking the IFN-a/p receptor proved that induction 
of cross-priming by those TLR agonists was dependent on IFN-a/p signalling, albeit 
to a varying degree. Induction of cross-priming by poly(I:C) and LPS from E. coli 
was completely dependent on IFN-a/p, while induction of cross-priming by CpG
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DNA was only partially dependent, which is consistent with a previous report 
showing that induction of cross-priming by CpG DNA is dependent on IFN-a/p, IL- 
12 and costimulatory molecules (Van Uden et al., 2001; Cho et al., 2002). Therefore, 
measuring IFN-a/p production may provide information on the types of innate 
signalling pathways activated by agonists, but cytokine secretion in early stages of a 
response may not be predictive of consequent adaptive responses. In addition, in the 
present study, only levels of IFN-a were measured, using a monoclonal anti-mouse 
IFN-a capture antibody; binding of this antibody to each IFN-a existing subtype has 
not been characterised by the manufacturer. The actual specificity of capture 
antibodies for IFN-a subtypes, as well as their affinity, could result in equally 
produced IFN-a subtypes not being equally detected; the IFN-a ELISA thus may not 
reflect accurately the contribution of each IFN-a subtype, which may be 
differentially induced by different agonists. If particular subtypes were responsible 
for licensing of cross-priming, then this ELISA does not allow one to establish a 
correlation between induction of IFN-a production by agonists and induction of 
cross-priming. This could provide an explanation for the observation that R-848 is a 
potent inducer of IFN-a, but was not able to induce cross-priming against a soluble 
protein antigen. It is also to note that the secretion of IFN-a in response to R-848 
was short-lasting. Furthermore, stimulation of IFN-P production by agonists, which 
was not examined because reagents were not commercially available at the time, may 
play an important role in the cross-priming licensing process. Although poly(I:C), 
LPS from E. coli, R-848 and CpG DNA have all been found to induce the production 
of IFN-P (Megyeri et al., 1995; Hoshino et al., 2002; Oshiumi et al., 2003a), it is 
possible that agonists induce different combinations of various IFN-a subtypes and 
IFN-P that are not equally effective at inducing cross-priming. Overall, it is thus 
possible that various factors, such as the source, nature, kinetics and magnitude of 
IFN-a/p response, all concur to license for cross-priming.
While the studies presented here focussed on investigating the mechanisms involved 
in induction of cross-priming, it is interesting to note that in vivo secretion, or lack 
of, of other innate cytokines in response to TLR agonists did not necessarily correlate 
either with expected adaptive responses. IL-12p70 for instance is an 
immunomodulatory cytokine that has been connected, through induction of IFN-y,
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with the promotion of IgG2a isotype switching (Germann et a l,  1995; Van Uden et 
al., 2001). Antigen-specific IgG2a isotype switching can also be dependent on IFN- 
a/p signalling (Le Bon et al., 2001; Van Uden et al., 2001). While zymosan, 
poly(I:C), LPS from E. coli, R-848, CpG 2216 and CpG 1668 were all found to 
enhance antigen-specific antibody responses and in particular promote IgG2a 
production (see Chapter 3), zymosan did not induce the production of IFN-a, and 
only R-848 and CpG 1668 stimulated the secretion of IL-12 p70. Accordingly, R-848 
and CpG 1668 induced the secretion of IFN-y, and both agonists were reported to 
induce antigen-specific IgG2a in an IFN-y-dependent manner, with IgG2a responses 
being reduced by more than 90% in IFN-y-deficient mice (Vasilakos et al., 2000). 
Although CpG 2216 did not stimulate the in vivo secretion of IL-12p70, it was the 
only agonist, other than R-848 and CpG 1168, that was able to induce the production 
of some IFN-y, possibly through induction of another immunostimmulatory cytokine 
such as IL-18 (Bohle et al., 1999; Gould et a l,  2004). CpG 2216 and CpG 1668 are 
two different CpG sequences that were included in the study as representative of two 
distinct CpG classes: A-class CpG sequences (CpG 2216) have been reported to 
stimulate the production of high levels IFN-a (Yamamoto et al., 1992; Hemmi et al., 
2003; Kerkmann et a l,  2003), from plasmacytoid DC in particular (Kadowaki et a l,  
2001; Krug et a l,  2001), and to stimulate NK cells functions such as IFN-y 
production and cytotoxicity (Balias et a l,  1996; Vollmer et a l,  2004). B-class CpG 
sequences (CpG 1668) have been reported to primarily stimulate B cell proliferation 
(Krieg et a l,  1995) and the production of cytokines such as IL-6 and IL-10 but only 
little IFN-a (Yi et a l,  1996; Anitescu et a l,  1997; Hartmann et a l,  1999; Krug et a l,  
2001). B-type CpG DNA are also reported to induce the production of high-levels of 
IL-12 (Krieg et a l,  1998; Schulz et a l,  2000; Vasilakos et a l,  2000; Krug et a l,
2001). In the present study, comparing the effect of CpG 2216 and CpG 1668 on 
cytokine secretion in vivo confirmed that CpG 1668, as opposed to CpG 2216, was a 
high inducer of IL-12p70. However, despite being described as a poor inducer of 
IFN-a, CpG 1668 was also found to be able to stimulate the release of more than 100 
pg/mL systemic IFN-a at the peak of the response (4 h after injection), though 
secretion was not as sustained as the response stimulated by CpG 2216 (over 90 
pg/mL IFN-a 24 h after injection).
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Cytokines form a network of signal mediators that is complex and redundant. 
Therefore, studying cytokine production and secretion pattern, whilst providing clues 
to activation mechanisms at various stages of the immune response, does not 
necessarily predict the triggering of particular responses such as antigen-specific 
isotype switching or cross-priming. When possible, it is important to use in vivo 
cytokine or cytokine receptor gene-deficient models to define more accurately the 
contribution of particular cytokines.
The ability of LPSs from various bacteria species to induce cross-priming against a 
soluble protein antigen was investigated in Chapter 3. In addition to LPS from E. 
coli, which is widely used as a prototypic LPS, less conventional LPSs such as LPSs 
from K. pneumoniae and N. meningitidis were found to induce antigen-specific CD8+ 
T cell responses. In contrast, LPS purified from a non-enterobacterial species, P. 
gingivalis, which is an LPS with a different lipid A structure, was not able to induce 
cross-priming. The results reported in the present chapter showed that the 
enterobacterial LPSs tested, irrelevant of their O-antigen structure, induced cross­
priming exclusively in an IFN-a/p-dependent manner.
In addition to studying induction of cross-priming by TLR agonists, including non- 
classical LPSs, this project involved assessing the ability of another category of 
PAMPs, that are high-mannose molecules, to generate CD8+ T cell responses against 
a soluble protein antigen, and examining possible cross-priming licensing 
mechanisms. Mannan, a component of yeast cell-wall, LPS from K. pneumoniae 
03:K55, which has a distinct polymannose O-polysaccharide, and hemagglutinin 
from Influenza A virus X:31 (H3N2), an envelope glycoprotein, were all found to be 
able to induce cross-priming (see Chapter 4). The contribution of various factors, 
such as CD4+ T cell help, CD40/CD40L ligation and cytokines, in the licensing of 
cross-priming had been investigated previously for other models. Cross-priming 
against cell-associated antigen, for instance, requires CD4+ T cell help or 
CD40/CD40L interaction (Bennett et al., 1997; Bennett et a l,  1998), while cross­
priming against a soluble antigen in the presence of bacterial products can be 
mediated by CD4-independent (Bennett et al., 1997; Hamilton et al., 2001), and 
CD40-independent mechanisms (Cho et al., 2000). IL-12 is a Thl cytokine that, 
although not necessarily essential in the licensing of CTL priming (Wan et al., 2001), 
was shown to be involved in the induction of cross-priming by CpG DNA (Cho et
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al., 2002). IFN-a, in turn, induces cross-priming against soluble antigen 
independently of CD4+ T cell help or CD40/CD40L ligation, and overcomes the need 
for CD4+ T cell help in cross-priming against cell-associated antigen (Le Bon et a l , 
2003). The work presented in this chapter showed that mannan and polymannose 
LPS Kp K55 induced cross-priming against a soluble antigen independently of 
CD40, as well as independently of CD4+ T cell help, which is consistent with studies 
reporting that CD4+ T cell help in cross-priming is actually mediated by CD40 
signalling. Induction of cross-priming by mannan and LPS Kp K55 did not require 
IL-12 either. In contrast, induction of cross-priming by mannan, LPS Kp K55 and 
HA was dependent on IFN-a/p signalling. Mannan did not appear to absolutely 
depend on IFN-a/p signalling for licensing of cross-priming, although it has been 
reported that other factors, such as CD80-86/CD28 interaction, may be involved in 
the development of cross-priming (Cho et a l , 2002).
LPS, CpG DNA, HA, poly(I:C) and mannan are PAMPs from bacteria, viruses and 
yeasts. Their detection by the immune system is mediated by different innate 
receptors. LPS, CpG DNA and poly(I:C) are representative TLR agonists, but can 
also be recognised by other molecules. LPS-binding protein (LBP), CD 14 and TLR4 
are all involved in the recognition of LPS from E. coli, for example. Bacterial DNA 
is recognised by TLR9 (Hemmi et a l,  2000), but can also bind members of the 
collectin family, surfactant protein D (SP-D) in particular (Palaniyar et a l,  2004), 
which have their own receptor(s) (Hickling et a l, 2004). Poly(I:C) can be recognised 
by TLR3 (Alexopoulou et a l,  2001), but also by PKR (Yang et a l,  1995; 
Balachandran et a l,  2000; Diebold et a l , 2003) and by the RNA helicases of RIG-1 
and mda-5 (Andrejeva et a l, 2004; Kato et a l, 2005). HA (Reading et a l,  1997; 
Reading et a l , 2000) and mannan can be recognised by lectins that have mannose- 
specific carbohydrate recognition domains, which, for mannan, include mannan- 
binding lectin (MBL), the mannose receptor and SIGNR1 (Taylor et a l,  1992; 
Takahara et a l,  2004; McGreal et a l, 2005). Mannan has been shown to interact 
with TLR4 (Tada et a l,  2002).
It has been demonstrated that induction of cross-priming by intracellular poly(I:C) 
against cell-associated antigen is dependent on TLR3 (Schulz et a l,  2005). However, 
this does not necessarily apply to induction of cross-priming against a soluble 
antigen. Therefore, the involvement of TLR3 and other receptors for dsRNA would
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need to be studied, although extracellular poly(I:C) is probably recognized by TLR3 
rather than by other receptors. CpG DNA, either co-administered with or conjugated 
to a soluble antigen, induces cross-priming (see Chapter 3 and (Cho et al., 2000; 
Sparwasser et a l., 2000). The contribution of TLR9 was investigated, but only in the 
case of CpG DNA-antigen conjugates and not for co-administered CpG DNA and 
antigen, and results showed that induction of cross-priming was mediated by TLR9 
(Heit et a l , 2003).
The mannose receptor (MR) is a C-type lectin with specificity, among others, for D- 
mannose. It has eight carbohydrate recognition domains (CRD) and clustering of 
CRD 4 to 8 is thought to allow high-avidity binding to branched-chain mannose 
oligosaccharides (Taylor et al., 1993; Feinberg et al., 2000). It has been implicated in 
the recognition of microbial structures, such as yeast mannan and viral glycoproteins 
(Kery et al., 1992; Miller et al., 2003; Nguyen et al., 2003), and has been shown to 
bind some LPS structures, including LPS from K. pneunomiae 03:K55 (Zamze et 
al., 2002). In order to assess the contribution of MR in induction of cross-priming by 
high-mannose molecules, the generation of CD8+ T cell responses against a soluble 
antigen was examined in MR-deficient mice. Results showed that, generally, 
induction of cross-priming by mannan and polymannose LPSs from K. pneumoniae 
K55 and from E. coli 0 9  occurred independently of MR. Therefore the MR is not 
indispensable, in the detection of high mannose molecules and subsequent licensing 
of cross-priming. The role of the MR in immune responses has been controversial, 
especially since MR-deficiency did not increase susceptibility of mice to 
disseminated yeast and fungal infection (Lee et al., 2003c; Swain et al., 2003), 
although this may only demonstrate that redundant mechanisms exist and/or that 
responses to P-glucan, rather than mannan, and mediated by a different lectin, such 
as dectin-1, are more crucial in controlling yeast and fungal infections.
Recognition of high-mannose molecules may be mediated by other C-type lectins 
with mannose-specificity. SIGNR1 and SIGNR3, for instance, belong to a family of 
five mouse lectins homologous to human DC-SIGN (Park et a l ,  2001). Mannan can 
be recognised by both SIGNR1 and SIGNR3 (Takahara et al., 2004). If SIGNR1 and 
SIGNR3 may contribute to capturing mannan and high-mannose molecules, 
induction of cross-priming still requires the initiation of signalling cascades that will 
result in licensing stimuli being released. Yet the cytoplasmic domain of mouse DC-
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SIGN and SIGNR lectins do not contain signalling motifs. Cooperation between 
receptors has however been demonstrated. For example, LPS-binding protein (LBP) 
binds LPS for transfer to CD 14 and TLR4-MD-2 complex, which transduces 
appropriate signals (Gioannini et al., 2004; Saitoh et a l., 2004; Jiang et a l , 2005). 
Association of SIGNR1 with TLR4-MD-2 complex has also been reported (Nagaoka 
et a l , 2005), which might be involved in the induction of cross-priming by mannan 
and HA. Indeed, mannan was found to induce TLR4-dependent, polymyxin B- 
resistant, signalling, (Tada et a l , 2002), and results presented in this chapter showed 
that mannan induced cross-priming against a soluble protein antigen in a TLR4- 
dependent manner. Results also demonstrated that induction of cross-priming by LPS 
from E. coli was TLR4-dependent. Interestingly though, LPS from K. pneumoniae 
K55 induced cross-priming independently of TLR4. Other LPS molecules have been 
shown to induce immune responses independently of TLR4. LPS from P. gingivalis 
and LPS from L. interrogans for example induce pro-inflammatory cytokine 
production independently of TLR4 (Kirikae et a l , 1999; Hirschfeld et a l , 2001; 
Werts et a l., 2001). The adjuvant activity of polymannose LPS from K. pneumoniae 
03 of inducing antigen-specific DTH and antibody responses was also shown to be 
TLR4-independent (Ohta et al., 1985).
All data collected indicate that the immune system has the capacity, even with a set 
number of innate receptors, to detect PAMPs in many various ways, probably by 
using combinative binding. Yet, diverse recognition mechanisms, dealing with 
structures originating from different families of organisms, can result in the induction 
of a same particular downstream adaptive immune response. Hence, PAMPs such as 
viral DNA, viral and yeast high-mannose carbohydrates, bacterial LPS and bacterial 
DNA, whether it is through the same innate receptor (LPS from E. coli and probably 
LPS from N. meningitidis) or not (LPS from K. pneumoniae K55), through TLRs 
(LPS from E. coli, CpG DNA) or yet unknown combination of other receptors, are 
able to trigger signalling programs that somewhere converge in the induction of IFN- 
a/p-dependent cross-priming.
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Chapter 6
Final Discussion
Microbial infections with intracellular organisms are a cause of morbidity and 
mortality world-wide, and vaccination is a strategy that would help preventing 
infection, and therefore its consequences. Vaccines in those cases need to elicit CD8+ 
T cells that kill infected cells and produce cytokines that support additional killing 
mechanisms by other cells. Because of concerns over the safety of using live 
organisms as vaccines, the use of recombinant target antigens is being evaluated 
instead. CD8+ T cell responses may be elicited against exogenously administered 
antigens, by cross-priming. Cross-priming is not constitutive, and studying the 
signals that induce and control cross-priming contributes to the understanding of a 
process that can be exploited for new safe vaccine strategies.
Bacterial stimuli such as CFA and CpG DNA had been shown to induce cross­
priming when co-administered with a soluble protein antigen (Bennett et a l , 1997; 
Cho et a l ,  2000). This research project examined the ability of a broader range of 
microbial stimuli to induce cross-priming. Of the stimuli tested, constituents of 
bacteria (LPS from some bacteria species, CpG DNA), of viruses (dsRNA, 
hemagglutinin from Influenza virus) and of fungi (mannan) were able to generate 
antigen-specific functional CD8+ T cells responses when co-administered with a 
soluble protein antigen. Together with studies published during the course of this 
work (Le Bon et a l ,  2003; Schulz et a l ,  2005), this confirmed that the capacity to 
induce cross-priming was not restricted to one class of organisms.
It had been demonstrated that signals generated during a viral infection could 
authorise the occurrence of cross-priming, and this process was found to depend on 
IFN-a/pR signalling (Le Bon et al., 2003). Therefore, as part of investigating the 
mechanisms by which cross-priming was induced, the contribution of IFN-a/pR 
signalling was examined. All microbial products tested that were able to induce 
cross-priming depended on IFN-a/pR signalling for licensing of cross-priming. In 
particular, poly(I:C), LPS from E. coli, LPS from K. pneumoniae K52 and K55, LPS 
from N. meningitidis and hemagglutinin from Influenza virus were almost completely 
dependent on IFN-a/p signalling. In the absence of IFN-a/pR, effector CD8+ T cell
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responses generated by cross-priming in response to mannan and CpG DNA were 
reduced approximately by three quarters and by half, respectively. This demonstrated 
that IFN-a/p signalling and other stimuli cooperated to induce cross-priming.
The use of anti-CD40 antibodies, co-injected with soluble OVA had shown that 
signalling through CD40 could be a licensing stimulus for cross-priming against non 
cell-associated exogenous antigens (Lefrancois et al., 2000). However, results 
showed that mannan induced cross-priming independently of CD40 signalling, and 
experiments using CD40L- and CD40-deficient mice showed that licensing in 
response to CpG DNA is also not mediated by CD40 signalling (Sparwasser et al., 
2000; Van Uden et al., 2001). While IL-12 was shown to contribute to induction of 
cross-priming by CpG DNA (Van Uden et al., 2001), results showed that responses 
to mannan were independent of IL-12. Which additional signal(s) mannan triggers 
remains to be determined, but as it is the case for CpG DNA (Cho et al., 2002), 
signalling through costimulatory molecules such as B7/CD28 may contribute to 
licensing of cross-priming.
Activation of IFN-a/pR signalling is therefore a major mechanism of licensing of 
cross-priming, which is triggered by signals from various microbial origins. Various 
factors may be involved in activation of IFN-a/pR signalling that is effective for 
licensing of cross-priming. For instance, the receptors stimulated by microbial 
stimuli, the intracellular pathways controlling IFN-a/p expression, the nature of IFN- 
a/p secreted and the cells producing them probably all influence whether IFN-a/p- 
dependent licensing of cross-priming can occur.
Induction of cross-priming by microbial stimuli initially depends on triggering of 
innate receptors that mediate the activation of intracellular signalling pathways, 
resulting in the expression of cross-priming licensing signals, including IFN-a/p. It 
has been shown that induction of cross-priming by poly(I:C) and CpG DNA is 
mediated through TLR3 and TLR9, respectively (Heit et al., 2003; Schulz et al., 
2005). Results demonstrated that LPS from E. coli induced cross-priming through 
TLR4. LPS from N. meningitidis has been shown to require TLR4 for the activation 
of IFN-p (Zughaier et a l., 2005), therefore it is probable that induction of cross­
priming by LPS from N. meningitidis is TLR4-dependent. The contribution of TLR4 
in the response to LPS from K. pneumoniae K52 remains to be determined. Results
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also showed that mannan required signalling through TLR4 to induce cross-priming. 
The triggering o f TLR4-mediated responses by mannan has been demonstrated 
previously, and the effect of mannan was not sensitive to polymyxin B, showing that 
environmental LPS contamination was not responsible for mannan’s properties (Tada 
et al., 2002). The contribution of CD 14 was not investigated, but CD 14 may play an 
important role in activating TLR4-mediated induction of cross-priming by mannan. 
Indeed, CD 14 has been shown to be involved in mannan- and other polysaccharide- 
induced TLR4-mediated responses (Shoham et a l , 2001; Flo et al., 2002; Tada et al.,
2002). Furthermore, CD 14 is required for TLR4/IRF3-mediated responses to VSV 
(Jiang et a l ,  2005). Therefore, CD 14 is able to activate IRF3-dependent IFN-a/p 
production through TLR4 in response to molecules other than LPS. In addition, since 
CD 14 is involved in the differential response to smooth LPS (with O-antigen, 
constituted o f carbohydrate repeating units) and rough LPS (no O-antigen), it is 
possible that the carbohydrate structure and/or conformation of mannan, VSV 
glycoprotein envelope (Stanley et al., 1984), and Influenza HA enables interactions 
with CD 14 and subsequent TLR4-dependent induction of cross-priming.
Therefore, TLR stimulation can mediate induction of cross-priming, probably 
through activation of pathways that control the expression of IFN-a/p. Further 
biochemical studies are however needed to define more precisely receptor/agonist 
interactions. Characterising the basic structural/conformational requirements for 
microbial component’s stimulatory activity through TLR and receptor complexes 
would help to develop adjuvants with essential agonistic features.
While LPS from E. coli and mannan required TLR4 for induction of cross-priming, 
LPS from K. pneumoniae K55 did not. Polymannose LPS Kp K55, and LPS with 
similar structures (Ohta et al., 1982; Kido et al., 1985a; Ohta et al., 1987), have 
previously been characterised as unusual LPSs, with potent adjuvant activities that 
were TLR4-independent (Ohta et al., 1985). Among other properties, polymannose 
LPS greatly activates the complement system through the lectin pathway (Shibazaki 
et al., 1999; Zhao et al., 2002). Activation of the complement cascade generates 
intermediate products, such as C3 and chemotactic C5a (Ehlers, 2000; Guo et a l ,  
2005), that have been shown to play an important role in regulating adaptive immune 
responses (Carroll, 2004), including the generation of CD8+ T cell responses (Kopf 
et al., 2002; Suresh et al., 2003; Kim et al., 2004). It is therefore possible that LPS
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Kp K55 is able to induce cross-priming in the absence of TLR4 through activation of 
complement, which may be verified by blocking TLR4 in C3-deficient mice for 
example. To characterise further the mechanisms of induction of cross-priming by 
stimuli such as polymannose LPS, the receptor(s) and signalling pathway(s) they 
activate would need to be defined.
Expression o f IFN-a/p, which stimulate the IFN-a/pR signalling pathways, is 
controlled by nuclear transcription factors NF-kB and/or IRF (Akira et al., 2004; 
Lohoff et a l , 2005), and activation of these factors has been characterised for a few 
but not all o f the microbial constituents tested in this study.
Poly(I:C) and LPS from E. coli are known to induce the production of IFN-a/p 
through activation of IRF-3 (Hoebe et al., 2003a; Hoebe et al., 2003b; Oshiumi et 
al., 2003a). dsRNA induces the production of IFN-a, including IFN-a4, and IFN-P 
(Juang et al., 1998; Marie et al., 1998), while LPS mainly induces the expression of 
IFN-p. To note, it is often inferred, based on the lack of detection of IFN-a mRNA 
or protein expression from LPS-stimulated bone-marrow derived DC or purified DC 
populations, that LPS does not induce the production of IFN-a (Hoshino et al., 2002; 
Asselin-Paturel et al., 2005; Honda et al., 2005b). Results however showed that LPS 
from E. coli stimulated the secretion of IFN-a in vivo (up to 250 pg/mL), although to 
lower levels than poly(I:C) for instance (see 5.2.2). The effect of IFN-a4 and IFN-p 
is illustrated by the fact that IFN-a4 induces cross-priming against a co-administered 
soluble protein antigen (Le Bon et al., 2003) and IFN-p shares this adjuvant property 
[Dr A. Le Bon, personal communication]. IFN-p and IFN-a4 have been shown to 
trigger an amplification loop by signalling through the IFN-a/pR, which induces the 
production of IRF7; IRF7 gets activated and induces the expression of IFN-a (Sato 
et al., 1998; Sato et al., 2000). Although exogenous poly(I:C) and dsRNA generated 
in the cytoplasm by viruses stimulate different receptors, both sources of dsRNA 
stimulate IRF-mediated expression of IFN-a/p through activation of the same 
kinases (TBK1 and IKKs) (Fitzgerald et al., 2003a; Hemmi et al., 2004; Kato et al., 
2005; Kawai et al., 2005b). It has recently been shown that IRF7 is not required for 
IFN-p expression in response to NDV infection, while activation of IRF3 was 
essential (Honda et al., 2005b). The same study confirmed that LPS induction of 
IFN-p is mediated by activation of IRF3 only. In addition, IFN-a and IFN-
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p expression in response to poly(I:C) or LPS from E. coli was shown not to require 
signalling through the IFN-a/pR (Hoshino et a l , 2002; Hoebe et al., 2003b).
CpG DNA in contrast induces the expression of IFN-a and IFN-p independently of 
IRF3, while activation of IRF7 is essential (Honda et al., 2005a; Honda et a l., 
2005b). It has also been shown that CpG DNA triggers an increase in IRF7 
expression, and that expression of IRF7, IFN-a and IFN-p in response to CpG DNA 
is dependent on IFN-a/pR signalling (Asselin-Paturel et al., 2005; Honda et a l., 
2005b).
Therefore, although poly(I:C), LPS and CpG DNA all induce cross-priming through 
IFN-a/pR signalling, they trigger that event in different ways. Importantly, since 
responses to microbial stimuli can be controlled by feedback mechanisms, IFN-a/p 
production, as measured in vitro  from purified cell populations or even in vivo from 
serum, is not a good correlate of downstream activation, as factors such as the nature 
of IFN-a/p secreted, the source of IFN-a/p, and therefore where IFN-a/p are 
produced, and kinetics of secretion most probably play a role in triggering signals 
such as cross-priming licensing. These factors may explain the fact that guanosine 
analogue R-848, although it induced the secretion of IFN-a systemically, was not 
able to induce cross-priming when co-administered with a soluble protein antigen. R- 
848 is known to induce IFN-a and IFN-p expression through activation of IRF7 and, 
as opposed to CpG DNA (Takaoka et al., 2005), through IRF5 (Honda et al., 2005b; 
Schoenemeyer et al., 2005). As for CpG DNA, R-848 induction of IFN-a is 
dependent on IFN-a/pR signalling (Asselin-Paturel et al., 2005). It is possible that 
R-848, as a result of IRF7 and IRF5 activation, induces the expression of IFN-a 
subtypes that are different from the ones produced in response to cross-priming- 
inducing stimuli such as poly(I:C), LPS and CpG DNA. There are fourteen different 
types of IFN-a in mice (van Pesch et al., 2004), and R-848 may induce the 
production of combinations of IFN-a subtypes that trigger IFN-a/pR signalling 
pathways that do not support licensing of cross-priming. Indeed, it has been reported 
that individual IFN-a subtypes, and combinations of IFN-a subtypes and IFN-p, 
activate different IFN-a/pR signalling pathways and induce the expression of 
different patterns of genes (Bartlett et al., 2002; Cull et a l., 2002; Harle et al., 2002;
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Cull et ah, 2003). The characterisation of IFN-a subtype secretion profiles is 
presently limited by the lack of specific detection reagents.
IFN-a production in vivo in response to both CpG DNA and R-848 is mainly 
performed by plasmacytoid DC (pDC) (Asselin-Paturel et al., 2005). However, 
responses to R-848 differ from responses to CpG DNA and notably R-848 induces 
different pDC migration patterns (Asselin-Paturel et al., 2005). Indeed, pDC cluster 
to different areas at different times in secondary lymphoid organs in response to R- 
848 or CpG DNA. pDC play an important role in DC-induced CD8+ T cell responses 
(Yoneyama et ah, 2005). Therefore, it is possible that, in response to R-848, pDC are 
not localised appropriately, or at the right time, for receiving positive feedback 
signals and secreting the IFN-a/p that would license DC to induce cross-priming.
It is known that DC are the APC that mediate cross-priming (Jung et al., 2002) and 
current knowledge indicates that CD8a+ DC are the particular subsets that perform 
cross-priming (den Haan et ah, 2000). While expression of TLR3, TLR4 and TLR9 
enables CD8a+ DC to respond directly to poly(I:C), LPS and CpG DNA, 
respectively, CD8a+ DC do not express TLR7 and therefore cannot respond directly 
to R-848 (Edwards et al., 2003). It is thus probable that poly(I:C) and LPS can 
directly trigger a cross-priming licensing state in CD8a+ DC, which as many cell 
types constitutively express IRF3 (Au et ah, 1995), through TLR3/IRF3/IRF7- and 
TLR4/IRF3/IRF7-mediated IFN-a/p activation pathways, respectively. CpG DNA 
does not directly induce production of IFN-a/p from CD8a+ DC, probably because 
these DC, as opposed to pDC, do not constitutively express IRF7, and CpG DNA 
does not activate IRF3. However, CpG can directly stimulate pDC to produce IFN- 
a/p, which in turn may induce the expression of IRF7 in CD8a+ DC. Direct 
activation of CD8a+ DC by CpG DNA, which can induce the production of 
cytokines as well as costimulatory molecules (Asselin-Paturel et ah, 2005; Honda et 
ah, 2005b), in combination/synergy with activation by pDC-produced IFN-a/p may 
induce a cross-priming licensing state in CD8a+ DC. This may be illustrated by the 
fact that induction of cross-priming by CpG DNA does not solely depend on IFN- 
a/p signalling pathways but depend on additional factors such as costimulatory 
molecules and IL-12 signalling pathways (Cho et ah, 2002). In contrast, R-848 is not 
able to induce cross-priming possibly because not only it cannot directly stimulate
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CD8a+ DC, but also because R-848-activated pDC may not be able to induce any 
cross-priming licensing state in CD8a+ DC through IFN-a/pR signalling, possibly 
due to the production of inefficient combinations of IFN-a subtypes and IFN-P, 
and/or due to a lack of pDC/CD8a+ DC co-localisation at the right time.
Therefore, in order to characterise the role of IFN-a/p signalling in the induction of 
cross-priming, the IFN-a/p-producing and -responding cells, as well as the nature, 
timing and location of IFN-a and IFN-p production, would need to be defined.
The downstream effects of IFN-a/p signalling pathways in licensing of cross­
priming remain to be determined, as it is still not known what IFN-a/p-induced 
factors control cross-priming of CD8+ T cells by DC, whether it involves soluble or 
membrane proteins, or both.
The generation of antigen-specific antibody responses contributes to increasing the 
efficiency of the immune responses. Antibodies can rapidly activate the complement 
cascade through the classical pathway, which leads to pathogen destruction by the 
membrane attack complex. Potent antibody responses are characterised by the 
secretion of antibody from different classes and isotypes, since different types of 
antibodies have different functions that cooperate to prevent infection and to 
eliminate pathogens. Isotype switching controls the production of different types of 
antibodies and it requires appropriate help from antigen-specific CD4+ T cells, 
through cytokine secretion and costimulatory molecule activation. Results 
demonstrated that antigen-specific CD4+ T cells primed in the presence of mannan 
and LPS from K. pneumoniae K52 and K55 differentiated into cytokine-producing 
cells. CD4+ T cell effector function corroborated the fact that the same microbial 
stimuli enhanced antigen-specific IgG responses and promoted isotype switching. 
CD4+ T cells specifically differentiated into Thl cells, as they produced IFN-y but no 
IL-4. IFN-y supports switching to IgG isotypes, and antigen-specific IgG2a responses 
in particular were enhanced by LPSs and mannan; the high-mannose viral 
glycoprotein HA also promotes antigen-specific IgG2a responses [Dr A. Le Bon, 
personal communication]. IgG2a antibodies play an important role in pathogen 
killing as they trigger CMC and ADCC against infected cells, and the latter 
mechanism is supported by IFN-y. Although the effect of poly(I:C), LPS from E. coli 
and CpG DNA on priming of CD4+ T cell responses was not examined, the fact that
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these stimuli enhanced antigen-specific IgG responses and promoted isotype 
switching, to IgG2a especially, is a strong indication that antigen-specific CD4+ T 
cell help was generated. The signals produced in response to poly(I:C), LPSs, 
mannan and CpG DNA were potent enough to stimulate the generation of memory 
antibody responses, including of the IgG2a isotype, probably, among other 
mechanisms, through the priming of effective CD4+ T cell help.
Therefore, detection of poly(I:C), LPS from E. coli, LPS from K. pneumoniae K52 
and K55, mannan and CpG DNA induces signals that enhance antigen-specific 
antibody responses and promote IgG switching to isotypes that are most appropriate 
for the killing of intracellular pathogens. The mechanisms mediating the effect of 
microbial stimuli on antigen-specific antibody responses were not investigated. 
However, IFN-a/p have been shown to enhance antibody responses against a soluble 
protein antigen and to promote isotype switching, and IFN-a/pR signalling mediated 
the adjuvant effect of poly(I:C) (Le Bon et al., 2001). Therefore it is probable that in 
response to LPSs, mannan and CpG DNA, IFN-a/pR signalling mediates both the 
enhancement of antibody responses and induction of cross-priming.
This investigation confirmed and extended results from previous studies 
demonstrating that the generation of functional CD8+ T cell responses against an 
exogenously administered antigen is possible in the presence of stimuli that induce 
IFN-a/p signalling-dependent cross-priming. However, efficient vaccines against 
intracellular pathogens would not only require the stimulation of primary antigen- 
specific CD8+ T cells responses, but also the development of protective immunity 
through the induction of immunological memory. Although results demonstrated that 
in response to poly(I:C), LPS from E. coli, LPS from K. pneumoniae K52 and K55 
and CpG DNA, B cells received appropriate help from CD4+ T cells to develop 
antigen-specific memory responses, it may have not been the case for CD8+ T cells.
Therefore, the ability of microbial stimuli to promote the generation of memory 
CD8+ T cells, capable of effector functions upon rechallenge, against an exogenous 
antigen needs to be assessed. Studying the effect of diverse microbial stimuli on the 
induction of memory CD8+ T cells would contribute to defining what signals activate 
the immune system in such a way that a memory program is imprinted into CD8+ T 
cells during priming. Indeed, although under intense investigation, mechanisms of
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and factors affecting immunological memory are insufficiently defined at present. 
Integration of knowledge in IFN-a/p-dependent cross-priming mechanisms and 
development of immunological memory would be required to design safe effective 
vaccines to prevent or combat a number of serious infections.
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